Arthritis, Rheumatoid
Conditions
Keywords
Janus Kinase 3 Clinical Trial
Brief summary
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)
Interventions
DRUGAdalimumab
40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
DRUGCP-690-550
15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
DRUGCP-690,550
3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
DRUGPlacebo
Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must have active rheumatoid arthritis * Subjects must have failed at least 1 disease modifying anti-rheumatic drug (DMARD) * Subjects must not be currently taking any DMARD other than an antimalarial
Exclusion criteria
* Subjects who discontinued any previous TNF inhibitor therapy for either lack of benefit or safety. * Subjects who previously received adalimumab (Humira®) therapy for any reason. * Subjects with evidence of blood disorders, chronic infections or untreated tuberculosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | Week 12 | ACR20 response: greater than or equal to (\>=) 20 % improvement in tender joint count (TJC); \>= 20% improvement in swollen joint count (SJC); and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient Global Assessment (PtGA) of Arthritis Pain | Baseline, 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | Participants answered: Considering all the ways your arthritis affects you, how are you feeling today? Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly. |
| Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR \[mm/hour\] and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) \<= 3.2 implies low disease activity and \> 3.2 to 5.1 implies moderate to high disease activity, and \< 2.6 = remission. |
| Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | Disease improvement was classified as good, moderate, and none based on improvement in DAS28-4 (ESR) from baseline and present DAS28-4 (ESR) score. Good: an improvement from baseline of \>1.2 and a present score of \<=3.2; none: an improvement of \<=0.6 or \>0.6 to \<=1.2 with a present score of \>5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response. |
| Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET | CRP value less than or equal to upper limit of normal (ULN) implied disease remission (ULN=4.9 mg/L). |
| Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET | DAS28-3 (CRP) defined remission was classified as a score of \<2.6. |
| 36-Item Short-Form Health Survey (SF-36) | Baseline, Week 12, 24/ ET | SF-36 is a standardized survey evaluating 8 domains (of 2 components \[C\]; physical \[Ph\] and mental \[Mn\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). |
| Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Baseline, Week 12, 24/ ET | SF-36 is a standardized survey evaluating 8 domains (of 2 components \[C\]; physical \[Ph\] and mental \[Mn\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). |
| Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline, Week 12, 24/ ET | EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. |
| Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Baseline, Week 12, 24/ ET | EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. |
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2, 4, 6, 8, 10, 16, 20 and 24/Early Termination (ET) | ACR20 response: 20% improvement in TJC; \>=20% improvement in SJC; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP. |
| Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | ACR50 response: \>= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP. |
| Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | ACR70 response: \>= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP. |
| Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | ACR90 response: \>= 90% improvement in TJC or SJC and 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP. |
| Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Baseline up to Week 2, 4, 6, 8, 10, 12 | ACR-n = calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. Area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC. |
| Tender Joint Count (TJC) | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. |
| Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicated an improvement. |
| Swollen Joint Counts (SJC) | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. |
| Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling = 1. A negative value in change from baseline indicated an improvement. |
| Patient Assessment of Arthritis Pain | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain. |
| Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain. |
| Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | Participants answered: Considering all the ways your arthritis affects you, how are you feeling today? Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly. |
| Physician Global Assessment (PGA) of Arthritis | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad. |
| Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad. |
| C-Reactive Protein (CRP) | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. |
| Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 mg/L to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. |
| Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. |
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET | HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. |
| Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET | DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (\<=) 3.2 implied low disease activity and greater than (\>) 3.2 to 5.1 implied moderate to high disease activity, and less than (\<) 2.6 = remission. |
| Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET | DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \> 3.2 to 5.1 implied moderate to high disease activity, and \< 2.6 = remission. |
| Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET | DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) \<= 3.2 implies low disease activity and \> 3.2 to 5.1 implies moderate to high disease activity, and \< 2.6 = remission. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline, Week 24/ ET | The following biomarkers were assessed: Cluster of Differentiation 3 (CD3), CD4, CD8, CD19 and CD56. FACS analysis for lymphocyte subset markers were used to assess the effects of repeated doses of CP-690,550. |
| Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | Baseline, Week 24/ ET | The following biomarkers were assessed: CD3, CD4, CD8, CD19 and CD56. FACS analysis for lymphocyte subset markers were used to assess the effects of repeated doses of CP-690,550. |
| Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline, Week 2, 12, 24/ ET | Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\* 100); total score range: 0 to 100; higher score = greater intensity of attribute. |
| Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Baseline, Week 2, 12, 24/ ET | Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (A SOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\*100); total score range: 0 to 100; higher score = greater intensity of attribute. |
| Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline, Week 2, 12, 24/ ET | FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status. |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Baseline, Week 2, 12, 24/ ET | FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status. |
| Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | Baseline, Week 24/ ET | Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgG, IgM, and IgA levels. |
| Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline, Week 24/ ET | Blood samples for immunoglobulin assessments were obtained to determine IgG, IgM, and IgA levels in serum. |
Countries
Brazil, Bulgaria, Chile, Croatia, Czechia, Germany, Greece, Hungary, Italy, Mexico, Romania, Slovakia, South Korea, Ukraine, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| CP-690,550 1 mg CP-690,550 1 mg tablet orally twice daily up to Week 24, along with placebo matched to adalimumab 40 mg subcutaneous injections every other week (QOW) up to Week 10. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks. | 54 |
| CP-690,550 3 mg CP-690,550 3 mg tablet orally twice daily up to Week 24, along with placebo matched to adalimumab 40 mg subcutaneous injections every other week (QOW) up to Week 10. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks. | 51 |
| CP-690,550 5 mg CP-690,550 5 mg tablet orally twice daily up to Week 24, along with placebo matched to adalimumab 40 mg subcutaneous injections every other week (QOW) up to Week 10. | 49 |
| CP-690,550 10 mg CP-690,550 10 mg tablet orally twice daily up to Week 24, along with placebo matched to adalimumab 40 mg subcutaneous injections every other week (QOW) up to Week 10. | 61 |
| CP-690,550 15 mg CP-690,550 15 mg tablet orally twice daily up to Week 24, along with placebo matched to adalimumab 40 mg subcutaneous injections every other week (QOW) up to Week 10. | 57 |
| Adalimumab Adalimumab 40 mg subcutaneous injections every other week (QOW) up to Week 10 along with placebo matched to CP-690,550 tablet orally twice daily up to Week 12, then CP-690,550 5 mg tablet orally twice daily up to Week 24. | 53 |
| Placebo Placebo matched to CP-690,550 tablet orally twice daily up to Week 24, along with placebo matched to adalimumab 40 mg subcutaneous injections QOW up to Week 10. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to placebo to 5 mg (R) treatment arm for next 12 weeks. | 59 |
| Total | 384 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Post Week 12 | Adverse Event | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 4 | 0 |
| Post Week 12 | Lack of Efficacy | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 |
| Post Week 12 | Lost to Follow-up | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Post Week 12 | Other | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
| Post Week 12 | Withdrawal by Subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Adverse Event | 2 | 2 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Lack of Efficacy | 3 | 1 | 0 | 1 | 0 | 3 | 3 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Lost to Follow-up | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Other | 3 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Randomized not treated | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Withdrawal by Subject | 2 | 0 | 3 | 2 | 0 | 1 | 3 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | CP-690,550 1 mg | CP-690,550 3 mg | CP-690,550 5 mg | CP-690,550 10 mg | CP-690,550 15 mg | Adalimumab | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Age Continuous | 55.1 years STANDARD_DEVIATION 13.3 | 53.4 years STANDARD_DEVIATION 12.2 | 53.7 years STANDARD_DEVIATION 13.5 | 52.4 years STANDARD_DEVIATION 10.9 | 53.2 years STANDARD_DEVIATION 13 | 53.5 years STANDARD_DEVIATION 11.9 | 52.5 years STANDARD_DEVIATION 13.7 | 53.3 years STANDARD_DEVIATION 12.6 |
| Sex: Female, Male Female | 46 Participants | 44 Participants | 43 Participants | 53 Participants | 50 Participants | 45 Participants | 52 Participants | 333 Participants |
| Sex: Female, Male Male | 8 Participants | 7 Participants | 6 Participants | 8 Participants | 7 Participants | 8 Participants | 7 Participants | 51 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 18 / 37 | 5 / 17 | 18 / 34 | 6 / 17 | 27 / 49 | 31 / 61 | 31 / 57 | 5 / 9 | 26 / 44 | 14 / 34 | 13 / 25 |
| serious Total, serious adverse events | 2 / 37 | 0 / 17 | 1 / 34 | 0 / 17 | 0 / 49 | 1 / 61 | 4 / 57 | 0 / 9 | 4 / 44 | 2 / 34 | 0 / 25 |
Outcome results
Primary
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
ACR20 response: greater than or equal to (\>=) 20 % improvement in tender joint count (TJC); \>= 20% improvement in swollen joint count (SJC); and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
Time frame: Week 12
Population: Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. The analysis used Baseline Observation Carried Forward (BOCF) imputation for missing values.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 31.48 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 45.10 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 61.22 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 72.13 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 71.93 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 39.62 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 23.73 percentage of participants |
Secondary
36-Item Short-Form Health Survey (SF-36)
SF-36 is a standardized survey evaluating 8 domains (of 2 components \[C\]; physical \[Ph\] and mental \[Mn\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Time frame: Baseline, Week 12, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 37.06 units on a scale | Standard Deviation 9.13 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 43.61 units on a scale | Standard Deviation 11.8 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | 40.30 units on a scale | Standard Deviation 10.21 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | 40.23 units on a scale | Standard Deviation 11.04 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | 31.49 units on a scale | Standard Deviation 7.32 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 36.35 units on a scale | Standard Deviation 11.46 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 37.86 units on a scale | Standard Deviation 10.67 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 37.60 units on a scale | Standard Deviation 8.48 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | 45.03 units on a scale | Standard Deviation 11.01 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | 32.82 units on a scale | Standard Deviation 9.11 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | 34.80 units on a scale | Standard Deviation 8.29 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 45.92 units on a scale | Standard Deviation 10.27 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 45.55 units on a scale | Standard Deviation 10.6 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 32.59 units on a scale | Standard Deviation 11.82 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 35.64 units on a scale | Standard Deviation 10.4 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | 37.35 units on a scale | Standard Deviation 8.62 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 45.85 units on a scale | Standard Deviation 12.21 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 29.75 units on a scale | Standard Deviation 10.4 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | 33.28 units on a scale | Standard Deviation 11.38 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 42.08 units on a scale | Standard Deviation 11.31 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 39.26 units on a scale | Standard Deviation 8.99 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 41.11 units on a scale | Standard Deviation 11.36 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | 44.79 units on a scale | Standard Deviation 12.57 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | 39.16 units on a scale | Standard Deviation 11.57 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | 35.76 units on a scale | Standard Deviation 7.89 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | 38.99 units on a scale | Standard Deviation 7.72 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | 32.60 units on a scale | Standard Deviation 7.89 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 39.14 units on a scale | Standard Deviation 7.96 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | 41.20 units on a scale | Standard Deviation 10.49 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 36.12 units on a scale | Standard Deviation 13.51 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 39.40 units on a scale | Standard Deviation 9.26 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 38.11 units on a scale | Standard Deviation 9.41 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 41.00 units on a scale | Standard Deviation 8.92 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 39.38 units on a scale | Standard Deviation 10.26 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 44.18 units on a scale | Standard Deviation 8.74 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 35.57 units on a scale | Standard Deviation 11.72 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | 37.51 units on a scale | Standard Deviation 9.25 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | 38.47 units on a scale | Standard Deviation 8.43 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | 42.61 units on a scale | Standard Deviation 9.01 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 39.03 units on a scale | Standard Deviation 13.44 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 45.37 units on a scale | Standard Deviation 10.41 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 35.48 units on a scale | Standard Deviation 11.31 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 49.29 units on a scale | Standard Deviation 9.71 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | 32.52 units on a scale | Standard Deviation 9.33 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | 40.46 units on a scale | Standard Deviation 11.21 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | 33.41 units on a scale | Standard Deviation 8.54 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | 38.17 units on a scale | Standard Deviation 8.7 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 41.55 units on a scale | Standard Deviation 11.76 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 42.33 units on a scale | Standard Deviation 9 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 44.76 units on a scale | Standard Deviation 11.28 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 42.15 units on a scale | Standard Deviation 10.95 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | 37.58 units on a scale | Standard Deviation 11.04 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | 33.09 units on a scale | Standard Deviation 12.32 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | 39.45 units on a scale | Standard Deviation 9.35 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 38.27 units on a scale | Standard Deviation 10.02 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 44.25 units on a scale | Standard Deviation 9.46 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 39.87 units on a scale | Standard Deviation 9.18 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | 47.43 units on a scale | Standard Deviation 9.51 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | 40.21 units on a scale | Standard Deviation 10.21 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | 42.82 units on a scale | Standard Deviation 11.64 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | 42.53 units on a scale | Standard Deviation 10.23 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 37.66 units on a scale | Standard Deviation 12.25 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 41.50 units on a scale | Standard Deviation 11.47 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | 35.60 units on a scale | Standard Deviation 8.88 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | 33.21 units on a scale | Standard Deviation 9.87 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 37.03 units on a scale | Standard Deviation 13.74 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 43.14 units on a scale | Standard Deviation 10.38 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 37.17 units on a scale | Standard Deviation 11.85 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 29.88 units on a scale | Standard Deviation 11.61 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | 39.47 units on a scale | Standard Deviation 11.11 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 32.81 units on a scale | Standard Deviation 13.42 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 45.78 units on a scale | Standard Deviation 9.47 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 40.12 units on a scale | Standard Deviation 8.86 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | 40.65 units on a scale | Standard Deviation 8.04 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | 37.35 units on a scale | Standard Deviation 9.07 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 33.32 units on a scale | Standard Deviation 12.79 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 34.98 units on a scale | Standard Deviation 9.64 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 39.87 units on a scale | Standard Deviation 8.37 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 41.89 units on a scale | Standard Deviation 9.03 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | 37.11 units on a scale | Standard Deviation 7.14 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 36.36 units on a scale | Standard Deviation 10.74 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | 38.15 units on a scale | Standard Deviation 9.3 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 39.98 units on a scale | Standard Deviation 10.35 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 43.20 units on a scale | Standard Deviation 11.53 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 35.14 units on a scale | Standard Deviation 10.88 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 36.23 units on a scale | Standard Deviation 12.04 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 29.93 units on a scale | Standard Deviation 11.75 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | 39.03 units on a scale | Standard Deviation 9.96 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 41.76 units on a scale | Standard Deviation 10.16 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | 33.89 units on a scale | Standard Deviation 8.57 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | 34.14 units on a scale | Standard Deviation 11.74 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 43.15 units on a scale | Standard Deviation 9.2 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | 45.49 units on a scale | Standard Deviation 9.96 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | 44.18 units on a scale | Standard Deviation 10.91 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | 32.21 units on a scale | Standard Deviation 7.3 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 46.28 units on a scale | Standard Deviation 10 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | 32.31 units on a scale | Standard Deviation 10.46 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | 31.12 units on a scale | Standard Deviation 9.52 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 45.22 units on a scale | Standard Deviation 10.15 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | 39.56 units on a scale | Standard Deviation 8.79 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 44.44 units on a scale | Standard Deviation 10.86 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | 40.00 units on a scale | Standard Deviation 7.9 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 39.82 units on a scale | Standard Deviation 11.02 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | 37.94 units on a scale | Standard Deviation 12.02 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | 39.52 units on a scale | Standard Deviation 11.82 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 39.00 units on a scale | Standard Deviation 9.31 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 41.26 units on a scale | Standard Deviation 9.13 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 38.97 units on a scale | Standard Deviation 12.29 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 42.05 units on a scale | Standard Deviation 10.07 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | 39.28 units on a scale | Standard Deviation 10.95 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 46.73 units on a scale | Standard Deviation 10.09 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | 34.40 units on a scale | Standard Deviation 14.35 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 45.65 units on a scale | Standard Deviation 9.4 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 39.72 units on a scale | Standard Deviation 12.8 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | 44.97 units on a scale | Standard Deviation 12.87 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 43.29 units on a scale | Standard Deviation 12.68 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 40.82 units on a scale | Standard Deviation 12.85 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 40.78 units on a scale | Standard Deviation 10.67 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | 31.44 units on a scale | Standard Deviation 8.16 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | 38.94 units on a scale | Standard Deviation 10.43 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | 41.89 units on a scale | Standard Deviation 9.7 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | 42.81 units on a scale | Standard Deviation 9.89 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | 34.24 units on a scale | Standard Deviation 8.23 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | 39.56 units on a scale | Standard Deviation 12.17 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 47.61 units on a scale | Standard Deviation 11.24 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | 44.46 units on a scale | Standard Deviation 12.89 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | 33.48 units on a scale | Standard Deviation 6.48 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 35.93 units on a scale | Standard Deviation 10.73 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 40.43 units on a scale | Standard Deviation 11.67 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 44.63 units on a scale | Standard Deviation 12.75 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 39.42 units on a scale | Standard Deviation 11.99 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 41.80 units on a scale | Standard Deviation 10.75 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | 31.44 units on a scale | Standard Deviation 9.32 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 44.26 units on a scale | Standard Deviation 12.32 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | 41.46 units on a scale | Standard Deviation 11.85 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | 37.73 units on a scale | Standard Deviation 12.1 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 43.93 units on a scale | Standard Deviation 11.78 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 48.59 units on a scale | Standard Deviation 11.74 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 30.30 units on a scale | Standard Deviation 10.65 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | 40.11 units on a scale | Standard Deviation 11.1 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | 38.34 units on a scale | Standard Deviation 10.7 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 46.51 units on a scale | Standard Deviation 10.98 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 49.20 units on a scale | Standard Deviation 11.73 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | 31.82 units on a scale | Standard Deviation 7.59 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 43.91 units on a scale | Standard Deviation 13.6 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 30.08 units on a scale | Standard Deviation 9.66 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 41.17 units on a scale | Standard Deviation 9.61 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 38.44 units on a scale | Standard Deviation 11.65 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 40.33 units on a scale | Standard Deviation 11.52 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 41.75 units on a scale | Standard Deviation 11.45 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | 31.63 units on a scale | Standard Deviation 8.07 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 45.37 units on a scale | Standard Deviation 9.66 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | 40.80 units on a scale | Standard Deviation 11.07 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 39.23 units on a scale | Standard Deviation 13.39 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 44.43 units on a scale | Standard Deviation 12.15 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 42.69 units on a scale | Standard Deviation 11.39 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | 38.64 units on a scale | Standard Deviation 12.45 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | 32.54 units on a scale | Standard Deviation 7.25 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 46.24 units on a scale | Standard Deviation 10.3 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | 44.91 units on a scale | Standard Deviation 14.05 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 36.28 units on a scale | Standard Deviation 12.11 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | 43.73 units on a scale | Standard Deviation 12.76 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | 39.63 units on a scale | Standard Deviation 10.19 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | 41.80 units on a scale | Standard Deviation 10.03 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | 37.80 units on a scale | Standard Deviation 12.62 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 39.67 units on a scale | Standard Deviation 10.91 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | 34.58 units on a scale | Standard Deviation 8.81 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 43.08 units on a scale | Standard Deviation 13.13 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | 32.21 units on a scale | Standard Deviation 12.92 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | 42.44 units on a scale | Standard Deviation 9.71 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | 44.22 units on a scale | Standard Deviation 12.02 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 30.55 units on a scale | Standard Deviation 8.64 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | 32.87 units on a scale | Standard Deviation 10.6 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | 36.42 units on a scale | Standard Deviation 10.29 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 33.28 units on a scale | Standard Deviation 10.95 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | 32.23 units on a scale | Standard Deviation 6.76 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | 35.55 units on a scale | Standard Deviation 9.6 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 36.83 units on a scale | Standard Deviation 10.02 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 37.67 units on a scale | Standard Deviation 9.5 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | 38.42 units on a scale | Standard Deviation 11.41 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 44.88 units on a scale | Standard Deviation 10.16 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 38.43 units on a scale | Standard Deviation 12.04 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 39.98 units on a scale | Standard Deviation 12.7 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 42.94 units on a scale | Standard Deviation 12.46 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | 35.89 units on a scale | Standard Deviation 10.39 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | 32.26 units on a scale | Standard Deviation 12.75 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | 36.22 units on a scale | Standard Deviation 12.78 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | 32.67 units on a scale | Standard Deviation 7.38 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | 36.46 units on a scale | Standard Deviation 12.03 |
| Adalimumab | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 35.61 units on a scale | Standard Deviation 10.91 |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | 39.62 units on a scale | Standard Deviation 9.2 |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | 45.53 units on a scale | Standard Deviation 10.29 |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 38.36 units on a scale | Standard Deviation 10.74 |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 44.94 units on a scale | Standard Deviation 10.13 |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 42.66 units on a scale | Standard Deviation 9.22 |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 46.24 units on a scale | Standard Deviation 9.33 |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 41.20 units on a scale | Standard Deviation 11.66 |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | 39.03 units on a scale | Standard Deviation 9.5 |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 38.98 units on a scale | Standard Deviation 9.51 |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 41.71 units on a scale | Standard Deviation 9.99 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | 35.00 units on a scale | Standard Deviation 9.77 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 39.91 units on a scale | Standard Deviation 7.67 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | 32.20 units on a scale | Standard Deviation 8.71 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 38.39 units on a scale | Standard Deviation 10.81 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 37.14 units on a scale | Standard Deviation 9.88 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 34.94 units on a scale | Standard Deviation 10.76 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 43.53 units on a scale | Standard Deviation 11.34 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | 45.22 units on a scale | Standard Deviation 10.88 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | 37.45 units on a scale | Standard Deviation 11.66 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | 36.55 units on a scale | Standard Deviation 9.64 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 43.89 units on a scale | Standard Deviation 10.98 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 39.23 units on a scale | Standard Deviation 12.58 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | 45.01 units on a scale | Standard Deviation 10.13 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 41.44 units on a scale | Standard Deviation 11.22 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 33.11 units on a scale | Standard Deviation 11.43 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | 33.21 units on a scale | Standard Deviation 14.49 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 43.20 units on a scale | Standard Deviation 11.23 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | 38.05 units on a scale | Standard Deviation 8.19 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 38.50 units on a scale | Standard Deviation 9.31 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 37.21 units on a scale | Standard Deviation 9.84 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 35.50 units on a scale | Standard Deviation 10.68 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | 31.94 units on a scale | Standard Deviation 6.71 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | 34.35 units on a scale | Standard Deviation 7.85 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | 33.19 units on a scale | Standard Deviation 8.04 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | 30.25 units on a scale | Standard Deviation 9.79 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | 38.96 units on a scale | Standard Deviation 12.17 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | 39.87 units on a scale | Standard Deviation 9.3 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 41.85 units on a scale | Standard Deviation 8.28 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 46.47 units on a scale | Standard Deviation 10.7 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | 38.16 units on a scale | Standard Deviation 8.74 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 49.10 units on a scale | Standard Deviation 9.72 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 41.60 units on a scale | Standard Deviation 10.62 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=24,15,29,15,43,55,52,0,40,20,24) | 42.87 units on a scale | Standard Deviation 9.13 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=24,15,29,15,43,55,52,0,40,20,24) | 42.84 units on a scale | Standard Deviation 9.18 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 43.96 units on a scale | Standard Deviation 10.01 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 47.08 units on a scale | Standard Deviation 9.37 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 42.27 units on a scale | Standard Deviation 10.38 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=54,0,51,0,49,61,56,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C (n=24,15,29,15,43,55,52,0,40,20,24) | 46.93 units on a scale | Standard Deviation 10.63 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 43.38 units on a scale | Standard Deviation 9.5 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 45.55 units on a scale | Standard Deviation 11.08 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
Secondary
Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve
ACR-n = calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. Area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.
Time frame: Baseline up to Week 2, 4, 6, 8, 10, 12
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. Missing values were imputed using Last Observation Carried Forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | -675.05 units on a scale | Standard Deviation 5160.91 |
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | -328.58 units on a scale | Standard Deviation 1190.65 |
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | -545.16 units on a scale | Standard Deviation 3121.09 |
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | -99.17 units on a scale | Standard Deviation 430.6 |
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | -488.95 units on a scale | Standard Deviation 2121.82 |
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 10 | -588.77 units on a scale | Standard Deviation 4109.74 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | -21.41 units on a scale | Standard Deviation 348.6 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | 30.98 units on a scale | Standard Deviation 2675.04 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | 145.08 units on a scale | Standard Deviation 4380.78 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | -31.17 units on a scale | Standard Deviation 1068.34 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 10 | 81.85 units on a scale | Standard Deviation 3510.17 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | -7.91 units on a scale | Standard Deviation 1840.8 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 10 | 1163.37 units on a scale | Standard Deviation 1985.69 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | 416.04 units on a scale | Standard Deviation 1117.6 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | 1579.56 units on a scale | Standard Deviation 2447.05 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | 761.40 units on a scale | Standard Deviation 1552.54 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | 36.11 units on a scale | Standard Deviation 254.6 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | 165.07 units on a scale | Standard Deviation 685.88 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 10 | 1857.57 units on a scale | Standard Deviation 2203 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | 117.91 units on a scale | Standard Deviation 236.4 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | 421.90 units on a scale | Standard Deviation 700.43 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | 839.12 units on a scale | Standard Deviation 1219.16 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | 1311.99 units on a scale | Standard Deviation 1736.67 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | 2443.62 units on a scale | Standard Deviation 2701.93 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | 1077.41 units on a scale | Standard Deviation 2543.43 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | 184.76 units on a scale | Standard Deviation 1317.14 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 10 | 1539.51 units on a scale | Standard Deviation 3768.28 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | 2053.03 units on a scale | Standard Deviation 4745.53 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | 584.69 units on a scale | Standard Deviation 1864.04 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | 16.24 units on a scale | Standard Deviation 507.7 |
| Adalimumab | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | -280.67 units on a scale | Standard Deviation 1925.43 |
| Adalimumab | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | -331.79 units on a scale | Standard Deviation 2727.74 |
| Adalimumab | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | -211.66 units on a scale | Standard Deviation 1178.51 |
| Adalimumab | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 10 | -337.47 units on a scale | Standard Deviation 3478.31 |
| Adalimumab | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | -82.12 units on a scale | Standard Deviation 436.48 |
| Adalimumab | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | -242.83 units on a scale | Standard Deviation 4111.62 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | -430.41 units on a scale | Standard Deviation 1471.1 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | -268.25 units on a scale | Standard Deviation 906.61 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | -803.67 units on a scale | Standard Deviation 3548.72 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | -531.80 units on a scale | Standard Deviation 2095.5 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 10 | -642.56 units on a scale | Standard Deviation 2805.9 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | -97.56 units on a scale | Standard Deviation 362.62 |
Secondary
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET
SF-36 is a standardized survey evaluating 8 domains (of 2 components \[C\]; physical \[Ph\] and mental \[Mn\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Time frame: Baseline, Week 12, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | 3.78 units on a scale | Standard Deviation 7.4 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | 4.78 units on a scale | Standard Deviation 7.89 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 6.36 units on a scale | Standard Deviation 8.79 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | 3.45 units on a scale | Standard Deviation 9.84 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 3.11 units on a scale | Standard Deviation 11.59 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 4.39 units on a scale | Standard Deviation 12.06 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | 4.23 units on a scale | Standard Deviation 11.06 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 4.86 units on a scale | Standard Deviation 11.15 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 3.38 units on a scale | Standard Deviation 9.2 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | 5.23 units on a scale | Standard Deviation 10.18 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 5.52 units on a scale | Standard Deviation 8.28 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 4.34 units on a scale | Standard Deviation 10.95 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 4.65 units on a scale | Standard Deviation 10.48 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 5.12 units on a scale | Standard Deviation 12.65 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 4.54 units on a scale | Standard Deviation 11.1 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 12.71 units on a scale | Standard Deviation 1.92 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 2.75 units on a scale | Standard Deviation 16.15 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 5.25 units on a scale | Standard Deviation 9.37 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 5.28 units on a scale | Standard Deviation 8.92 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | 3.46 units on a scale | Standard Deviation 7.75 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 7.30 units on a scale | Standard Deviation 10.84 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | 6.50 units on a scale | Standard Deviation 7.44 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 7.51 units on a scale | Standard Deviation 10.73 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 7.77 units on a scale | Standard Deviation 14.09 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 7.27 units on a scale | Standard Deviation 12.82 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 8.12 units on a scale | Standard Deviation 10 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | 5.91 units on a scale | Standard Deviation 8.6 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 7.86 units on a scale | Standard Deviation 11.86 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | 7.51 units on a scale | Standard Deviation 11.2 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 6.86 units on a scale | Standard Deviation 9.49 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 3.12 units on a scale | Standard Deviation 9.92 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 6.43 units on a scale | Standard Deviation 9.13 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | 5.10 units on a scale | Standard Deviation 8.04 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | 6.40 units on a scale | Standard Deviation 9.31 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 5.49 units on a scale | Standard Deviation 9.01 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 5.01 units on a scale | Standard Deviation 10.6 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 4.01 units on a scale | Standard Deviation 9.01 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | 2.33 units on a scale | Standard Deviation 9.78 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 2.70 units on a scale | Standard Deviation 12.67 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 7.18 units on a scale | Standard Deviation 9 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 4.90 units on a scale | Standard Deviation 8.72 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 3.50 units on a scale | Standard Deviation 9.18 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | 3.59 units on a scale | Standard Deviation 8.51 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 2.07 units on a scale | Standard Deviation 11.61 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | 4.96 units on a scale | Standard Deviation 8.33 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 5.37 units on a scale | Standard Deviation 9.19 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 7.40 units on a scale | Standard Deviation 9.78 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 10.31 units on a scale | Standard Deviation 1.52 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 3.87 units on a scale | Standard Deviation 9.31 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | 3.50 units on a scale | Standard Deviation 7.24 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | 6.05 units on a scale | Standard Deviation 10.51 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 3.11 units on a scale | Standard Deviation 13.72 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 3.65 units on a scale | Standard Deviation 11.91 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 7.64 units on a scale | Standard Deviation 7.38 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 8.46 units on a scale | Standard Deviation 12.53 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | 5.10 units on a scale | Standard Deviation 8.7 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | 2.51 units on a scale | Standard Deviation 7.65 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 6.87 units on a scale | Standard Deviation 9.85 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 5.44 units on a scale | Standard Deviation 7.33 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 8.93 units on a scale | Standard Deviation 9.7 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | 5.45 units on a scale | Standard Deviation 11.77 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 6.13 units on a scale | Standard Deviation 11.63 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 10.03 units on a scale | Standard Deviation 1.5 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 6.12 units on a scale | Standard Deviation 11.54 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 9.89 units on a scale | Standard Deviation 9.07 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | 7.72 units on a scale | Standard Deviation 9.12 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 9.15 units on a scale | Standard Deviation 8.4 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 4.70 units on a scale | Standard Deviation 10.37 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 6.64 units on a scale | Standard Deviation 9.87 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 5.37 units on a scale | Standard Deviation 13.1 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 5.53 units on a scale | Standard Deviation 13.45 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | 6.21 units on a scale | Standard Deviation 7.48 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | 7.29 units on a scale | Standard Deviation 7.95 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | 5.64 units on a scale | Standard Deviation 7.18 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 6.21 units on a scale | Standard Deviation 11.51 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 6.75 units on a scale | Standard Deviation 8.31 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 6.64 units on a scale | Standard Deviation 10.6 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 5.76 units on a scale | Standard Deviation 8.93 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 7.18 units on a scale | Standard Deviation 9.19 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | 4.57 units on a scale | Standard Deviation 11.28 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 7.68 units on a scale | Standard Deviation 8.32 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 8.90 units on a scale | Standard Deviation 9.85 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 8.98 units on a scale | Standard Deviation 9.94 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 12.06 units on a scale | Standard Deviation 9.21 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | 6.00 units on a scale | Standard Deviation 8.92 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 9.75 units on a scale | Standard Deviation 11.53 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 11.91 units on a scale | Standard Deviation 1.58 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 5.86 units on a scale | Standard Deviation 11.48 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 6.08 units on a scale | Standard Deviation 8.39 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | 10.01 units on a scale | Standard Deviation 9.31 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | 5.38 units on a scale | Standard Deviation 9.61 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 9.60 units on a scale | Standard Deviation 9.63 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 10.02 units on a scale | Standard Deviation 11.19 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 13.19 units on a scale | Standard Deviation 9.64 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | 7.37 units on a scale | Standard Deviation 9.15 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 9.20 units on a scale | Standard Deviation 10.89 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 7.93 units on a scale | Standard Deviation 12.46 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 7.07 units on a scale | Standard Deviation 14.41 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | 10.77 units on a scale | Standard Deviation 9.8 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | 6.25 units on a scale | Standard Deviation 10.22 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 8.17 units on a scale | Standard Deviation 12.01 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | 4.23 units on a scale | Standard Deviation 12.36 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 9.37 units on a scale | Standard Deviation 9.78 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 5.42 units on a scale | Standard Deviation 14.02 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 9.71 units on a scale | Standard Deviation 11.64 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | 6.63 units on a scale | Standard Deviation 9.64 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 5.94 units on a scale | Standard Deviation 14.19 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 7.55 units on a scale | Standard Deviation 11.09 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | 5.44 units on a scale | Standard Deviation 9.03 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 9.67 units on a scale | Standard Deviation 11.58 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 13.88 units on a scale | Standard Deviation 1.89 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 10.75 units on a scale | Standard Deviation 12.76 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 13.73 units on a scale | Standard Deviation 10.95 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 4.55 units on a scale | Standard Deviation 13.22 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | 6.12 units on a scale | Standard Deviation 13.57 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | 10.58 units on a scale | Standard Deviation 10.83 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 6.61 units on a scale | Standard Deviation 13.46 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 8.18 units on a scale | Standard Deviation 10.11 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 13.13 units on a scale | Standard Deviation 10.51 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | 10.70 units on a scale | Standard Deviation 9.83 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 5.91 units on a scale | Standard Deviation 8.98 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 7.48 units on a scale | Standard Deviation 10.42 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | 7.59 units on a scale | Standard Deviation 11.64 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | 3.47 units on a scale | Standard Deviation 8.25 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 6.82 units on a scale | Standard Deviation 15.75 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 5.05 units on a scale | Standard Deviation 8.09 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 14.01 units on a scale | Standard Deviation 2.09 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 8.12 units on a scale | Standard Deviation 10.7 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | 4.05 units on a scale | Standard Deviation 9.96 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 3.43 units on a scale | Standard Deviation 12.06 |
| Adalimumab | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 10.51 units on a scale | Standard Deviation 9.55 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 7.77 units on a scale | Standard Deviation 13.47 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 9.13 units on a scale | Standard Deviation 10.13 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 7.21 units on a scale | Standard Deviation 9.8 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 9.19 units on a scale | Standard Deviation 12.03 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 5.14 units on a scale | Standard Deviation 12.41 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | 5.77 units on a scale | Standard Deviation 8.35 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | 8.67 units on a scale | Standard Deviation 12.28 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | 6.32 units on a scale | Standard Deviation 9.21 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 7.77 units on a scale | Standard Deviation 16.06 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | NA units on a scale | — |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 6.63 units on a scale | Standard Deviation 7.01 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | 2.43 units on a scale | Standard Deviation 9.05 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 6.61 units on a scale | Standard Deviation 7.95 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | 6.00 units on a scale | Standard Deviation 10.91 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 6.23 units on a scale | Standard Deviation 7.24 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | 6.17 units on a scale | Standard Deviation 13.85 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | 5.46 units on a scale | Standard Deviation 6.54 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 12.71 units on a scale | Standard Deviation 1.87 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 7.80 units on a scale | Standard Deviation 10.1 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | 3.73 units on a scale | Standard Deviation 10 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 10.36 units on a scale | Standard Deviation 10.15 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | 3.41 units on a scale | Standard Deviation 6.49 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 6.22 units on a scale | Standard Deviation 16.32 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | 4.91 units on a scale | Standard Deviation 8.51 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 5.63 units on a scale | Standard Deviation 10.81 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | 4.84 units on a scale | Standard Deviation 9.88 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | 7.03 units on a scale | Standard Deviation 12.02 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | 6.18 units on a scale | Standard Deviation 6.21 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | 1.83 units on a scale | Standard Deviation 9.89 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | 6.74 units on a scale | Standard Deviation 9.72 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 10.23 units on a scale | Standard Deviation 9.69 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=24,15,29,15,43,55,52,0,40,20,24) | 9.37 units on a scale | Standard Deviation 7.92 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=24,15,29,15,43,55,51,0,40,20,24) | 6.87 units on a scale | Standard Deviation 10.73 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=24,15,29,15,43,55,52,0,40,20,24) | 8.98 units on a scale | Standard Deviation 9.3 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=24,15,29,15,43,55,51,0,40,20,24) | 8.73 units on a scale | Standard Deviation 9.45 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=44,0,46,0,45,57,52,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=44,0,46,0,45,57,52,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn (n=24,15,29,15,43,55,52,0,40,20,24) | 7.80 units on a scale | Standard Deviation 11.06 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=24,15,29,15,43,55,51,0,40,20,24) | 7.91 units on a scale | Standard Deviation 10.04 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=24,15,29,15,43,55,52,0,40,20,24) | 7.45 units on a scale | Standard Deviation 12.18 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=44,0,46,0,45,57,53,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=24,15,29,15,43,55,52,0,40,20,24) | 7.86 units on a scale | Standard Deviation 10.14 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=24,15,29,15,43,55,52,0,40,20,24) | 11.11 units on a scale | Standard Deviation 10.03 |
Secondary
Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 mg/L to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | -5.08 mg/L | Standard Deviation 21.05 |
| CP-690,550 1 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | -5.62 mg/L | Standard Deviation 19.89 |
| CP-690,550 1 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | -5.35 mg/L | Standard Deviation 15.23 |
| CP-690,550 1 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | -8.39 mg/L | Standard Deviation 13.06 |
| CP-690,550 1 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | -4.19 mg/L | Standard Deviation 14.9 |
| CP-690,550 1 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | -7.41 mg/L | Standard Deviation 17.95 |
| CP-690,550 1 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | -5.59 mg/L | Standard Deviation 12 |
| CP-690,550 1 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | -7.04 mg/L | Standard Deviation 17.82 |
| CP-690,550 1 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | -0.88 mg/L | Standard Deviation 34.23 |
| CP-690,550 3 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA mg/L | — |
| CP-690,550 3 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | -18.87 mg/L | Standard Deviation 31.77 |
| CP-690,550 3 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | -25.36 mg/L | Standard Deviation 28.34 |
| CP-690,550 3 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA mg/L | — |
| CP-690,550 3 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | NA mg/L | — |
| CP-690,550 3 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | -21.54 mg/L | Standard Deviation 34.58 |
| CP-690,550 3 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA mg/L | — |
| CP-690,550 3 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA mg/L | — |
| CP-690,550 3 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA mg/L | — |
| CP-690,550 5 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | -3.61 mg/L | Standard Deviation 29.34 |
| CP-690,550 5 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | -5.33 mg/L | Standard Deviation 17.1 |
| CP-690,550 5 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | -4.59 mg/L | Standard Deviation 11.53 |
| CP-690,550 5 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | -2.25 mg/L | Standard Deviation 20.44 |
| CP-690,550 5 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | -7.46 mg/L | Standard Deviation 15.68 |
| CP-690,550 5 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | -6.79 mg/L | Standard Deviation 18.44 |
| CP-690,550 5 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | -7.97 mg/L | Standard Deviation 16.96 |
| CP-690,550 5 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | -4.63 mg/L | Standard Deviation 17.15 |
| CP-690,550 5 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | -6.84 mg/L | Standard Deviation 13.87 |
| CP-690,550 10 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | -17.13 mg/L | Standard Deviation 26.1 |
| CP-690,550 10 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA mg/L | — |
| CP-690,550 10 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA mg/L | — |
| CP-690,550 10 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA mg/L | — |
| CP-690,550 10 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | -14.73 mg/L | Standard Deviation 25.04 |
| CP-690,550 10 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA mg/L | — |
| CP-690,550 10 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | -12.89 mg/L | Standard Deviation 23.41 |
| CP-690,550 10 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA mg/L | — |
| CP-690,550 10 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | NA mg/L | — |
| CP-690,550 15 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | -15.57 mg/L | Standard Deviation 28.2 |
| CP-690,550 15 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | -19.21 mg/L | Standard Deviation 28.52 |
| CP-690,550 15 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | -17.80 mg/L | Standard Deviation 30.17 |
| CP-690,550 15 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | -16.47 mg/L | Standard Deviation 27.76 |
| CP-690,550 15 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | -19.43 mg/L | Standard Deviation 29.21 |
| CP-690,550 15 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | -18.20 mg/L | Standard Deviation 25.77 |
| CP-690,550 15 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | -17.68 mg/L | Standard Deviation 26.27 |
| CP-690,550 15 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | -15.67 mg/L | Standard Deviation 27.63 |
| CP-690,550 15 mg | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | -15.32 mg/L | Standard Deviation 25.84 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | -13.09 mg/L | Standard Deviation 18.13 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | -12.54 mg/L | Standard Deviation 19.07 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | -13.88 mg/L | Standard Deviation 15.71 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | -10.50 mg/L | Standard Deviation 19.53 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | -13.28 mg/L | Standard Deviation 16.77 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | -14.46 mg/L | Standard Deviation 17.28 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | -12.70 mg/L | Standard Deviation 16.84 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | -11.77 mg/L | Standard Deviation 16.87 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | -14.08 mg/L | Standard Deviation 17.85 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | -18.12 mg/L | Standard Deviation 33.97 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | -17.78 mg/L | Standard Deviation 31.72 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | -19.68 mg/L | Standard Deviation 33.41 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | -16.29 mg/L | Standard Deviation 32.42 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | -20.43 mg/L | Standard Deviation 33.71 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | -18.41 mg/L | Standard Deviation 33.75 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | -17.12 mg/L | Standard Deviation 29.92 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | -17.67 mg/L | Standard Deviation 35.23 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | -15.53 mg/L | Standard Deviation 28.18 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | -7.29 mg/L | Standard Deviation 23.48 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | NA mg/L | — |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | -7.65 mg/L | Standard Deviation 22.81 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | -6.73 mg/L | Standard Deviation 19.31 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | -5.64 mg/L | Standard Deviation 21.52 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | -10.82 mg/L | Standard Deviation 17.7 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | -7.02 mg/L | Standard Deviation 21.73 |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | NA mg/L | — |
| Adalimumab | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | -15.09 mg/L | Standard Deviation 25.59 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | -16.00 mg/L | Standard Deviation 25.94 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | -16.19 mg/L | Standard Deviation 25.25 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 1.68 mg/L | Standard Deviation 25.86 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 6.60 mg/L | Standard Deviation 26.07 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 4.13 mg/L | Standard Deviation 24.29 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | -6.87 mg/L | Standard Deviation 17.01 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | 3.68 mg/L | Standard Deviation 30.09 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 13.27 mg/L | Standard Deviation 45.76 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 7.63 mg/L | Standard Deviation 20.15 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | -4.18 mg/L | Standard Deviation 21.73 |
| Placebo | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | -0.54 mg/L | Standard Deviation 19.76 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | -19.77 mg/L | Standard Deviation 30.92 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | -19.68 mg/L | Standard Deviation 30.1 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | -18.29 mg/L | Standard Deviation 27.14 |
Secondary
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \> 3.2 to 5.1 implied moderate to high disease activity, and \< 2.6 = remission.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | -1.04 units on a scale | Standard Deviation 1.26 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | -1.27 units on a scale | Standard Deviation 1.22 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | -0.75 units on a scale | Standard Deviation 1.05 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | -1.09 units on a scale | Standard Deviation 1.07 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | -0.55 units on a scale | Standard Deviation 0.91 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | -1.24 units on a scale | Standard Deviation 1.13 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | -1.83 units on a scale | Standard Deviation 1.25 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | -1.17 units on a scale | Standard Deviation 1 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | -1.52 units on a scale | Standard Deviation 1.39 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | -1.33 units on a scale | Standard Deviation 1.36 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | -1.61 units on a scale | Standard Deviation 1.23 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | -1.36 units on a scale | Standard Deviation 1.07 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | NA units on a scale | — |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | -1.96 units on a scale | Standard Deviation 1.18 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | -1.17 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | -1.36 units on a scale | Standard Deviation 1.2 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | -1.80 units on a scale | Standard Deviation 1.19 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | -1.43 units on a scale | Standard Deviation 1.13 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | -1.34 units on a scale | Standard Deviation 1.23 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | -1.31 units on a scale | Standard Deviation 1.18 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | -2.08 units on a scale | Standard Deviation 1.34 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | -0.77 units on a scale | Standard Deviation 0.95 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | -1.25 units on a scale | Standard Deviation 1.13 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | -1.28 units on a scale | Standard Deviation 1.02 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | -0.95 units on a scale | Standard Deviation 0.96 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | NA units on a scale | — |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | -1.50 units on a scale | Standard Deviation 0.95 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | -1.60 units on a scale | Standard Deviation 1.09 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | -0.95 units on a scale | Standard Deviation 0.85 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | -1.87 units on a scale | Standard Deviation 1.29 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | -2.05 units on a scale | Standard Deviation 1.33 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | -1.96 units on a scale | Standard Deviation 1.33 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | -1.87 units on a scale | Standard Deviation 1.18 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | -1.26 units on a scale | Standard Deviation 0.95 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | -2.07 units on a scale | Standard Deviation 1.24 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | -2.40 units on a scale | Standard Deviation 1.12 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | -1.28 units on a scale | Standard Deviation 0.99 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | -1.75 units on a scale | Standard Deviation 1.23 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | -1.99 units on a scale | Standard Deviation 1.25 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | -2.05 units on a scale | Standard Deviation 1.13 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | -2.29 units on a scale | Standard Deviation 1.25 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | -2.41 units on a scale | Standard Deviation 1.2 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | -2.54 units on a scale | Standard Deviation 1.17 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | -2.51 units on a scale | Standard Deviation 1.2 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | -2.49 units on a scale | Standard Deviation 1.31 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | -1.72 units on a scale | Standard Deviation 1.27 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | -2.41 units on a scale | Standard Deviation 1.25 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | -2.62 units on a scale | Standard Deviation 1.47 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | -2.14 units on a scale | Standard Deviation 1.44 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | -2.52 units on a scale | Standard Deviation 1.4 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | -1.14 units on a scale | Standard Deviation 1.03 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | -2.37 units on a scale | Standard Deviation 1.26 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | -2.31 units on a scale | Standard Deviation 1.44 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | -0.91 units on a scale | Standard Deviation 1.13 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | -1.18 units on a scale | Standard Deviation 1.12 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | -1.23 units on a scale | Standard Deviation 1.24 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | -1.12 units on a scale | Standard Deviation 1.31 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | -0.73 units on a scale | Standard Deviation 0.9 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | -1.08 units on a scale | Standard Deviation 1.23 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | -2.01 units on a scale | Standard Deviation 1.07 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | -2.01 units on a scale | Standard Deviation 1.12 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | -1.94 units on a scale | Standard Deviation 1.29 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | -0.80 units on a scale | Standard Deviation 1.33 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | -0.84 units on a scale | Standard Deviation 1.14 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | -0.73 units on a scale | Standard Deviation 1.17 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | -1.73 units on a scale | Standard Deviation 1.19 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | -0.63 units on a scale | Standard Deviation 0.97 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | -1.71 units on a scale | Standard Deviation 1.26 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | -1.77 units on a scale | Standard Deviation 0.91 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | -0.37 units on a scale | Standard Deviation 0.8 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | -0.76 units on a scale | Standard Deviation 1.21 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=26,16,29,16,43,52,52,0,43,18,24) | -1.76 units on a scale | Standard Deviation 1.27 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,43,56,53,48,0,52,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,44,54,51,0,43,20,24) | -1.54 units on a scale | Standard Deviation 1.16 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,28,15,39,54,52,0,39,20,23) | -2.04 units on a scale | Standard Deviation 1.43 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=47,0,48,0,43,56,55,47,0,51,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,43,53,52,44,0,44,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,44,56,52,44,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,46,58,57,51,0,55,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,45,54,53,46,0,44,0) | NA units on a scale | — |
Secondary
Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR \[mm/hour\] and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) \<= 3.2 implies low disease activity and \> 3.2 to 5.1 implies moderate to high disease activity, and \< 2.6 = remission.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | -1.16 units on a scale | Standard Deviation 1.44 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | -1.33 units on a scale | Standard Deviation 1.46 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | -0.82 units on a scale | Standard Deviation 1.15 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | -1.30 units on a scale | Standard Deviation 1.35 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | -0.56 units on a scale | Standard Deviation 1.01 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | -1.37 units on a scale | Standard Deviation 1.29 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | -1.97 units on a scale | Standard Deviation 1.42 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | -1.26 units on a scale | Standard Deviation 1.19 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | -1.54 units on a scale | Standard Deviation 1.58 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | -1.58 units on a scale | Standard Deviation 1.58 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | -1.58 units on a scale | Standard Deviation 1.34 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | -1.51 units on a scale | Standard Deviation 1.08 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | NA units on a scale | — |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | -2.02 units on a scale | Standard Deviation 1.37 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | -1.29 units on a scale | Standard Deviation 1.27 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | -1.52 units on a scale | Standard Deviation 1.43 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | -2.06 units on a scale | Standard Deviation 1.38 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | -1.48 units on a scale | Standard Deviation 1.26 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | -1.40 units on a scale | Standard Deviation 1.36 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | -1.41 units on a scale | Standard Deviation 1.42 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | -2.38 units on a scale | Standard Deviation 1.5 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | -0.81 units on a scale | Standard Deviation 1.01 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | -1.47 units on a scale | Standard Deviation 1.15 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | -1.51 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | -1.18 units on a scale | Standard Deviation 0.93 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | NA units on a scale | — |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | -1.67 units on a scale | Standard Deviation 0.97 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | -1.84 units on a scale | Standard Deviation 0.99 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | -0.98 units on a scale | Standard Deviation 0.88 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | -2.16 units on a scale | Standard Deviation 1.32 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | -2.30 units on a scale | Standard Deviation 1.29 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | -2.02 units on a scale | Standard Deviation 1.34 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | -2.05 units on a scale | Standard Deviation 1.28 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | -1.31 units on a scale | Standard Deviation 0.89 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | -2.24 units on a scale | Standard Deviation 1.31 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | -2.55 units on a scale | Standard Deviation 1.3 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | -1.32 units on a scale | Standard Deviation 1.05 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | -1.81 units on a scale | Standard Deviation 1.32 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | -2.16 units on a scale | Standard Deviation 1.4 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | -2.28 units on a scale | Standard Deviation 1.21 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | -2.55 units on a scale | Standard Deviation 1.46 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | -2.63 units on a scale | Standard Deviation 1.37 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | -2.68 units on a scale | Standard Deviation 1.29 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | -2.79 units on a scale | Standard Deviation 1.37 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | -2.83 units on a scale | Standard Deviation 1.53 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | -1.95 units on a scale | Standard Deviation 1.5 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | -2.78 units on a scale | Standard Deviation 1.42 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | -2.78 units on a scale | Standard Deviation 1.52 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | -2.39 units on a scale | Standard Deviation 1.58 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | -2.88 units on a scale | Standard Deviation 1.46 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | -1.27 units on a scale | Standard Deviation 1.28 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | -2.65 units on a scale | Standard Deviation 1.41 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | -2.63 units on a scale | Standard Deviation 1.56 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | -1.14 units on a scale | Standard Deviation 1.26 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | -1.35 units on a scale | Standard Deviation 1.29 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | -1.37 units on a scale | Standard Deviation 1.31 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | -1.29 units on a scale | Standard Deviation 1.37 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | -0.82 units on a scale | Standard Deviation 1 |
| Adalimumab | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | -1.29 units on a scale | Standard Deviation 1.33 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | -2.33 units on a scale | Standard Deviation 1.28 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | -2.29 units on a scale | Standard Deviation 1.15 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | -2.08 units on a scale | Standard Deviation 1.32 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | -1.17 units on a scale | Standard Deviation 1.4 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | -1.00 units on a scale | Standard Deviation 1.19 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | -0.97 units on a scale | Standard Deviation 1.22 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | -1.97 units on a scale | Standard Deviation 1.28 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | -0.87 units on a scale | Standard Deviation 1.09 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | -1.99 units on a scale | Standard Deviation 1.27 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | -2.03 units on a scale | Standard Deviation 1.11 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | -0.53 units on a scale | Standard Deviation 1.02 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | -1.00 units on a scale | Standard Deviation 1.29 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=24,15,28,15,43,49,50,0,42,19,22) | -1.91 units on a scale | Standard Deviation 1.03 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=46,0,45,0,44,55,51,45,0,50,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=25,15,29,16,43,53,52,0,41,20,22) | -1.63 units on a scale | Standard Deviation 0.93 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=22,15,28,14,41,52,49,0,37,20,21) | -2.30 units on a scale | Standard Deviation 1.24 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=43,0,46,0,43,56,52,46,0,49,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=40,0,44,0,44,54,51,44,0,43,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 10 (n=42,0,47,0,43,54,51,42,0,42,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=48,0,49,0,45,58,52,50,0,53,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=43,0,46,0,45,54,52,45,0,42,0) | NA units on a scale | — |
Secondary
Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline, Week 12, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.15 units on a scale | Standard Deviation 0.36 |
| CP-690,550 1 mg | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.23 units on a scale | Standard Deviation 0.33 |
| CP-690,550 3 mg | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.15 units on a scale | Standard Deviation 0.34 |
| CP-690,550 5 mg | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.14 units on a scale | Standard Deviation 0.33 |
| CP-690,550 5 mg | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.23 units on a scale | Standard Deviation 0.28 |
| CP-690,550 10 mg | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.36 units on a scale | Standard Deviation 0.36 |
| CP-690,550 10 mg | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | NA units on a scale | — |
| CP-690,550 15 mg | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.21 units on a scale | Standard Deviation 0.33 |
| CP-690,550 15 mg | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.23 units on a scale | Standard Deviation 0.32 |
| Adalimumab | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.27 units on a scale | Standard Deviation 0.31 |
| Adalimumab | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.27 units on a scale | Standard Deviation 0.29 |
| Placebo | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.32 units on a scale | Standard Deviation 0.4 |
| Placebo | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.30 units on a scale | Standard Deviation 0.37 |
| Adalimumab | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.16 units on a scale | Standard Deviation 0.33 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.24 units on a scale | Standard Deviation 0.36 |
| Placebo | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.11 units on a scale | Standard Deviation 0.37 |
| Placebo | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.21 units on a scale | Standard Deviation 0.28 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.32 units on a scale | Standard Deviation 0.28 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | NA units on a scale | — |
Secondary
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | -0.30 units on a scale | Standard Deviation 0.51 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | -0.58 units on a scale | Standard Deviation 0.67 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | -0.14 units on a scale | Standard Deviation 0.62 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | -0.34 units on a scale | Standard Deviation 0.56 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | -0.13 units on a scale | Standard Deviation 0.41 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | -0.36 units on a scale | Standard Deviation 0.51 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | -0.54 units on a scale | Standard Deviation 0.63 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | -0.31 units on a scale | Standard Deviation 0.48 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | -0.51 units on a scale | Standard Deviation 0.73 |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | -0.26 units on a scale | Standard Deviation 0.62 |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | -0.35 units on a scale | Standard Deviation 0.57 |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | -0.29 units on a scale | Standard Deviation 0.58 |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | NA units on a scale | — |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | -0.49 units on a scale | Standard Deviation 0.56 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | -0.30 units on a scale | Standard Deviation 0.53 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | -0.42 units on a scale | Standard Deviation 0.63 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | -0.46 units on a scale | Standard Deviation 0.55 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | -0.34 units on a scale | Standard Deviation 0.52 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | -0.40 units on a scale | Standard Deviation 0.63 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | -0.28 units on a scale | Standard Deviation 0.6 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | -0.53 units on a scale | Standard Deviation 0.59 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | -0.25 units on a scale | Standard Deviation 0.44 |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | -0.51 units on a scale | Standard Deviation 0.69 |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | -0.56 units on a scale | Standard Deviation 0.75 |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | -0.31 units on a scale | Standard Deviation 0.54 |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | NA units on a scale | — |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | -0.30 units on a scale | Standard Deviation 0.56 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | -0.37 units on a scale | Standard Deviation 0.61 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | -0.16 units on a scale | Standard Deviation 0.47 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | -0.43 units on a scale | Standard Deviation 0.65 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | -0.47 units on a scale | Standard Deviation 0.66 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | -0.42 units on a scale | Standard Deviation 0.66 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | -0.45 units on a scale | Standard Deviation 0.68 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | -0.26 units on a scale | Standard Deviation 0.51 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | -0.45 units on a scale | Standard Deviation 0.75 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | -0.59 units on a scale | Standard Deviation 0.56 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | -0.27 units on a scale | Standard Deviation 0.37 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | -0.44 units on a scale | Standard Deviation 0.6 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | -0.49 units on a scale | Standard Deviation 0.49 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | -0.54 units on a scale | Standard Deviation 0.6 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | -0.63 units on a scale | Standard Deviation 0.58 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | -0.60 units on a scale | Standard Deviation 0.68 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | -0.62 units on a scale | Standard Deviation 0.67 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | -0.63 units on a scale | Standard Deviation 0.66 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | -0.86 units on a scale | Standard Deviation 0.67 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | -0.55 units on a scale | Standard Deviation 0.61 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | -0.78 units on a scale | Standard Deviation 0.67 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | -0.82 units on a scale | Standard Deviation 0.67 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | -0.68 units on a scale | Standard Deviation 0.73 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | -0.87 units on a scale | Standard Deviation 0.68 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | -0.36 units on a scale | Standard Deviation 0.63 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | -0.81 units on a scale | Standard Deviation 0.71 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | -0.73 units on a scale | Standard Deviation 0.66 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | -0.14 units on a scale | Standard Deviation 0.68 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | -0.32 units on a scale | Standard Deviation 0.59 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | -0.29 units on a scale | Standard Deviation 0.66 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | -0.25 units on a scale | Standard Deviation 0.63 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | -0.21 units on a scale | Standard Deviation 0.44 |
| Adalimumab | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | -0.32 units on a scale | Standard Deviation 0.62 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | -0.50 units on a scale | Standard Deviation 0.66 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | -0.49 units on a scale | Standard Deviation 0.56 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | -0.53 units on a scale | Standard Deviation 0.66 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | -0.24 units on a scale | Standard Deviation 0.52 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | -0.24 units on a scale | Standard Deviation 0.51 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | -0.17 units on a scale | Standard Deviation 0.46 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | -0.33 units on a scale | Standard Deviation 0.52 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | -0.09 units on a scale | Standard Deviation 0.67 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | -0.41 units on a scale | Standard Deviation 0.6 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | -0.28 units on a scale | Standard Deviation 0.39 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | -0.04 units on a scale | Standard Deviation 0.4 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | -0.24 units on a scale | Standard Deviation 0.52 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,15,45,52,52,0,44,19,24) | -0.59 units on a scale | Standard Deviation 0.62 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,56,55,49,0,52,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,46,55,54,0,43,20,24) | -0.55 units on a scale | Standard Deviation 0.65 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,54,52,0,40,20,23) | -0.72 units on a scale | Standard Deviation 0.55 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,44,58,54,48,0,51,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,56,54,46,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,56,53,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,59,57,53,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,46,56,54,47,0,45,0) | NA units on a scale | — |
Secondary
Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -11.61 mm | Standard Deviation 31.51 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -9.83 mm | Standard Deviation 29.65 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | -6.78 mm | Standard Deviation 30.17 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -11.68 mm | Standard Deviation 29.48 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | -5.98 mm | Standard Deviation 25.77 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -13.98 mm | Standard Deviation 27.46 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -19.00 mm | Standard Deviation 33.3 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | -11.42 mm | Standard Deviation 28.68 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -14.33 mm | Standard Deviation 28.92 |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -21.56 mm | Standard Deviation 35.86 |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -22.19 mm | Standard Deviation 29.73 |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -17.29 mm | Standard Deviation 29.71 |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -19.66 mm | Standard Deviation 25 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | -19.04 mm | Standard Deviation 19.15 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -16.04 mm | Standard Deviation 22.11 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -18.73 mm | Standard Deviation 25.91 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -17.39 mm | Standard Deviation 22.24 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -18.77 mm | Standard Deviation 20.45 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | -17.23 mm | Standard Deviation 23.04 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -23.69 mm | Standard Deviation 24.12 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | -16.00 mm | Standard Deviation 17.89 |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -29.50 mm | Standard Deviation 25.8 |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -36.00 mm | Standard Deviation 18.57 |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -21.00 mm | Standard Deviation 22.29 |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | NA mm | — |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | -25.04 mm | Standard Deviation 22.63 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -30.02 mm | Standard Deviation 25.59 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | -16.33 mm | Standard Deviation 20.7 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -31.24 mm | Standard Deviation 24.72 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -32.54 mm | Standard Deviation 23.55 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -31.67 mm | Standard Deviation 20.98 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -29.30 mm | Standard Deviation 26.46 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | -20.28 mm | Standard Deviation 21.33 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -32.84 mm | Standard Deviation 25.37 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -34.77 mm | Standard Deviation 25.6 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | -19.33 mm | Standard Deviation 22.5 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | -28.60 mm | Standard Deviation 24.09 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | -28.80 mm | Standard Deviation 22.13 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -29.07 mm | Standard Deviation 23.84 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -34.47 mm | Standard Deviation 25.63 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -33.77 mm | Standard Deviation 27.27 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -34.66 mm | Standard Deviation 23.72 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -39.69 mm | Standard Deviation 22.62 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -38.33 mm | Standard Deviation 30.31 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | -32.41 mm | Standard Deviation 29.39 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -38.94 mm | Standard Deviation 29.33 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -37.83 mm | Standard Deviation 28.84 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | -33.50 mm | Standard Deviation 29.39 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -39.55 mm | Standard Deviation 31.04 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | -23.11 mm | Standard Deviation 29.72 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -35.31 mm | Standard Deviation 31.92 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -35.83 mm | Standard Deviation 30.52 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | -16.96 mm | Standard Deviation 28.05 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | NA mm | — |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | NA mm | — |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -23.15 mm | Standard Deviation 27.7 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -16.80 mm | Standard Deviation 26.12 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | -18.35 mm | Standard Deviation 26.77 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | NA mm | — |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | -16.36 mm | Standard Deviation 23.18 |
| Adalimumab | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -20.83 mm | Standard Deviation 27.49 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -35.09 mm | Standard Deviation 27.62 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -36.37 mm | Standard Deviation 22.95 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -31.48 mm | Standard Deviation 28.9 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -13.65 mm | Standard Deviation 24.4 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -10.28 mm | Standard Deviation 23.46 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | -9.08 mm | Standard Deviation 22.68 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -16.05 mm | Standard Deviation 24.3 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | -7.89 mm | Standard Deviation 23.27 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -22.25 mm | Standard Deviation 25.21 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -15.58 mm | Standard Deviation 25.51 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | -5.14 mm | Standard Deviation 25.64 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -12.63 mm | Standard Deviation 21.45 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -29.92 mm | Standard Deviation 23.24 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,54,49,0,53,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -33.40 mm | Standard Deviation 25.97 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -31.63 mm | Standard Deviation 24.22 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,54,48,0,52,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,51,0,48,60,56,53,0,57,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
Secondary
Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Participants answered: Considering all the ways your arthritis affects you, how are you feeling today? Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -15.05 mm | Standard Deviation 29.31 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -12.96 mm | Standard Deviation 26.46 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -6.62 mm | Standard Deviation 28.2 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -13.79 mm | Standard Deviation 27.05 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | -5.72 mm | Standard Deviation 22.55 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -14.70 mm | Standard Deviation 26.43 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -19.81 mm | Standard Deviation 29.62 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -13.58 mm | Standard Deviation 29.19 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | -16.15 mm | Standard Deviation 30.54 |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -21.19 mm | Standard Deviation 33.96 |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | -19.69 mm | Standard Deviation 31.12 |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -15.65 mm | Standard Deviation 29.98 |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | -20.38 mm | Standard Deviation 23.79 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -15.51 mm | Standard Deviation 22.14 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -16.96 mm | Standard Deviation 22.92 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -20.60 mm | Standard Deviation 24.26 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -16.21 mm | Standard Deviation 21.93 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -16.27 mm | Standard Deviation 21.81 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -17.77 mm | Standard Deviation 25.31 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -22.72 mm | Standard Deviation 25.1 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | -11.27 mm | Standard Deviation 18.57 |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | -21.00 mm | Standard Deviation 17.74 |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -27.93 mm | Standard Deviation 15.08 |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -19.35 mm | Standard Deviation 22.34 |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -28.89 mm | Standard Deviation 24.62 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -32.91 mm | Standard Deviation 28.68 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | -16.33 mm | Standard Deviation 26.14 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -34.17 mm | Standard Deviation 25.62 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -37.33 mm | Standard Deviation 25.23 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | -34.73 mm | Standard Deviation 24.52 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -32.93 mm | Standard Deviation 28.11 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -23.15 mm | Standard Deviation 24.65 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -34.72 mm | Standard Deviation 26.19 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -33.21 mm | Standard Deviation 27.96 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | -21.48 mm | Standard Deviation 25.18 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -26.52 mm | Standard Deviation 25.06 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -28.39 mm | Standard Deviation 25.53 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -28.18 mm | Standard Deviation 26.81 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -33.09 mm | Standard Deviation 28.82 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -31.50 mm | Standard Deviation 28.85 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | -32.87 mm | Standard Deviation 24.1 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -37.31 mm | Standard Deviation 25.58 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -37.46 mm | Standard Deviation 29.8 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -28.29 mm | Standard Deviation 28.34 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -39.25 mm | Standard Deviation 28.87 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -36.10 mm | Standard Deviation 29.3 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -31.49 mm | Standard Deviation 29.39 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | -37.65 mm | Standard Deviation 32.14 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | -20.75 mm | Standard Deviation 28.26 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -35.80 mm | Standard Deviation 30.9 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -34.11 mm | Standard Deviation 29.33 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -15.35 mm | Standard Deviation 25.66 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | NA mm | — |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | NA mm | — |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -19.80 mm | Standard Deviation 29.7 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -17.42 mm | Standard Deviation 26.53 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -18.69 mm | Standard Deviation 24.71 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | NA mm | — |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | -14.15 mm | Standard Deviation 25.21 |
| Adalimumab | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -18.23 mm | Standard Deviation 29.39 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | -33.64 mm | Standard Deviation 28.3 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -33.19 mm | Standard Deviation 25.1 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -29.33 mm | Standard Deviation 34.25 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -15.33 mm | Standard Deviation 22.06 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -13.24 mm | Standard Deviation 19.77 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -11.27 mm | Standard Deviation 18.6 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -16.75 mm | Standard Deviation 24.67 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -9.64 mm | Standard Deviation 22.16 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -23.35 mm | Standard Deviation 16.74 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | -18.74 mm | Standard Deviation 20.4 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | -2.84 mm | Standard Deviation 26.71 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -12.93 mm | Standard Deviation 22.3 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | -28.72 mm | Standard Deviation 22.8 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -32.44 mm | Standard Deviation 22.4 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | -36.75 mm | Standard Deviation 21.95 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
Secondary
Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | -19.33 mm | Standard Deviation 20.91 |
| CP-690,550 1 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | -24.38 mm | Standard Deviation 13.92 |
| CP-690,550 1 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | -14.24 mm | Standard Deviation 18.08 |
| CP-690,550 1 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | -21.72 mm | Standard Deviation 21.14 |
| CP-690,550 1 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | -9.83 mm | Standard Deviation 18.32 |
| CP-690,550 1 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | -20.04 mm | Standard Deviation 22.75 |
| CP-690,550 1 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | -28.11 mm | Standard Deviation 19.93 |
| CP-690,550 1 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | -22.10 mm | Standard Deviation 22.45 |
| CP-690,550 1 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | -25.44 mm | Standard Deviation 17.89 |
| CP-690,550 3 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | -24.87 mm | Standard Deviation 25.37 |
| CP-690,550 3 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | -20.38 mm | Standard Deviation 20.91 |
| CP-690,550 3 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | -18.59 mm | Standard Deviation 24.63 |
| CP-690,550 3 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | NA mm | — |
| CP-690,550 5 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | -33.29 mm | Standard Deviation 28.8 |
| CP-690,550 5 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | -21.93 mm | Standard Deviation 22.49 |
| CP-690,550 5 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | -24.57 mm | Standard Deviation 23.98 |
| CP-690,550 5 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | -31.24 mm | Standard Deviation 31.83 |
| CP-690,550 5 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | -23.31 mm | Standard Deviation 24.67 |
| CP-690,550 5 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | -25.53 mm | Standard Deviation 24 |
| CP-690,550 5 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | -26.70 mm | Standard Deviation 23.32 |
| CP-690,550 5 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | -34.78 mm | Standard Deviation 32.39 |
| CP-690,550 5 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | -14.24 mm | Standard Deviation 19.94 |
| CP-690,550 10 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | -25.19 mm | Standard Deviation 18.46 |
| CP-690,550 10 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | -33.73 mm | Standard Deviation 17.12 |
| CP-690,550 10 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | -23.59 mm | Standard Deviation 17.14 |
| CP-690,550 10 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | NA mm | — |
| CP-690,550 15 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | -26.36 mm | Standard Deviation 21.04 |
| CP-690,550 15 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | -33.48 mm | Standard Deviation 22.13 |
| CP-690,550 15 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | -14.93 mm | Standard Deviation 22.19 |
| CP-690,550 15 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | -35.84 mm | Standard Deviation 20.73 |
| CP-690,550 15 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | -35.60 mm | Standard Deviation 22.92 |
| CP-690,550 15 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | -38.55 mm | Standard Deviation 21.77 |
| CP-690,550 15 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | -32.20 mm | Standard Deviation 23.25 |
| CP-690,550 15 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | -22.24 mm | Standard Deviation 21.63 |
| CP-690,550 15 mg | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | -35.55 mm | Standard Deviation 24.81 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | -36.93 mm | Standard Deviation 23.9 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | -21.14 mm | Standard Deviation 20.74 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | -26.61 mm | Standard Deviation 23.51 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | -30.48 mm | Standard Deviation 22.57 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | -31.88 mm | Standard Deviation 21.14 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | -36.50 mm | Standard Deviation 22.13 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | -37.87 mm | Standard Deviation 21.09 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | -41.49 mm | Standard Deviation 18.87 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | -41.59 mm | Standard Deviation 18.94 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | -44.66 mm | Standard Deviation 26.28 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | -36.24 mm | Standard Deviation 26.36 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | -42.70 mm | Standard Deviation 25.85 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | -47.12 mm | Standard Deviation 23.42 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | -38.24 mm | Standard Deviation 27.62 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | -47.11 mm | Standard Deviation 23.87 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | -22.21 mm | Standard Deviation 26.01 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | -42.04 mm | Standard Deviation 24.6 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | -41.04 mm | Standard Deviation 26.88 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | -18.65 mm | Standard Deviation 23.07 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | NA mm | — |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | NA mm | — |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | -25.74 mm | Standard Deviation 23.17 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | -23.31 mm | Standard Deviation 24.37 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | -23.44 mm | Standard Deviation 21.38 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | NA mm | — |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | -15.19 mm | Standard Deviation 19.07 |
| Adalimumab | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | -24.45 mm | Standard Deviation 21.7 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | -36.86 mm | Standard Deviation 20.07 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | -37.28 mm | Standard Deviation 19.72 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | -35.83 mm | Standard Deviation 22.06 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | -19.48 mm | Standard Deviation 27.84 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | -20.22 mm | Standard Deviation 25.4 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | -17.38 mm | Standard Deviation 27 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | -35.15 mm | Standard Deviation 25.29 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | -12.47 mm | Standard Deviation 25.24 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | -39.80 mm | Standard Deviation 24.35 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | -32.89 mm | Standard Deviation 19.37 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | -8.00 mm | Standard Deviation 21.96 |
| Placebo | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | -19.41 mm | Standard Deviation 24.91 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 20 (n=27,16,28,16,44,51,53,0,44,19,25) | -31.56 mm | Standard Deviation 24.08 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 16 (n=27,17,29,17,45,55,53,0,43,20,25) | -29.96 mm | Standard Deviation 23.75 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 24 (n=24,15,27,15,42,54,51,0,40,20,24) | -35.13 mm | Standard Deviation 23.7 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 6 (n=48,0,47,0,44,58,55,48,0,52,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 12 (n=43,0,46,0,45,56,54,46,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 10 (n=46,0,48,0,45,56,53,45,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 2 (n=54,0,50,0,46,59,57,53,0,57,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET | Week 8 (n=47,0,47,0,46,56,54,47,0,46,0) | NA mm | — |
Secondary
Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling = 1. A negative value in change from baseline indicated an improvement.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -6.07 swollen joints | Standard Deviation 9.67 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -8.58 swollen joints | Standard Deviation 8.98 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -4.08 swollen joints | Standard Deviation 10.31 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -6.36 swollen joints | Standard Deviation 10.05 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -4.83 swollen joints | Standard Deviation 7.04 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -6.70 swollen joints | Standard Deviation 8.6 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -11.00 swollen joints | Standard Deviation 8.75 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -7.88 swollen joints | Standard Deviation 9.28 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -9.56 swollen joints | Standard Deviation 9.21 |
| CP-690,550 3 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA swollen joints | — |
| CP-690,550 3 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA swollen joints | — |
| CP-690,550 3 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -5.44 swollen joints | Standard Deviation 9.33 |
| CP-690,550 3 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA swollen joints | — |
| CP-690,550 3 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -6.06 swollen joints | Standard Deviation 9.7 |
| CP-690,550 3 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA swollen joints | — |
| CP-690,550 3 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -6.65 swollen joints | Standard Deviation 9.84 |
| CP-690,550 3 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA swollen joints | — |
| CP-690,550 3 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA swollen joints | — |
| CP-690,550 5 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -9.90 swollen joints | Standard Deviation 9.32 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -4.66 swollen joints | Standard Deviation 9.88 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -5.85 swollen joints | Standard Deviation 10.7 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -9.97 swollen joints | Standard Deviation 6.98 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -6.33 swollen joints | Standard Deviation 9.4 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -5.75 swollen joints | Standard Deviation 9.94 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -5.54 swollen joints | Standard Deviation 9.76 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -10.07 swollen joints | Standard Deviation 9.7 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -3.08 swollen joints | Standard Deviation 8.86 |
| CP-690,550 10 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -2.19 swollen joints | Standard Deviation 14.28 |
| CP-690,550 10 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA swollen joints | — |
| CP-690,550 10 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -1.60 swollen joints | Standard Deviation 14.34 |
| CP-690,550 10 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA swollen joints | — |
| CP-690,550 10 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA swollen joints | — |
| CP-690,550 10 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -1.24 swollen joints | Standard Deviation 13.15 |
| CP-690,550 10 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA swollen joints | — |
| CP-690,550 10 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA swollen joints | — |
| CP-690,550 10 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA swollen joints | — |
| CP-690,550 15 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -8.69 swollen joints | Standard Deviation 9.13 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -8.70 swollen joints | Standard Deviation 9.6 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -4.85 swollen joints | Standard Deviation 9.65 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -9.74 swollen joints | Standard Deviation 10.28 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -11.11 swollen joints | Standard Deviation 9.87 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -10.40 swollen joints | Standard Deviation 10.4 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -9.89 swollen joints | Standard Deviation 9.78 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -6.63 swollen joints | Standard Deviation 9.01 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -11.60 swollen joints | Standard Deviation 11.55 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -11.11 swollen joints | Standard Deviation 7.99 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -5.67 swollen joints | Standard Deviation 6.94 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -8.02 swollen joints | Standard Deviation 7.03 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -9.36 swollen joints | Standard Deviation 7.6 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -9.19 swollen joints | Standard Deviation 7.7 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -10.91 swollen joints | Standard Deviation 8.48 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -11.27 swollen joints | Standard Deviation 8.86 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -11.17 swollen joints | Standard Deviation 7.92 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -11.75 swollen joints | Standard Deviation 7.82 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -12.30 swollen joints | Standard Deviation 10.98 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -9.55 swollen joints | Standard Deviation 11 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -11.28 swollen joints | Standard Deviation 10.79 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -13.10 swollen joints | Standard Deviation 10.44 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -10.51 swollen joints | Standard Deviation 10.61 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -12.68 swollen joints | Standard Deviation 10.65 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -5.68 swollen joints | Standard Deviation 9.98 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -11.65 swollen joints | Standard Deviation 10.26 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -10.85 swollen joints | Standard Deviation 10.6 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -4.57 swollen joints | Standard Deviation 8.52 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | NA swollen joints | — |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | NA swollen joints | — |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -7.83 swollen joints | Standard Deviation 7.52 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -6.00 swollen joints | Standard Deviation 9.66 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -5.75 swollen joints | Standard Deviation 8.32 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | NA swollen joints | — |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -3.32 swollen joints | Standard Deviation 9.25 |
| Adalimumab | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -6.17 swollen joints | Standard Deviation 8.5 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -9.91 swollen joints | Standard Deviation 7.5 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -10.86 swollen joints | Standard Deviation 8.03 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -9.46 swollen joints | Standard Deviation 9.37 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -4.41 swollen joints | Standard Deviation 9.89 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -5.33 swollen joints | Standard Deviation 9.12 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -3.87 swollen joints | Standard Deviation 10.53 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -10.25 swollen joints | Standard Deviation 6.77 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -4.06 swollen joints | Standard Deviation 8.76 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -10.20 swollen joints | Standard Deviation 7.78 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -11.47 swollen joints | Standard Deviation 7.46 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -3.74 swollen joints | Standard Deviation 8.33 |
| Placebo | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -3.50 swollen joints | Standard Deviation 11.31 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -8.84 swollen joints | Standard Deviation 9.92 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -7.00 swollen joints | Standard Deviation 11.08 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -11.00 swollen joints | Standard Deviation 11.16 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA swollen joints | — |
Secondary
Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicated an improvement.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -9.57 tender joints | Standard Deviation 15.8 |
| CP-690,550 1 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -12.63 tender joints | Standard Deviation 14.37 |
| CP-690,550 1 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -6.56 tender joints | Standard Deviation 14.49 |
| CP-690,550 1 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -11.83 tender joints | Standard Deviation 13.56 |
| CP-690,550 1 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -5.04 tender joints | Standard Deviation 12.12 |
| CP-690,550 1 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -11.07 tender joints | Standard Deviation 16.23 |
| CP-690,550 1 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -19.11 tender joints | Standard Deviation 13.88 |
| CP-690,550 1 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -11.96 tender joints | Standard Deviation 15.35 |
| CP-690,550 1 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -16.15 tender joints | Standard Deviation 16.26 |
| CP-690,550 3 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA tender joints | — |
| CP-690,550 3 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA tender joints | — |
| CP-690,550 3 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -8.25 tender joints | Standard Deviation 13.75 |
| CP-690,550 3 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA tender joints | — |
| CP-690,550 3 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -13.38 tender joints | Standard Deviation 11.59 |
| CP-690,550 3 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA tender joints | — |
| CP-690,550 3 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -10.53 tender joints | Standard Deviation 12.43 |
| CP-690,550 3 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA tender joints | — |
| CP-690,550 3 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA tender joints | — |
| CP-690,550 5 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -15.28 tender joints | Standard Deviation 11.11 |
| CP-690,550 5 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -10.43 tender joints | Standard Deviation 10.53 |
| CP-690,550 5 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -11.04 tender joints | Standard Deviation 11.42 |
| CP-690,550 5 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -15.03 tender joints | Standard Deviation 9.88 |
| CP-690,550 5 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -11.65 tender joints | Standard Deviation 10.87 |
| CP-690,550 5 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -10.65 tender joints | Standard Deviation 11.06 |
| CP-690,550 5 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -11.38 tender joints | Standard Deviation 11.02 |
| CP-690,550 5 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -15.45 tender joints | Standard Deviation 13.03 |
| CP-690,550 5 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -7.61 tender joints | Standard Deviation 9.31 |
| CP-690,550 10 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -10.00 tender joints | Standard Deviation 13.23 |
| CP-690,550 10 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA tender joints | — |
| CP-690,550 10 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -10.47 tender joints | Standard Deviation 13.6 |
| CP-690,550 10 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA tender joints | — |
| CP-690,550 10 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA tender joints | — |
| CP-690,550 10 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -8.47 tender joints | Standard Deviation 12.51 |
| CP-690,550 10 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA tender joints | — |
| CP-690,550 10 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA tender joints | — |
| CP-690,550 10 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA tender joints | — |
| CP-690,550 15 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -13.40 tender joints | Standard Deviation 13.5 |
| CP-690,550 15 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -13.70 tender joints | Standard Deviation 13.86 |
| CP-690,550 15 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -8.23 tender joints | Standard Deviation 12.61 |
| CP-690,550 15 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -16.24 tender joints | Standard Deviation 13.32 |
| CP-690,550 15 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -16.91 tender joints | Standard Deviation 13.06 |
| CP-690,550 15 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -15.98 tender joints | Standard Deviation 13.2 |
| CP-690,550 15 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -15.93 tender joints | Standard Deviation 13.92 |
| CP-690,550 15 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -10.33 tender joints | Standard Deviation 10.76 |
| CP-690,550 15 mg | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -17.58 tender joints | Standard Deviation 15.22 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -17.51 tender joints | Standard Deviation 14.08 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -10.28 tender joints | Standard Deviation 12.57 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -13.00 tender joints | Standard Deviation 12.73 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -14.49 tender joints | Standard Deviation 13.52 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -15.61 tender joints | Standard Deviation 13.82 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -16.74 tender joints | Standard Deviation 14.23 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -17.48 tender joints | Standard Deviation 13.24 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -17.53 tender joints | Standard Deviation 12.86 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -18.42 tender joints | Standard Deviation 13.64 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -17.50 tender joints | Standard Deviation 13.29 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -12.85 tender joints | Standard Deviation 14.91 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -15.77 tender joints | Standard Deviation 12.77 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -17.02 tender joints | Standard Deviation 14.14 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -14.38 tender joints | Standard Deviation 14.86 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -17.57 tender joints | Standard Deviation 13.62 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -8.46 tender joints | Standard Deviation 12.87 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -16.28 tender joints | Standard Deviation 12.25 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -15.57 tender joints | Standard Deviation 13.8 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -7.67 tender joints | Standard Deviation 11.4 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | NA tender joints | — |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | NA tender joints | — |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -9.30 tender joints | Standard Deviation 11.96 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -9.89 tender joints | Standard Deviation 12.54 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -8.83 tender joints | Standard Deviation 13.02 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | NA tender joints | — |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -4.72 tender joints | Standard Deviation 10.97 |
| Adalimumab | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -8.57 tender joints | Standard Deviation 12.44 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -15.18 tender joints | Standard Deviation 11.25 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -15.09 tender joints | Standard Deviation 12.35 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -13.10 tender joints | Standard Deviation 12.94 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | -10.43 tender joints | Standard Deviation 14.72 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | -9.67 tender joints | Standard Deviation 11.63 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | -8.69 tender joints | Standard Deviation 13.86 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -19.55 tender joints | Standard Deviation 13.02 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | -7.23 tender joints | Standard Deviation 11.39 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -19.10 tender joints | Standard Deviation 14.88 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -18.16 tender joints | Standard Deviation 13 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | -6.19 tender joints | Standard Deviation 11.84 |
| Placebo | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | -8.72 tender joints | Standard Deviation 13.22 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | -12.20 tender joints | Standard Deviation 12.02 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | -12.40 tender joints | Standard Deviation 10.17 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | -14.21 tender joints | Standard Deviation 12.25 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA tender joints | — |
Secondary
C-Reactive Protein (CRP)
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 12.41 mg/L | Standard Deviation 13.51 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 8.90 mg/L | Standard Deviation 7.91 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 16.09 mg/L | Standard Deviation 17.96 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 21.80 mg/L | Standard Deviation 33.09 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 15.47 mg/L | Standard Deviation 16.19 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 16.89 mg/L | Standard Deviation 21.34 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 21.39 mg/L | Standard Deviation 22.17 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | 16.81 mg/L | Standard Deviation 19.66 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 11.64 mg/L | Standard Deviation 15.98 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 15.89 mg/L | Standard Deviation 21.85 |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 9.86 mg/L | Standard Deviation 18.85 |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA mg/L | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 10.51 mg/L | Standard Deviation 18.33 |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA mg/L | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 4.02 mg/L | Standard Deviation 3.32 |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | NA mg/L | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA mg/L | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA mg/L | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA mg/L | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA mg/L | — |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 8.76 mg/L | Standard Deviation 12.52 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | 9.33 mg/L | Standard Deviation 13.2 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 8.20 mg/L | Standard Deviation 12.04 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 7.32 mg/L | Standard Deviation 8.75 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 16.22 mg/L | Standard Deviation 19.53 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 11.63 mg/L | Standard Deviation 16.13 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 12.61 mg/L | Standard Deviation 26.98 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 9.23 mg/L | Standard Deviation 12.64 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 10.02 mg/L | Standard Deviation 15.12 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 7.64 mg/L | Standard Deviation 11.06 |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA mg/L | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 5.74 mg/L | Standard Deviation 6.42 |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | NA mg/L | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA mg/L | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA mg/L | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA mg/L | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA mg/L | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA mg/L | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 7.20 mg/L | Standard Deviation 12.14 |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 9.21 mg/L | Standard Deviation 12.03 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | 7.32 mg/L | Standard Deviation 10.2 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 24.51 mg/L | Standard Deviation 30.39 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 9.33 mg/L | Standard Deviation 17.71 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 7.73 mg/L | Standard Deviation 9.8 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 7.22 mg/L | Standard Deviation 11.35 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 7.49 mg/L | Standard Deviation 10.77 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 8.13 mg/L | Standard Deviation 12.01 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 8.03 mg/L | Standard Deviation 16.57 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 4.72 mg/L | Standard Deviation 4.57 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 6.31 mg/L | Standard Deviation 7.79 |
| Adalimumab | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | 3.15 mg/L | Standard Deviation 5.93 |
| Adalimumab | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 3.12 mg/L | Standard Deviation 3.48 |
| Adalimumab | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 4.65 mg/L | Standard Deviation 7.38 |
| Adalimumab | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 4.00 mg/L | Standard Deviation 7.25 |
| Adalimumab | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 2.34 mg/L | Standard Deviation 1.9 |
| Adalimumab | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 3.52 mg/L | Standard Deviation 5.82 |
| Adalimumab | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 2.85 mg/L | Standard Deviation 3.81 |
| Adalimumab | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 4.37 mg/L | Standard Deviation 5.98 |
| Adalimumab | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 5.65 mg/L | Standard Deviation 10.51 |
| Adalimumab | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 16.66 mg/L | Standard Deviation 16.85 |
| Placebo | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | 5.04 mg/L | Standard Deviation 7.15 |
| Placebo | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 3.14 mg/L | Standard Deviation 4.45 |
| Placebo | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 3.62 mg/L | Standard Deviation 3.88 |
| Placebo | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 4.50 mg/L | Standard Deviation 7.8 |
| Placebo | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 6.18 mg/L | Standard Deviation 9.45 |
| Placebo | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 4.43 mg/L | Standard Deviation 6.21 |
| Placebo | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 4.50 mg/L | Standard Deviation 7.05 |
| Placebo | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 21.70 mg/L | Standard Deviation 33.01 |
| Placebo | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 5.34 mg/L | Standard Deviation 9.65 |
| Placebo | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 2.51 mg/L | Standard Deviation 2.5 |
| Adalimumab | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 14.53 mg/L | Standard Deviation 20.3 |
| Adalimumab | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 13.60 mg/L | Standard Deviation 18.86 |
| Adalimumab | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 14.31 mg/L | Standard Deviation 18.37 |
| Adalimumab | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | 13.74 mg/L | Standard Deviation 19.51 |
| Adalimumab | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | NA mg/L | — |
| Adalimumab | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 9.54 mg/L | Standard Deviation 13.93 |
| Adalimumab | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | NA mg/L | — |
| Adalimumab | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | NA mg/L | — |
| Adalimumab | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 20.09 mg/L | Standard Deviation 23.47 |
| Adalimumab | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 15.47 mg/L | Standard Deviation 21.75 |
| Adalimumab to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 6.01 mg/L | Standard Deviation 9.02 |
| Adalimumab to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 5.73 mg/L | Standard Deviation 7.66 |
| Adalimumab to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA mg/L | — |
| Adalimumab to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 6.82 mg/L | Standard Deviation 9.21 |
| Adalimumab to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA mg/L | — |
| Placebo | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 29.87 mg/L | Standard Deviation 36.82 |
| Placebo | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 23.53 mg/L | Standard Deviation 27.07 |
| Placebo | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 18.35 mg/L | Standard Deviation 17.49 |
| Placebo | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | 26.69 mg/L | Standard Deviation 35.34 |
| Placebo | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 31.14 mg/L | Standard Deviation 36.74 |
| Placebo | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 17.89 mg/L | Standard Deviation 15.34 |
| Placebo | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 27.13 mg/L | Standard Deviation 33.02 |
| Placebo | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 27.06 mg/L | Standard Deviation 33.94 |
| Placebo | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 37.00 mg/L | Standard Deviation 52.65 |
| Placebo | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 21.98 mg/L | Standard Deviation 28.43 |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 6.04 mg/L | Standard Deviation 7.33 |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 4 (n=50,0,48,0,45,57,53,49,0,53,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 5.39 mg/L | Standard Deviation 8.57 |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA mg/L | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 4.65 mg/L | Standard Deviation 5.85 |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA mg/L | — |
Secondary
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (\<=) 3.2 implied low disease activity and greater than (\>) 3.2 to 5.1 implied moderate to high disease activity, and less than (\<) 2.6 = remission.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 4.42 units on a scale | Standard Deviation 1.17 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | 4.77 units on a scale | Standard Deviation 1.25 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 4.11 units on a scale | Standard Deviation 1.26 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 3.94 units on a scale | Standard Deviation 1.4 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 3.63 units on a scale | Standard Deviation 1.35 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 4.57 units on a scale | Standard Deviation 1.51 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 4.96 units on a scale | Standard Deviation 1.11 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | 5.51 units on a scale | Standard Deviation 0.88 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 4.37 units on a scale | Standard Deviation 1.46 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 4.52 units on a scale | Standard Deviation 1.27 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 4.42 units on a scale | Standard Deviation 1.12 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 4.14 units on a scale | Standard Deviation 0.92 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 4.47 units on a scale | Standard Deviation 1.13 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA units on a scale | — |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 4.60 units on a scale | Standard Deviation 1.23 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | 5.37 units on a scale | Standard Deviation 0.87 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | 4.16 units on a scale | Standard Deviation 1.22 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 4.02 units on a scale | Standard Deviation 1.26 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 4.00 units on a scale | Standard Deviation 1.37 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 3.92 units on a scale | Standard Deviation 1.27 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 3.96 units on a scale | Standard Deviation 1.36 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 3.30 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 3.26 units on a scale | Standard Deviation 1 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 3.11 units on a scale | Standard Deviation 1.25 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 4.44 units on a scale | Standard Deviation 1.32 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 4.75 units on a scale | Standard Deviation 1.16 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 4.33 units on a scale | Standard Deviation 1.28 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | NA units on a scale | — |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 3.68 units on a scale | Standard Deviation 1.38 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 3.80 units on a scale | Standard Deviation 1.21 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 3.76 units on a scale | Standard Deviation 1.38 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 3.55 units on a scale | Standard Deviation 1.41 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 4.63 units on a scale | Standard Deviation 1.15 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 3.64 units on a scale | Standard Deviation 1.22 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 4.01 units on a scale | Standard Deviation 1.25 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 4.16 units on a scale | Standard Deviation 1.06 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | 4.36 units on a scale | Standard Deviation 1 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | 5.58 units on a scale | Standard Deviation 0.88 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | 5.46 units on a scale | Standard Deviation 0.82 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 3.45 units on a scale | Standard Deviation 1.11 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 4.16 units on a scale | Standard Deviation 0.96 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 2.92 units on a scale | Standard Deviation 1.03 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 3.37 units on a scale | Standard Deviation 1.06 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 3.06 units on a scale | Standard Deviation 0.98 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 3.11 units on a scale | Standard Deviation 1.18 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 3.06 units on a scale | Standard Deviation 1.13 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 2.85 units on a scale | Standard Deviation 1.1 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | 3.71 units on a scale | Standard Deviation 1.15 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 4.32 units on a scale | Standard Deviation 1.09 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 2.82 units on a scale | Standard Deviation 1.17 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 3.06 units on a scale | Standard Deviation 1.13 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 2.93 units on a scale | Standard Deviation 1.2 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 3.05 units on a scale | Standard Deviation 1.18 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | 5.46 units on a scale | Standard Deviation 0.96 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 2.92 units on a scale | Standard Deviation 1.14 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | 3.71 units on a scale | Standard Deviation 1.09 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 3.34 units on a scale | Standard Deviation 1.29 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 3.13 units on a scale | Standard Deviation 1.21 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 4.12 units on a scale | Standard Deviation 1.56 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 4.19 units on a scale | Standard Deviation 1.55 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | NA units on a scale | — |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | NA units on a scale | — |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 4.13 units on a scale | Standard Deviation 1.33 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | 5.35 units on a scale | Standard Deviation 0.98 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 4.23 units on a scale | Standard Deviation 1.33 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | 4.40 units on a scale | Standard Deviation 1.45 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | NA units on a scale | — |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 4.59 units on a scale | Standard Deviation 1.26 |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 3.33 units on a scale | Standard Deviation 1.17 |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 3.32 units on a scale | Standard Deviation 1.13 |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 3.40 units on a scale | Standard Deviation 1.17 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | 5.24 units on a scale | Standard Deviation 1.03 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | 4.83 units on a scale | Standard Deviation 1.36 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | 5.62 units on a scale | Standard Deviation 0.87 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | 5.01 units on a scale | Standard Deviation 1.13 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | 4.83 units on a scale | Standard Deviation 1.42 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | 4.92 units on a scale | Standard Deviation 1.35 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 3.93 units on a scale | Standard Deviation 1.22 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 3.96 units on a scale | Standard Deviation 1.36 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 3.97 units on a scale | Standard Deviation 1.08 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | 4.84 units on a scale | Standard Deviation 1.24 |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 4.01 units on a scale | Standard Deviation 1.08 |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 3.61 units on a scale | Standard Deviation 1.13 |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=53,0,51,0,48,60,57,52,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=50,0,47,0,45,57,53,49,0,53,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=47,0,48,0,45,58,55,48,0,52,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=47,0,48,0,47,56,53,47,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 10 (n=46,0,48,0,46,57,52,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=43,0,46,0,45,54,52,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=54,0,51,0,47,59,57,52,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 3.78 units on a scale | Standard Deviation 1.11 |
Secondary
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])
DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) \<= 3.2 implies low disease activity and \> 3.2 to 5.1 implies moderate to high disease activity, and \< 2.6 = remission.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | 5.36 units on a scale | Standard Deviation 1.1 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | 5.73 units on a scale | Standard Deviation 1.25 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | 4.87 units on a scale | Standard Deviation 1.43 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | 4.76 units on a scale | Standard Deviation 1.5 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | 4.39 units on a scale | Standard Deviation 1.33 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | 5.41 units on a scale | Standard Deviation 1.56 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | 5.92 units on a scale | Standard Deviation 1.2 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | 6.51 units on a scale | Standard Deviation 0.9 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | 5.22 units on a scale | Standard Deviation 1.55 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | 5.31 units on a scale | Standard Deviation 1.46 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | 5.27 units on a scale | Standard Deviation 1.42 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | 5.22 units on a scale | Standard Deviation 0.93 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | 5.36 units on a scale | Standard Deviation 1.23 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | 5.57 units on a scale | Standard Deviation 1.3 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | 6.35 units on a scale | Standard Deviation 0.95 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | 5.10 units on a scale | Standard Deviation 1.48 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | 4.91 units on a scale | Standard Deviation 1.55 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | 4.89 units on a scale | Standard Deviation 1.5 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | 4.81 units on a scale | Standard Deviation 1.52 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | 4.78 units on a scale | Standard Deviation 1.64 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | 3.96 units on a scale | Standard Deviation 1.31 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | 4.08 units on a scale | Standard Deviation 1.3 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | 3.72 units on a scale | Standard Deviation 1.58 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | 5.31 units on a scale | Standard Deviation 1.37 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | 5.70 units on a scale | Standard Deviation 1.22 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | 5.19 units on a scale | Standard Deviation 1.23 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | NA units on a scale | — |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | 4.47 units on a scale | Standard Deviation 1.47 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | 4.50 units on a scale | Standard Deviation 1.31 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | 4.37 units on a scale | Standard Deviation 1.43 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | 4.25 units on a scale | Standard Deviation 1.47 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | 5.61 units on a scale | Standard Deviation 1.34 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | 4.33 units on a scale | Standard Deviation 1.4 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | 4.70 units on a scale | Standard Deviation 1.24 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | 4.90 units on a scale | Standard Deviation 1.19 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | 5.23 units on a scale | Standard Deviation 1.09 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | 6.57 units on a scale | Standard Deviation 0.87 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | 6.46 units on a scale | Standard Deviation 0.85 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | 4.33 units on a scale | Standard Deviation 1.32 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | 5.20 units on a scale | Standard Deviation 1.07 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | 3.62 units on a scale | Standard Deviation 1.26 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | 4.22 units on a scale | Standard Deviation 1.18 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | 3.93 units on a scale | Standard Deviation 1.17 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | 3.95 units on a scale | Standard Deviation 1.38 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | 3.86 units on a scale | Standard Deviation 1.36 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | 3.67 units on a scale | Standard Deviation 1.39 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | 4.69 units on a scale | Standard Deviation 1.31 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | 5.20 units on a scale | Standard Deviation 1.29 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | 3.61 units on a scale | Standard Deviation 1.31 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | 3.77 units on a scale | Standard Deviation 1.32 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | 3.54 units on a scale | Standard Deviation 1.29 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | 3.71 units on a scale | Standard Deviation 1.31 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | 6.46 units on a scale | Standard Deviation 0.95 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | 3.63 units on a scale | Standard Deviation 1.39 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | 4.46 units on a scale | Standard Deviation 1.43 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | 4.02 units on a scale | Standard Deviation 1.57 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | 3.80 units on a scale | Standard Deviation 1.45 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | 4.98 units on a scale | Standard Deviation 1.72 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | 4.99 units on a scale | Standard Deviation 1.7 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | NA units on a scale | — |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | NA units on a scale | — |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | 5.00 units on a scale | Standard Deviation 1.5 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | 6.30 units on a scale | Standard Deviation 0.97 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | 5.01 units on a scale | Standard Deviation 1.42 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | 5.22 units on a scale | Standard Deviation 1.52 |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | NA units on a scale | — |
| Adalimumab | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | 5.53 units on a scale | Standard Deviation 1.33 |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | 4.04 units on a scale | Standard Deviation 1.35 |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | 4.08 units on a scale | Standard Deviation 1.19 |
| Adalimumab to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | 4.22 units on a scale | Standard Deviation 1.26 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | 6.04 units on a scale | Standard Deviation 1.15 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | 5.54 units on a scale | Standard Deviation 1.53 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | 6.56 units on a scale | Standard Deviation 0.95 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | 5.70 units on a scale | Standard Deviation 1.3 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | 5.39 units on a scale | Standard Deviation 1.57 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | 5.64 units on a scale | Standard Deviation 1.39 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | 4.53 units on a scale | Standard Deviation 1.34 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | 4.51 units on a scale | Standard Deviation 1.41 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | 4.47 units on a scale | Standard Deviation 1.5 |
| Placebo | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | 5.56 units on a scale | Standard Deviation 1.4 |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 16 (n=27,17,30,17,45,55,54,0,42,20,24) | 4.95 units on a scale | Standard Deviation 1.3 |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 24 (n=24,16,29,15,43,54,51,0,38,20,23) | 4.28 units on a scale | Standard Deviation 1.2 |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 2 (n=51,0,50,0,47,60,54,51,0,53,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 4 (n=49,0,46,0,46,57,53,46,0,51,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 6 (n=46,0,47,0,45,58,54,47,0,51,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 8 (n=47,0,48,0,47,56,54,46,0,44,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 10 (n=46,0,49,0,45,56,53,43,0,44,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 12 (n=44,0,46,0,46,56,53,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Baseline (n=49,0,49,0,47,59,54,51,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) | Week 20 (n=26,16,29,16,45,51,52,0,43,19,24) | 4.62 units on a scale | Standard Deviation 1.27 |
Secondary
Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline, Week 12, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.56 units on a scale | Standard Deviation 0.26 |
| CP-690,550 1 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.64 units on a scale | Standard Deviation 0.23 |
| CP-690,550 1 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 0.41 units on a scale | Standard Deviation 0.32 |
| CP-690,550 3 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.55 units on a scale | Standard Deviation 0.3 |
| CP-690,550 3 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 5 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.67 units on a scale | Standard Deviation 0.22 |
| CP-690,550 5 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.50 units on a scale | Standard Deviation 0.32 |
| CP-690,550 5 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 0.33 units on a scale | Standard Deviation 0.32 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.58 units on a scale | Standard Deviation 0.25 |
| CP-690,550 15 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.61 units on a scale | Standard Deviation 0.3 |
| CP-690,550 15 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 0.39 units on a scale | Standard Deviation 0.37 |
| CP-690,550 15 mg | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.60 units on a scale | Standard Deviation 0.27 |
| Adalimumab | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.68 units on a scale | Standard Deviation 0.25 |
| Adalimumab | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 0.41 units on a scale | Standard Deviation 0.3 |
| Adalimumab | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.68 units on a scale | Standard Deviation 0.26 |
| Placebo | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 0.34 units on a scale | Standard Deviation 0.35 |
| Placebo | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.66 units on a scale | Standard Deviation 0.27 |
| Placebo | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.67 units on a scale | Standard Deviation 0.26 |
| Adalimumab | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 0.36 units on a scale | Standard Deviation 0.31 |
| Adalimumab | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.51 units on a scale | Standard Deviation 0.26 |
| Adalimumab | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.60 units on a scale | Standard Deviation 0.24 |
| Adalimumab to CP-690,550 5 mg (R) | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | NA units on a scale | — |
| Placebo | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 0.38 units on a scale | Standard Deviation 0.32 |
| Placebo | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.63 units on a scale | Standard Deviation 0.22 |
| Placebo | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | 0.53 units on a scale | Standard Deviation 0.32 |
| Placebo to CP-690,550 5 mg (R) | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 12 (n=43,0,46,0,45,56,54,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score | Week 24 (n=24,15,29,14,43,55,52,0,40,20,24) | 0.73 units on a scale | Standard Deviation 0.17 |
Secondary
Health Assessment Questionnaire-Disability Index (HAQ-DI)
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | 1.02 units on a scale | Standard Deviation 0.72 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | 1.45 units on a scale | Standard Deviation 0.65 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | 1.30 units on a scale | Standard Deviation 0.63 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | 1.05 units on a scale | Standard Deviation 0.71 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 1.28 units on a scale | Standard Deviation 0.72 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | 1.45 units on a scale | Standard Deviation 0.66 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 1.25 units on a scale | Standard Deviation 0.77 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | 1.29 units on a scale | Standard Deviation 0.72 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 1.02 units on a scale | Standard Deviation 0.65 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | 1.57 units on a scale | Standard Deviation 0.69 |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | 1.34 units on a scale | Standard Deviation 0.81 |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | 1.20 units on a scale | Standard Deviation 0.65 |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 1.29 units on a scale | Standard Deviation 0.66 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | 1.24 units on a scale | Standard Deviation 0.65 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | 1.53 units on a scale | Standard Deviation 0.63 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | 1.00 units on a scale | Standard Deviation 0.78 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | 1.28 units on a scale | Standard Deviation 0.63 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 0.96 units on a scale | Standard Deviation 0.83 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | 1.04 units on a scale | Standard Deviation 0.79 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 1.09 units on a scale | Standard Deviation 0.72 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | 1.23 units on a scale | Standard Deviation 0.69 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 1.20 units on a scale | Standard Deviation 0.7 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | 1.12 units on a scale | Standard Deviation 0.7 |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | 1.31 units on a scale | Standard Deviation 0.72 |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | 1.04 units on a scale | Standard Deviation 0.67 |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 1.00 units on a scale | Standard Deviation 0.74 |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | NA units on a scale | — |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | 1.14 units on a scale | Standard Deviation 0.71 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | 1.40 units on a scale | Standard Deviation 0.73 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | 1.22 units on a scale | Standard Deviation 0.73 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | 1.14 units on a scale | Standard Deviation 0.67 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | 0.99 units on a scale | Standard Deviation 0.65 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 0.94 units on a scale | Standard Deviation 0.75 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 0.94 units on a scale | Standard Deviation 0.73 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | 0.91 units on a scale | Standard Deviation 0.74 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | 0.96 units on a scale | Standard Deviation 0.76 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 0.95 units on a scale | Standard Deviation 0.81 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | 1.22 units on a scale | Standard Deviation 0.68 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 0.81 units on a scale | Standard Deviation 0.68 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | 1.49 units on a scale | Standard Deviation 0.74 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 0.81 units on a scale | Standard Deviation 0.73 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 0.86 units on a scale | Standard Deviation 0.68 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | 1.00 units on a scale | Standard Deviation 0.72 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | 0.80 units on a scale | Standard Deviation 0.75 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | 1.04 units on a scale | Standard Deviation 0.74 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | 0.85 units on a scale | Standard Deviation 0.72 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | 0.97 units on a scale | Standard Deviation 0.75 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | 0.73 units on a scale | Standard Deviation 0.63 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 0.81 units on a scale | Standard Deviation 0.71 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 0.78 units on a scale | Standard Deviation 0.66 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | 0.86 units on a scale | Standard Deviation 0.68 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | 1.26 units on a scale | Standard Deviation 0.66 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | 0.93 units on a scale | Standard Deviation 0.71 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | 1.62 units on a scale | Standard Deviation 0.7 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | 0.71 units on a scale | Standard Deviation 0.65 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | 1.08 units on a scale | Standard Deviation 0.68 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 0.79 units on a scale | Standard Deviation 0.67 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | 1.31 units on a scale | Standard Deviation 0.77 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | 1.12 units on a scale | Standard Deviation 0.75 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 1.18 units on a scale | Standard Deviation 0.73 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 1.13 units on a scale | Standard Deviation 0.74 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | 1.23 units on a scale | Standard Deviation 0.68 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | NA units on a scale | — |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | 1.44 units on a scale | Standard Deviation 0.64 |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | NA units on a scale | — |
| Adalimumab | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | 1.19 units on a scale | Standard Deviation 0.83 |
| Adalimumab to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 0.93 units on a scale | Standard Deviation 0.65 |
| Adalimumab to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | 0.95 units on a scale | Standard Deviation 0.67 |
| Adalimumab to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | 0.95 units on a scale | Standard Deviation 0.71 |
| Adalimumab to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA units on a scale | — |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 1.24 units on a scale | Standard Deviation 0.68 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | 1.30 units on a scale | Standard Deviation 0.69 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | 1.49 units on a scale | Standard Deviation 0.67 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 1.20 units on a scale | Standard Deviation 0.81 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | 1.24 units on a scale | Standard Deviation 0.7 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | 1.38 units on a scale | Standard Deviation 0.72 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | 1.28 units on a scale | Standard Deviation 0.66 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 1.24 units on a scale | Standard Deviation 0.76 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | 1.54 units on a scale | Standard Deviation 0.68 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | 1.31 units on a scale | Standard Deviation 0.7 |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 0.69 units on a scale | Standard Deviation 0.75 |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=47,0,48,0,46,57,54,47,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=27,16,29,15,45,53,52,0,44,19,25) | 0.82 units on a scale | Standard Deviation 0.78 |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=48,0,48,0,44,59,54,48,0,52,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=54,0,51,0,49,60,57,53,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=50,0,46,0,45,57,55,49,0,53,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=54,0,51,0,48,60,57,53,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=27,17,29,17,46,56,54,0,43,20,25) | 0.86 units on a scale | Standard Deviation 0.82 |
Secondary
Patient Assessment of Arthritis Pain
Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 47.31 mm | Standard Deviation 24.21 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 51.72 mm | Standard Deviation 24.91 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 44.13 mm | Standard Deviation 24.32 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 39.67 mm | Standard Deviation 27.28 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 35.00 mm | Standard Deviation 26.63 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 47.25 mm | Standard Deviation 25.81 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 53.76 mm | Standard Deviation 24.49 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | 59.74 mm | Standard Deviation 23.56 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 45.70 mm | Standard Deviation 26.3 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 47.28 mm | Standard Deviation 25.46 |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 44.00 mm | Standard Deviation 28.63 |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 43.38 mm | Standard Deviation 24.69 |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 49.29 mm | Standard Deviation 29.81 |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 45.25 mm | Standard Deviation 24.19 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | 61.25 mm | Standard Deviation 23.93 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 41.91 mm | Standard Deviation 23.8 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 42.75 mm | Standard Deviation 22.17 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 41.21 mm | Standard Deviation 22.19 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 43.24 mm | Standard Deviation 23.23 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 42.30 mm | Standard Deviation 26.89 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 34.97 mm | Standard Deviation 29.16 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 34.66 mm | Standard Deviation 29.75 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 30.62 mm | Standard Deviation 28.36 |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 38.81 mm | Standard Deviation 25.45 |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 47.88 mm | Standard Deviation 25.87 |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 31.87 mm | Standard Deviation 20.47 |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | NA mm | — |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 33.13 mm | Standard Deviation 24.57 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 34.67 mm | Standard Deviation 24.34 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 32.70 mm | Standard Deviation 25.23 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 31.39 mm | Standard Deviation 23.72 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 47.10 mm | Standard Deviation 24.48 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 31.81 mm | Standard Deviation 27.72 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 33.91 mm | Standard Deviation 23.56 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 39.24 mm | Standard Deviation 22.73 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 43.65 mm | Standard Deviation 22.56 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | 64.14 mm | Standard Deviation 23.55 |
| Adalimumab | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | 62.92 mm | Standard Deviation 18.74 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 33.68 mm | Standard Deviation 22.52 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 43.90 mm | Standard Deviation 23.43 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 22.85 mm | Standard Deviation 22.04 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 33.05 mm | Standard Deviation 22.34 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 28.11 mm | Standard Deviation 21.8 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 28.14 mm | Standard Deviation 22.79 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 29.05 mm | Standard Deviation 26.23 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 27.43 mm | Standard Deviation 23.98 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 33.28 mm | Standard Deviation 22.37 |
| Placebo | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 41.28 mm | Standard Deviation 28.06 |
| Placebo | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 25.31 mm | Standard Deviation 22.28 |
| Placebo | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 27.26 mm | Standard Deviation 25.88 |
| Placebo | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 23.21 mm | Standard Deviation 22.6 |
| Placebo | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 23.38 mm | Standard Deviation 22.03 |
| Placebo | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | 63.46 mm | Standard Deviation 25.26 |
| Placebo | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 24.24 mm | Standard Deviation 23.6 |
| Placebo | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 32.69 mm | Standard Deviation 23.77 |
| Placebo | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 30.24 mm | Standard Deviation 25.46 |
| Placebo | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 26.74 mm | Standard Deviation 26.01 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 48.73 mm | Standard Deviation 27.32 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 46.27 mm | Standard Deviation 28.16 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | NA mm | — |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | NA mm | — |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 42.87 mm | Standard Deviation 25.76 |
| Adalimumab | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | 64.36 mm | Standard Deviation 21.46 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 43.17 mm | Standard Deviation 25.22 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 46.78 mm | Standard Deviation 23.85 |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | NA mm | — |
| Adalimumab | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 48.00 mm | Standard Deviation 25.09 |
| Adalimumab to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 31.68 mm | Standard Deviation 22.68 |
| Adalimumab to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 30.16 mm | Standard Deviation 21.52 |
| Adalimumab to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 34.33 mm | Standard Deviation 24.87 |
| Placebo | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 55.26 mm | Standard Deviation 26.7 |
| Placebo | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 44.96 mm | Standard Deviation 24.72 |
| Placebo | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | 60.29 mm | Standard Deviation 23.23 |
| Placebo | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 50.89 mm | Standard Deviation 23.5 |
| Placebo | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 43.93 mm | Standard Deviation 24.16 |
| Placebo | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 49.63 mm | Standard Deviation 24.08 |
| Placebo | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 37.55 mm | Standard Deviation 22.42 |
| Placebo | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 31.35 mm | Standard Deviation 22.51 |
| Placebo | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 36.95 mm | Standard Deviation 25.8 |
| Placebo | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 47.26 mm | Standard Deviation 23.25 |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 28.16 mm | Standard Deviation 22.28 |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 29.83 mm | Standard Deviation 18.37 |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Baseline (n=54,0,51,0,49,61,56,53,0,59,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 31.64 mm | Standard Deviation 20.22 |
Secondary
Patient Global Assessment (PtGA) of Arthritis Pain
Participants answered: Considering all the ways your arthritis affects you, how are you feeling today? Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
Time frame: Baseline, 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | 39.74 mm | Standard Deviation 27.72 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 45.39 mm | Standard Deviation 26.12 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | 54.36 mm | Standard Deviation 23.84 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 47.08 mm | Standard Deviation 23.11 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 36.07 mm | Standard Deviation 25.88 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 46.57 mm | Standard Deviation 27.58 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 45.80 mm | Standard Deviation 27.9 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 43.08 mm | Standard Deviation 23.92 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 52.96 mm | Standard Deviation 23.69 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 60.74 mm | Standard Deviation 24.83 |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 45.69 mm | Standard Deviation 26.15 |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | 47.19 mm | Standard Deviation 24.36 |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 52.00 mm | Standard Deviation 28.93 |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 35.03 mm | Standard Deviation 29.52 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 43.57 mm | Standard Deviation 24.39 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 43.02 mm | Standard Deviation 23.13 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | 35.41 mm | Standard Deviation 29.13 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 59.76 mm | Standard Deviation 22.75 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 41.52 mm | Standard Deviation 21.65 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 44.68 mm | Standard Deviation 23.55 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | 48.49 mm | Standard Deviation 24.49 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 40.78 mm | Standard Deviation 26.08 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 33.07 mm | Standard Deviation 27.9 |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 44.24 mm | Standard Deviation 25.78 |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | 41.44 mm | Standard Deviation 24.86 |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 33.20 mm | Standard Deviation 19.77 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | 33.91 mm | Standard Deviation 24.9 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 33.77 mm | Standard Deviation 28.44 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 39.07 mm | Standard Deviation 22.47 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 35.04 mm | Standard Deviation 24.26 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 67.55 mm | Standard Deviation 22.44 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | 50.58 mm | Standard Deviation 24.55 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 33.52 mm | Standard Deviation 24.26 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 44.54 mm | Standard Deviation 23.1 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 34.81 mm | Standard Deviation 23.95 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 30.37 mm | Standard Deviation 23.58 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 34.86 mm | Standard Deviation 23.15 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 29.02 mm | Standard Deviation 23.09 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | 41.82 mm | Standard Deviation 24.09 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 24.85 mm | Standard Deviation 22.29 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 33.42 mm | Standard Deviation 23.39 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 33.63 mm | Standard Deviation 22.01 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | 28.06 mm | Standard Deviation 23.26 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 29.09 mm | Standard Deviation 21.52 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 62.41 mm | Standard Deviation 19.94 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 30.71 mm | Standard Deviation 25.69 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 34.73 mm | Standard Deviation 25.05 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 22.72 mm | Standard Deviation 23.36 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 31.09 mm | Standard Deviation 25.2 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 28.07 mm | Standard Deviation 26.86 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | 42.02 mm | Standard Deviation 25.77 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 24.72 mm | Standard Deviation 23.11 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | 23.90 mm | Standard Deviation 22.38 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 26.39 mm | Standard Deviation 26.55 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 26.58 mm | Standard Deviation 23.04 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 62.77 mm | Standard Deviation 27.24 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | 48.00 mm | Standard Deviation 24.15 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 43.85 mm | Standard Deviation 23.6 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 62.15 mm | Standard Deviation 21.87 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 46.11 mm | Standard Deviation 25.71 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 43.46 mm | Standard Deviation 25.41 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | NA mm | — |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 44.04 mm | Standard Deviation 25.24 |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | NA mm | — |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | NA mm | — |
| Adalimumab | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 46.24 mm | Standard Deviation 23.1 |
| Adalimumab to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 31.33 mm | Standard Deviation 18.8 |
| Adalimumab to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | 30.95 mm | Standard Deviation 21.47 |
| Adalimumab to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 34.45 mm | Standard Deviation 23.6 |
| Adalimumab to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA mm | — |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 49.71 mm | Standard Deviation 22.73 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 38.65 mm | Standard Deviation 22.37 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 61.41 mm | Standard Deviation 21.32 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 47.24 mm | Standard Deviation 24.12 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 32.05 mm | Standard Deviation 22.63 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | 58.93 mm | Standard Deviation 25.12 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | 35.84 mm | Standard Deviation 26.21 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 46.74 mm | Standard Deviation 23.66 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 51.40 mm | Standard Deviation 23.47 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 44.85 mm | Standard Deviation 23.59 |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 32.48 mm | Standard Deviation 20.69 |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 24 (n=24,16,29,15,43,55,52,0,40,20,24) | 28.13 mm | Standard Deviation 17.42 |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 2 (n=53,0,51,0,48,60,57,53,0,57,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 20 (n=27,16,29,16,45,53,52,0,44,19,25) | 36.20 mm | Standard Deviation 21.44 |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis Pain | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
Secondary
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
ACR20 response: 20% improvement in TJC; \>=20% improvement in SJC; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Time frame: Week 2, 4, 6, 8, 10, 16, 20 and 24/Early Termination (ET)
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Missing values were imputed using BOCF. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 38.89 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 51.4 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 35.19 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 37.04 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 16.67 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 22.22 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 35.1 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 45.9 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 37.25 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 64.7 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 58.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 47.06 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 47.06 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 31.37 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 37.25 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 58.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 69.4 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 57.14 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 63.27 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 67.3 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 32.65 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 63.27 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 40.82 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 57.1 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 63.93 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 75.41 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 52.46 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 73.8 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 65.57 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 50.82 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 70.5 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 73.8 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 71.93 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 71.9 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 66.67 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 63.16 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 75.44 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 38.60 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 68.4 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 71.9 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 28.30 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 26.42 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 30.19 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 35.85 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 35.85 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 15.25 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 25.42 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 35.3 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 27.12 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 47.1 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 27.12 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 32.4 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 23.73 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
Secondary
Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response
ACR50 response: \>= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Missing values were imputed using BOCF. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 18.9 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 9.26 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 12.96 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 12.96 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 14.81 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 18.9 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 10.8 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 11.11 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.85 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 21.57 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 25.49 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 15.69 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 38.2 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 17.65 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 44.1 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 7.84 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 13.73 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 44.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 24.49 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 34.69 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 14.29 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 34.7 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 10.20 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 32.7 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 38.78 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 8.16 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 36.7 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 36.07 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 18.03 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 45.9 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 31.15 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 42.6 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 42.6 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 29.51 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 50.82 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 45.90 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 56.1 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 49.12 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 42.11 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 59.6 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 40.35 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 54.4 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 17.54 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 50.88 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 43.86 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 7.55 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 9.43 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 16.98 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 16.98 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 15.09 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 20.75 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 17.6 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 20.6 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 6.78 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 6.78 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 5.08 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 17.6 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 8.47 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.69 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 10.17 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
Secondary
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
ACR70 response: \>= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Missing values were imputed using BOCF. n=number of participants evaluable at specific time points for each arm group respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 8.1 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 10.8 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 9.26 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 3.70 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.85 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 3.70 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 10.8 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 5.56 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.96 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 26.5 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 11.76 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 17.6 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 3.92 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 5.88 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 7.84 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.96 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 23.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 16.33 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 2.04 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 2.04 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 4.08 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 8.16 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 14.29 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 20.4 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 18.4 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 22.4 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 24.59 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 19.67 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 37.7 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 3.28 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 31.1 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 26.23 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 18.03 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 11.48 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 29.5 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 17.54 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 21.05 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 24.56 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 26.32 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 33.3 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 8.77 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 31.6 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 7.02 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 33.3 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 3.77 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 5.66 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 5.66 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.89 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 3.77 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 5.66 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.69 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 8.8 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.69 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.69 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.69 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 3.39 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 11.8 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
Secondary
Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response
ACR90 response: \>= 90% improvement in TJC or SJC and 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Missing values were imputed using BOCF. n=number of participants evaluable at specific time points for each arm group respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 2.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 2.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 2.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.85 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.85 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.85 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.85 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 2.9 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.96 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 5.9 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.96 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 5.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 2.04 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 8.2 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 6.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 4.08 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 2.04 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 6.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 2.04 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 4.08 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 9.84 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.64 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 6.56 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 14.8 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 3.28 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 13.1 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 11.48 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 9.84 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 11.5 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 8.8 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.75 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.75 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 10.5 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 10.53 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 7.02 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 12.3 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.75 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 1.89 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | 0.00 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 12 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 20 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 2 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 6 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 8 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 10 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 24 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 16 (n=37,17,34,17,49,61,57,9,44,34,25) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response | Week 4 (n=54,0,51,0,49,61,57,53,0,59,0) | NA percentage of participants |
Secondary
Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR)
Disease improvement was classified as good, moderate, and none based on improvement in DAS28-4 (ESR) from baseline and present DAS28-4 (ESR) score. Good: an improvement from baseline of \>1.2 and a present score of \<=3.2; none: an improvement of \<=0.6 or \>0.6 to \<=1.2 with a present score of \>5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | 43.5 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | 45.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | 41.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | 11.5 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | 37.5 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | 2.0 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | 13.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | 42.3 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | 6.4 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | 44.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | 12.5 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | 76.5 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | 31.8 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | 8.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | 44.4 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | 37.0 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | 47.8 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | 2.2 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | 50.0 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | 40.4 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | 63.3 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | 28.6 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | 3.9 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | 18.5 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | 38.5 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | 9.1 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | 29.6 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | 29.4 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | 56.3 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | 5.9 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | 43.8 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | 52.9 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | 12.5 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | 37.5 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | 37.5 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | 28.0 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | 13.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | 43.5 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | 10.9 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | 41.4 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | 55.1 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | 43.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | 30.6 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | 20.0 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | 13.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | 14.9 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | 2.0 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | 39.6 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | 55.2 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | 43.5 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | 15.2 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | 41.4 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | 10.2 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | 27.6 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | 68.0 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | 37.0 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | 36.2 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | 50.0 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | 12.5 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | 46.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | 26.7 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | 43.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | 26.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | 60.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | 6.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | 31.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | 62.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | 52.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | 35.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | 5.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | 16.3 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | 21.7 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | 15.6 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | 19.6 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | 48.9 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | 19.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | 22.2 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | 22.2 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | 31.9 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | 8.5 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | 2.2 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | 4.3 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | 68.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | 57.8 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | 26.7 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | 60.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | 59.6 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | 2.2 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | 20.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | 20.9 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | 54.3 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | 58.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | 66.7 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | 26.7 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | 37.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | 56.5 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | 13.3 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | 29.8 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | 52.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | 52.6 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | 14.3 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | 20.7 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | 14.0 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | 52.7 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | 5.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | 50.0 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | 48.1 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | 14.3 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | 32.1 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | 40.0 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | 38.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | 9.3 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | 53.3 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | 25.0 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | 64.3 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | 32.7 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | 3.3 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | 10.7 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | 60.7 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | 17.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | 22.4 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | 37.3 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | 53.4 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | 10.9 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | 9.6 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | 37.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | 40.7 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | 7.4 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | 42.6 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | 46.3 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | 17.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | 50.9 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | 28.3 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | 29.6 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | 50.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | 16.7 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | 18.5 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | 41.5 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | 45.3 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | 9.4 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | 37.7 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | 47.2 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | 11.3 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | 44.4 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | 40.7 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | 11.1 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | 38.5 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | 48.1 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | 43.1 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | 45.1 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | 7.8 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | 41.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | 14.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | 3.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | 40.4 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | 10.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | 42.2 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | 42.6 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | 46.5 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | 39.2 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | 43.5 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | 9.3 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | 54.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | 11.1 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | 10.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | 44.4 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | 43.5 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | 43.5 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | 43.5 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | 15.8 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | 23.8 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | 61.9 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | 11.9 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | 27.9 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | 60.5 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | 9.3 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | 23.7 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | 57.9 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | 42.2 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | 51.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | 41.2 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | 60.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | 52.3 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | 47.4 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | 2.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | 73.6 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | 20.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | 6.7 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | 26.3 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | 6.8 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | 26.4 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | 2.3 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | 47.7 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | 45.5 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | 20.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | 0.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | 36.4 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | 41.2 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | 30.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | 3.9 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | 20.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | 54.9 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | 50.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | 46.7 percentage of participants |
| Placebo | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | 26.3 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: None (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Good (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Mod (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: None (n=27,17,30,17,45,55,54,0,42,20,24) | 29.2 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Good (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: None (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Good (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: None (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Good (n=24,16,29,15,43,54,51,0,38,20,23) | 8.7 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Mod (n=26,16,29,16,45,51,52,0,43,19,24) | 62.5 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 4: Good (n=49,0,46,0,46,57,53,46,0,51,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: Good (n=26,16,29,16,45,51,52,0,43,19,24) | 12.5 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: Mod (n=24,16,29,15,43,54,51,0,38,20,23) | 65.2 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Good (n=27,17,30,17,45,55,54,0,42,20,24) | 8.3 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: None (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: Mod (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Good (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: None (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Mod (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 24: None (n=24,16,29,15,43,54,51,0,38,20,23) | 17.4 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 20: None (n=26,16,29,16,45,51,52,0,43,19,24) | 16.7 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 12: Mod (n=44,0,46,0,46,56,53,45,0,45,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 16: Mod (n=27,17,30,17,45,55,54,0,42,20,24) | 54.2 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 2: Mod (n=51,0,50,0,47,60,54,51,0,53,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 6: Mod (n=46,0,47,0,45,58,54,47,0,51,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 8: Good (n=47,0,48,0,47,56,54,46,0,44,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR) | Week 10: None (n=46,0,49,0,45,56,53,43,0,44,0) | NA percentage of participants |
Secondary
Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)
DAS28-3 (CRP) defined remission was classified as a score of \<2.6.
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | 10.87 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 16.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | 6.00 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 22.2 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | 2.13 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 19.2 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | 8.51 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | 9.30 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | 1.89 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 6.3 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 5.9 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 6.3 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | NA percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | 12.77 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | 12.77 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 39.3 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 20.7 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 30.0 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | 4.00 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | 8.89 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | 6.52 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | 8.51 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 6.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 6.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 5.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | NA percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | 24.44 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | 4.17 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 28.3 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | 4.44 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 20.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | 14.89 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 22.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | 21.74 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | 8.89 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 36.4 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 36.4 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | 5.00 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | 17.54 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | 24.14 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | 21.43 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | 31.58 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | 33.33 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 43.4 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 42.3 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | 15.09 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | 38.46 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | 41.51 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 43.1 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 50.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | 32.73 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | 7.02 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | 40.38 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | 12.77 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | 12.50 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | 15.56 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | 12.24 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | 4.44 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | 1.92 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 23.1 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 25.6 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 25.6 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | NA percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 5.6 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | 0.00 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | 1.89 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | 6.67 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | 1.92 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 15.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | 4.44 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 15.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | 4.35 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=47,0,47,0,45,58,55,48,0,52,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 12.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=50,0,46,0,45,57,53,49,0,53,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 12.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=43,0,45,0,45,54,52,45,0,45,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=53,0,50,0,48,60,57,52,0,56,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=47,0,47,0,47,56,53,47,0,45,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 10 (n=46,0,47,0,46,57,52,45,0,46,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,39,20,24) | 25.0 percentage of participants |
Secondary
Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP)
CRP value less than or equal to upper limit of normal (ULN) implied disease remission (ULN=4.9 mg/L).
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | 22.22 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 33.3 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | 30.00 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | 25.64 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | 25.58 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | 26.32 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 48.1 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | 20.51 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 46.2 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 75.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 75.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 41.2 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | NA percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 58.6 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | 33.33 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | 42.86 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 53.3 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | 53.33 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | 46.67 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | 43.33 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 46.4 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | 33.33 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 75.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 60.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 64.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | NA percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | 56.41 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | 66.67 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | 62.50 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | 62.16 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 69.6 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 68.9 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | 65.79 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | 62.16 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 65.9 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | 90.70 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | 71.11 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | 83.72 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | 79.55 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | 78.57 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | 75.61 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 78.2 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 88.7 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 72.7 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 82.4 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | 62.16 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | 79.41 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 84.6 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | 67.57 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 76.9 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | 66.67 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | 68.57 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | 75.00 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | 35.14 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | 30.30 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | 21.21 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | 30.56 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | NA percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | 40.00 percentage of participants |
| Adalimumab | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | 25.71 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 67.4 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 67.4 percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | NA percentage of participants |
| Adalimumab to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 72.5 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | 6.67 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | 9.68 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | 5.88 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 35.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | 5.71 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 30.0 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 16.7 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | 2.70 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | 3.33 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 20 (n=26,16,29,16,45,53,52,0,43,18,25) | 72.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 4 (n=40,0,30,0,37,43,37,37,0,35,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 16 (n=27,17,30,17,46,55,51,0,43,20,25) | 68.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 24 (n=24,16,28,15,41,55,52,0,40,20,24) | 66.7 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 6 (n=39,0,30,0,39,44,37,36,0,34,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 12 (n=36,0,28,0,37,41,35,33,0,30,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 10 (n=38,0,30,0,38,43,34,33,0,30,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 2 (n=43,0,33,0,40,45,39,40,0,37,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP) | Week 8 (n=39,0,30,0,39,42,36,35,0,31,0) | NA percentage of participants |
Secondary
Physician Global Assessment (PGA) of Arthritis
Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | 39.75 mm | Standard Deviation 21.73 |
| CP-690,550 1 mg | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | 62.13 mm | Standard Deviation 16.69 |
| CP-690,550 1 mg | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | 41.72 mm | Standard Deviation 23.11 |
| CP-690,550 1 mg | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | 32.59 mm | Standard Deviation 20.17 |
| CP-690,550 1 mg | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 41.65 mm | Standard Deviation 23.12 |
| CP-690,550 1 mg | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 47.30 mm | Standard Deviation 20.4 |
| CP-690,550 1 mg | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 40.06 mm | Standard Deviation 22.39 |
| CP-690,550 1 mg | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | 52.30 mm | Standard Deviation 21.9 |
| CP-690,550 1 mg | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | 29.93 mm | Standard Deviation 19.58 |
| CP-690,550 1 mg | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | 35.21 mm | Standard Deviation 23.91 |
| CP-690,550 3 mg | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | 48.59 mm | Standard Deviation 20.92 |
| CP-690,550 3 mg | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | 45.69 mm | Standard Deviation 15.98 |
| CP-690,550 3 mg | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | 41.20 mm | Standard Deviation 19.27 |
| CP-690,550 3 mg | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | NA mm | — |
| CP-690,550 5 mg | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | 26.97 mm | Standard Deviation 23.53 |
| CP-690,550 5 mg | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | 23.86 mm | Standard Deviation 20.45 |
| CP-690,550 5 mg | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | 47.88 mm | Standard Deviation 20.86 |
| CP-690,550 5 mg | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 41.23 mm | Standard Deviation 20.8 |
| CP-690,550 5 mg | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | 22.50 mm | Standard Deviation 23.37 |
| CP-690,550 5 mg | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | 34.98 mm | Standard Deviation 21.3 |
| CP-690,550 5 mg | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 36.54 mm | Standard Deviation 23.22 |
| CP-690,550 5 mg | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | 62.10 mm | Standard Deviation 18.37 |
| CP-690,550 5 mg | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 38.78 mm | Standard Deviation 24.18 |
| CP-690,550 5 mg | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | 36.65 mm | Standard Deviation 23.47 |
| CP-690,550 10 mg | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | 44.59 mm | Standard Deviation 21.99 |
| CP-690,550 10 mg | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | 41.25 mm | Standard Deviation 23.77 |
| CP-690,550 10 mg | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | 32.00 mm | Standard Deviation 19.13 |
| CP-690,550 15 mg | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 31.79 mm | Standard Deviation 19.94 |
| CP-690,550 15 mg | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 43.3 mm | Standard Deviation 19.49 |
| CP-690,550 15 mg | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | 30.26 mm | Standard Deviation 20.91 |
| CP-690,550 15 mg | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | 65.85 mm | Standard Deviation 14.36 |
| CP-690,550 15 mg | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | 39.40 mm | Standard Deviation 20.4 |
| CP-690,550 15 mg | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | 29.74 mm | Standard Deviation 20.31 |
| CP-690,550 15 mg | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | 29.80 mm | Standard Deviation 19.13 |
| CP-690,550 15 mg | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | 50.37 mm | Standard Deviation 21.9 |
| CP-690,550 15 mg | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 33.70 mm | Standard Deviation 20.03 |
| CP-690,550 15 mg | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | 27.04 mm | Standard Deviation 17.16 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | 39.85 mm | Standard Deviation 18.69 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | 31.22 mm | Standard Deviation 19.51 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 29.56 mm | Standard Deviation 18.6 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | 61.05 mm | Standard Deviation 15.78 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | 24.39 mm | Standard Deviation 19.14 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 24.72 mm | Standard Deviation 18.83 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | 19.35 mm | Standard Deviation 14.1 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | 25.37 mm | Standard Deviation 20.01 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | 20.13 mm | Standard Deviation 16.5 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 34.55 mm | Standard Deviation 20.68 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | 19.42 mm | Standard Deviation 17.92 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | 28.56 mm | Standard Deviation 21.47 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 23.68 mm | Standard Deviation 18.76 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | 24.20 mm | Standard Deviation 18.74 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | 44.98 mm | Standard Deviation 21.61 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | 21.09 mm | Standard Deviation 19.71 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | 19.06 mm | Standard Deviation 16.73 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | 67.19 mm | Standard Deviation 17.93 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 31.89 mm | Standard Deviation 20.38 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 25.20 mm | Standard Deviation 21.85 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | 39.83 mm | Standard Deviation 22.75 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 40.69 mm | Standard Deviation 25.21 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | 47.58 mm | Standard Deviation 20.95 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | NA mm | — |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 44.02 mm | Standard Deviation 20.06 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | NA mm | — |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | 38.22 mm | Standard Deviation 23.33 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 38.34 mm | Standard Deviation 21.38 |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | NA mm | — |
| Adalimumab | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | 62.77 mm | Standard Deviation 15.18 |
| Adalimumab to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | 26.36 mm | Standard Deviation 17.76 |
| Adalimumab to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| Adalimumab to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | 25.74 mm | Standard Deviation 15.96 |
| Adalimumab to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | 27.05 mm | Standard Deviation 17.55 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | 28.70 mm | Standard Deviation 22.76 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | 44.76 mm | Standard Deviation 24.9 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 44.83 mm | Standard Deviation 21.34 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 43.91 mm | Standard Deviation 20.78 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | 29.95 mm | Standard Deviation 21.31 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | 46.12 mm | Standard Deviation 24.57 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 50.15 mm | Standard Deviation 20.92 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | 55.19 mm | Standard Deviation 19.98 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | 63.02 mm | Standard Deviation 18.74 |
| Placebo | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | 24.05 mm | Standard Deviation 17.75 |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Baseline (n=54,0,50,0,48,60,57,53,0,59,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 12 (n=43,0,46,0,46,57,54,46,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 16 (n=27,17,30,17,46,56,53,0,43,20,25) | 34.00 mm | Standard Deviation 20.65 |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 2 (n=54,0,51,0,46,60,57,53,0,57,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 24 (n=24,15,28,15,43,55,51,0,40,20,24) | 29.42 mm | Standard Deviation 21.01 |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 20 (n=27,16,29,16,45,52,53,0,44,19,25) | 32.40 mm | Standard Deviation 19.24 |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment (PGA) of Arthritis | Week 6 (n=48,0,47,0,45,59,55,48,0,52,0) | NA mm | — |
Secondary
Swollen Joint Counts (SJC)
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 11.11 swollen joints | Standard Deviation 11.67 |
| CP-690,550 1 mg | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 8.92 swollen joints | Standard Deviation 11.01 |
| CP-690,550 1 mg | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 12.78 swollen joints | Standard Deviation 13.24 |
| CP-690,550 1 mg | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 6.44 swollen joints | Standard Deviation 7.29 |
| CP-690,550 1 mg | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 11.39 swollen joints | Standard Deviation 11.23 |
| CP-690,550 1 mg | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 10.63 swollen joints | Standard Deviation 10.89 |
| CP-690,550 1 mg | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 7.89 swollen joints | Standard Deviation 7.95 |
| CP-690,550 1 mg | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 9.58 swollen joints | Standard Deviation 9.11 |
| CP-690,550 1 mg | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 11.87 swollen joints | Standard Deviation 7.69 |
| CP-690,550 1 mg | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 16.70 swollen joints | Standard Deviation 8.89 |
| CP-690,550 3 mg | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 10.82 swollen joints | Standard Deviation 7.63 |
| CP-690,550 3 mg | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 10.94 swollen joints | Standard Deviation 9.04 |
| CP-690,550 3 mg | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 10.31 swollen joints | Standard Deviation 8.55 |
| CP-690,550 3 mg | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA swollen joints | — |
| CP-690,550 5 mg | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 15.90 swollen joints | Standard Deviation 8.5 |
| CP-690,550 5 mg | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 9.35 swollen joints | Standard Deviation 9.52 |
| CP-690,550 5 mg | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 4.50 swollen joints | Standard Deviation 5.48 |
| CP-690,550 5 mg | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 9.26 swollen joints | Standard Deviation 10.74 |
| CP-690,550 5 mg | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 12.82 swollen joints | Standard Deviation 10.23 |
| CP-690,550 5 mg | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 9.88 swollen joints | Standard Deviation 10.87 |
| CP-690,550 5 mg | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 4.86 swollen joints | Standard Deviation 7.81 |
| CP-690,550 5 mg | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 10.98 swollen joints | Standard Deviation 10.67 |
| CP-690,550 5 mg | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 5.03 swollen joints | Standard Deviation 7.59 |
| CP-690,550 5 mg | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 10.08 swollen joints | Standard Deviation 9.55 |
| CP-690,550 10 mg | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 13.27 swollen joints | Standard Deviation 13.01 |
| CP-690,550 10 mg | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 14.38 swollen joints | Standard Deviation 13.99 |
| CP-690,550 10 mg | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 14.88 swollen joints | Standard Deviation 13.15 |
| CP-690,550 15 mg | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 6.71 swollen joints | Standard Deviation 6.96 |
| CP-690,550 15 mg | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 17.35 swollen joints | Standard Deviation 10.26 |
| CP-690,550 15 mg | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 6.93 swollen joints | Standard Deviation 7.11 |
| CP-690,550 15 mg | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 5.88 swollen joints | Standard Deviation 6.38 |
| CP-690,550 15 mg | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 5.96 swollen joints | Standard Deviation 6.54 |
| CP-690,550 15 mg | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 10.43 swollen joints | Standard Deviation 9.15 |
| CP-690,550 15 mg | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 8.15 swollen joints | Standard Deviation 7.46 |
| CP-690,550 15 mg | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 8.29 swollen joints | Standard Deviation 5.77 |
| CP-690,550 15 mg | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 12.27 swollen joints | Standard Deviation 8.9 |
| CP-690,550 15 mg | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 7.33 swollen joints | Standard Deviation 7.15 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 7.03 swollen joints | Standard Deviation 7.24 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 8.50 swollen joints | Standard Deviation 7.6 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 10.55 swollen joints | Standard Deviation 9.13 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 7.02 swollen joints | Standard Deviation 8.63 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 4.44 swollen joints | Standard Deviation 7.78 |
| Adalimumab | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 16.33 swollen joints | Standard Deviation 8.28 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 5.58 swollen joints | Standard Deviation 7.84 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 5.39 swollen joints | Standard Deviation 7.47 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 4.60 swollen joints | Standard Deviation 7.82 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 5.34 swollen joints | Standard Deviation 7.91 |
| Placebo | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 5.11 swollen joints | Standard Deviation 7.15 |
| Placebo | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 7.55 swollen joints | Standard Deviation 8.89 |
| Placebo | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 5.68 swollen joints | Standard Deviation 7.96 |
| Placebo | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 5.91 swollen joints | Standard Deviation 7.65 |
| Placebo | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 6.55 swollen joints | Standard Deviation 8.02 |
| Placebo | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 4.46 swollen joints | Standard Deviation 7.64 |
| Placebo | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 4.10 swollen joints | Standard Deviation 6.83 |
| Placebo | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 16.93 swollen joints | Standard Deviation 9.03 |
| Placebo | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 4.36 swollen joints | Standard Deviation 7.17 |
| Placebo | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 11.25 swollen joints | Standard Deviation 8.91 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | NA swollen joints | — |
| Adalimumab | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 14.91 swollen joints | Standard Deviation 8.12 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 11.58 swollen joints | Standard Deviation 9.96 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 10.08 swollen joints | Standard Deviation 8.75 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 9.27 swollen joints | Standard Deviation 9.52 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 8.89 swollen joints | Standard Deviation 10.84 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 9.11 swollen joints | Standard Deviation 11.81 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 7.41 swollen joints | Standard Deviation 7.83 |
| Adalimumab | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | NA swollen joints | — |
| Adalimumab | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 5.52 swollen joints | Standard Deviation 7.68 |
| Adalimumab to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 4.56 swollen joints | Standard Deviation 5.59 |
| Adalimumab to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA swollen joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 5.67 swollen joints | Standard Deviation 7.46 |
| Placebo | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 11.85 swollen joints | Standard Deviation 9.64 |
| Placebo | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 12.76 swollen joints | Standard Deviation 11.21 |
| Placebo | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 5.95 swollen joints | Standard Deviation 6.26 |
| Placebo | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 5.90 swollen joints | Standard Deviation 6.02 |
| Placebo | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 11.37 swollen joints | Standard Deviation 9.64 |
| Placebo | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 13.44 swollen joints | Standard Deviation 11.47 |
| Placebo | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 13.11 swollen joints | Standard Deviation 9.1 |
| Placebo | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 5.21 swollen joints | Standard Deviation 4.5 |
| Placebo | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 13.25 swollen joints | Standard Deviation 8.95 |
| Placebo | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 16.90 swollen joints | Standard Deviation 9.77 |
| Placebo to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 9.76 swollen joints | Standard Deviation 8.53 |
| Placebo to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 7.92 swollen joints | Standard Deviation 6.95 |
| Placebo to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 6.04 swollen joints | Standard Deviation 6.4 |
| Placebo to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joint Counts (SJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA swollen joints | — |
Secondary
Tender Joint Count (TJC)
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 16.30 tender joints | Standard Deviation 14.14 |
| CP-690,550 1 mg | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 10.41 tender joints | Standard Deviation 10.69 |
| CP-690,550 1 mg | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 15.13 tender joints | Standard Deviation 13.52 |
| CP-690,550 1 mg | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 18.32 tender joints | Standard Deviation 16.77 |
| CP-690,550 1 mg | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 21.98 tender joints | Standard Deviation 14.45 |
| CP-690,550 1 mg | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 11.92 tender joints | Standard Deviation 13.64 |
| CP-690,550 1 mg | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 17.15 tender joints | Standard Deviation 17.32 |
| CP-690,550 1 mg | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 7.44 tender joints | Standard Deviation 8.38 |
| CP-690,550 1 mg | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 27.02 tender joints | Standard Deviation 15.39 |
| CP-690,550 1 mg | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 20.54 tender joints | Standard Deviation 17.43 |
| CP-690,550 3 mg | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 16.19 tender joints | Standard Deviation 9.72 |
| CP-690,550 3 mg | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 21.31 tender joints | Standard Deviation 14.81 |
| CP-690,550 3 mg | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 19.47 tender joints | Standard Deviation 14.06 |
| CP-690,550 5 mg | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 6.59 tender joints | Standard Deviation 10.58 |
| CP-690,550 5 mg | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 6.27 tender joints | Standard Deviation 6.49 |
| CP-690,550 5 mg | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 13.83 tender joints | Standard Deviation 11.8 |
| CP-690,550 5 mg | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 16.94 tender joints | Standard Deviation 10.75 |
| CP-690,550 5 mg | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 13.40 tender joints | Standard Deviation 12.74 |
| CP-690,550 5 mg | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 12.67 tender joints | Standard Deviation 12.06 |
| CP-690,550 5 mg | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 6.76 tender joints | Standard Deviation 8.25 |
| CP-690,550 5 mg | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 12.33 tender joints | Standard Deviation 12.88 |
| CP-690,550 5 mg | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 24.55 tender joints | Standard Deviation 11.31 |
| CP-690,550 5 mg | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 12.65 tender joints | Standard Deviation 11.89 |
| CP-690,550 10 mg | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 19.41 tender joints | Standard Deviation 12.25 |
| CP-690,550 10 mg | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 16.60 tender joints | Standard Deviation 13.49 |
| CP-690,550 10 mg | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 18.25 tender joints | Standard Deviation 15.65 |
| CP-690,550 10 mg | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA tender joints | — |
| CP-690,550 15 mg | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 18.79 tender joints | Standard Deviation 12.42 |
| CP-690,550 15 mg | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 13.68 tender joints | Standard Deviation 12.57 |
| CP-690,550 15 mg | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 27.14 tender joints | Standard Deviation 14.62 |
| CP-690,550 15 mg | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 17.43 tender joints | Standard Deviation 13.01 |
| CP-690,550 15 mg | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 11.52 tender joints | Standard Deviation 12.35 |
| CP-690,550 15 mg | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 11.87 tender joints | Standard Deviation 11.17 |
| CP-690,550 15 mg | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 10.85 tender joints | Standard Deviation 11.11 |
| CP-690,550 15 mg | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 11.80 tender joints | Standard Deviation 12.82 |
| CP-690,550 15 mg | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 10.47 tender joints | Standard Deviation 11.5 |
| CP-690,550 15 mg | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 14.33 tender joints | Standard Deviation 11.06 |
| Adalimumab | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 7.57 tender joints | Standard Deviation 11.08 |
| Adalimumab | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 8.09 tender joints | Standard Deviation 12.02 |
| Adalimumab | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 12.84 tender joints | Standard Deviation 12.55 |
| Adalimumab | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 6.66 tender joints | Standard Deviation 10.62 |
| Adalimumab | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 7.68 tender joints | Standard Deviation 10.94 |
| Adalimumab | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 15.33 tender joints | Standard Deviation 12.74 |
| Adalimumab | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 10.95 tender joints | Standard Deviation 11.95 |
| Adalimumab | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 6.25 tender joints | Standard Deviation 10.12 |
| Adalimumab | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 10.00 tender joints | Standard Deviation 11.81 |
| Adalimumab | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 25.70 tender joints | Standard Deviation 13.92 |
| Placebo | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 25.88 tender joints | Standard Deviation 13.37 |
| Placebo | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 8.44 tender joints | Standard Deviation 11.26 |
| Placebo | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 9.23 tender joints | Standard Deviation 12.88 |
| Placebo | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 17.42 tender joints | Standard Deviation 14.33 |
| Placebo | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 13.16 tender joints | Standard Deviation 14.95 |
| Placebo | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 11.27 tender joints | Standard Deviation 14.89 |
| Placebo | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 7.22 tender joints | Standard Deviation 11.34 |
| Placebo | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 9.15 tender joints | Standard Deviation 12.18 |
| Placebo | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 6.79 tender joints | Standard Deviation 9.69 |
| Placebo | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 7.27 tender joints | Standard Deviation 11.35 |
| Adalimumab | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | NA tender joints | — |
| Adalimumab | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 19.40 tender joints | Standard Deviation 14.76 |
| Adalimumab | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 14.74 tender joints | Standard Deviation 14.73 |
| Adalimumab | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 14.47 tender joints | Standard Deviation 15.2 |
| Adalimumab | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | NA tender joints | — |
| Adalimumab | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 24.11 tender joints | Standard Deviation 13.86 |
| Adalimumab | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 16.78 tender joints | Standard Deviation 14.79 |
| Adalimumab | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 14.87 tender joints | Standard Deviation 13.11 |
| Adalimumab | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 15.73 tender joints | Standard Deviation 13.94 |
| Adalimumab | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 8.70 tender joints | Standard Deviation 9.47 |
| Adalimumab to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 8.95 tender joints | Standard Deviation 10.56 |
| Adalimumab to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 10.44 tender joints | Standard Deviation 9.97 |
| Adalimumab to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA tender joints | — |
| Adalimumab to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA tender joints | — |
| Placebo | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | 17.77 tender joints | Standard Deviation 14.45 |
| Placebo | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 8.75 tender joints | Standard Deviation 8.59 |
| Placebo | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | 25.92 tender joints | Standard Deviation 12.92 |
| Placebo | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | 15.93 tender joints | Standard Deviation 12.33 |
| Placebo | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 8.16 tender joints | Standard Deviation 8.74 |
| Placebo | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 8.30 tender joints | Standard Deviation 9.07 |
| Placebo | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | 15.50 tender joints | Standard Deviation 13.14 |
| Placebo | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | 20.00 tender joints | Standard Deviation 11.82 |
| Placebo | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | 17.22 tender joints | Standard Deviation 14.38 |
| Placebo | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | 18.94 tender joints | Standard Deviation 13.3 |
| Placebo to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 12 (n=44,0,46,0,46,57,54,46,0,46,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 4 (n=50,0,47,0,46,58,55,49,0,53,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 24 (n=24,16,29,15,43,55,52,0,39,20,24) | 10.54 tender joints | Standard Deviation 13.09 |
| Placebo to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 6 (n=48,0,48,0,45,59,55,48,0,52,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 2 (n=54,0,51,0,48,60,57,53,0,57,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 10 (n=46,0,49,0,46,57,53,45,0,46,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 8 (n=47,0,48,0,47,57,54,47,0,46,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 20 (n=27,16,29,16,45,53,53,0,44,19,25) | 12.60 tender joints | Standard Deviation 13.28 |
| Placebo to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Baseline (n=54,0,51,0,49,61,57,53,0,59,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joint Count (TJC) | Week 16 (n=27,17,30,17,46,56,54,0,43,20,25) | 12.40 tender joints | Standard Deviation 12.24 |
Other Pre-specified
Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24
The following biomarkers were assessed: CD3, CD4, CD8, CD19 and CD56. FACS analysis for lymphocyte subset markers were used to assess the effects of repeated doses of CP-690,550.
Time frame: Baseline, Week 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD8 | 0.01 cells/mcL | Standard Deviation 0.28 |
| CP-690,550 1 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD3 | 0.01 cells/mcL | Standard Deviation 0.77 |
| CP-690,550 1 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD19 | 0.03 cells/mcL | Standard Deviation 0.24 |
| CP-690,550 1 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD56 | -0.05 cells/mcL | Standard Deviation 0.05 |
| CP-690,550 1 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD4 | -0.03 cells/mcL | Standard Deviation 0.5 |
| CP-690,550 3 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD4 | -0.05 cells/mcL | Standard Deviation 0.31 |
| CP-690,550 3 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD8 | 0.04 cells/mcL | Standard Deviation 0.14 |
| CP-690,550 3 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD19 | 0.01 cells/mcL | Standard Deviation 0.1 |
| CP-690,550 3 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD3 | 0.00 cells/mcL | Standard Deviation 0.44 |
| CP-690,550 3 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD56 | 0.03 cells/mcL | Standard Deviation 0.08 |
| CP-690,550 5 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD19 | -0.00 cells/mcL | Standard Deviation 0.17 |
| CP-690,550 5 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD56 | -0.03 cells/mcL | Standard Deviation 0.05 |
| CP-690,550 5 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD4 | 0.06 cells/mcL | Standard Deviation 0.48 |
| CP-690,550 5 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD3 | 0.07 cells/mcL | Standard Deviation 0.62 |
| CP-690,550 5 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD8 | 0.01 cells/mcL | Standard Deviation 0.17 |
| CP-690,550 10 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD8 | -0.01 cells/mcL | Standard Deviation 0.14 |
| CP-690,550 10 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD3 | 0.07 cells/mcL | Standard Deviation 0.39 |
| CP-690,550 10 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD56 | -0.06 cells/mcL | Standard Deviation 0.15 |
| CP-690,550 10 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD4 | 0.07 cells/mcL | Standard Deviation 0.3 |
| CP-690,550 10 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD19 | 0.07 cells/mcL | Standard Deviation 0.07 |
| CP-690,550 15 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD19 | -0.03 cells/mcL | Standard Deviation 0.21 |
| CP-690,550 15 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD4 | -0.16 cells/mcL | Standard Deviation 0.41 |
| CP-690,550 15 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD56 | -0.06 cells/mcL | Standard Deviation 0.09 |
| CP-690,550 15 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD3 | -0.19 cells/mcL | Standard Deviation 0.52 |
| CP-690,550 15 mg | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD8 | -0.03 cells/mcL | Standard Deviation 0.18 |
| Adalimumab | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD3 | 0.01 cells/mcL | Standard Deviation 0.45 |
| Adalimumab | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD4 | 0.03 cells/mcL | Standard Deviation 0.32 |
| Adalimumab | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD8 | -0.02 cells/mcL | Standard Deviation 0.15 |
| Adalimumab | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD19 | 0.12 cells/mcL | Standard Deviation 0.14 |
| Adalimumab | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD56 | -0.06 cells/mcL | Standard Deviation 0.07 |
| Placebo | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD4 | -0.11 cells/mcL | Standard Deviation 0.31 |
| Placebo | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD3 | -0.13 cells/mcL | Standard Deviation 0.44 |
| Placebo | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD56 | -0.08 cells/mcL | Standard Deviation 0.04 |
| Placebo | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD8 | -0.03 cells/mcL | Standard Deviation 0.14 |
| Placebo | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD19 | 0.06 cells/mcL | Standard Deviation 0.1 |
| Adalimumab | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD19 | 0.09 cells/mcL | Standard Deviation 0.13 |
| Adalimumab | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD56 | -0.03 cells/mcL | Standard Deviation 0.08 |
| Adalimumab | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD8 | 0.04 cells/mcL | Standard Deviation 0.19 |
| Adalimumab | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD4 | 0.08 cells/mcL | Standard Deviation 0.49 |
| Adalimumab | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD3 | 0.12 cells/mcL | Standard Deviation 0.6 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD4 | 0.20 cells/mcL | Standard Deviation 0.33 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD3 | 0.36 cells/mcL | Standard Deviation 0.38 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD8 | 0.11 cells/mcL | Standard Deviation 0.11 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD56 | 0.01 cells/mcL | Standard Deviation 0.07 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD19 | 0.02 cells/mcL | Standard Deviation 0.03 |
| Placebo | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD3 | 0.20 cells/mcL | Standard Deviation 0.5 |
| Placebo | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD4 | 0.18 cells/mcL | Standard Deviation 0.37 |
| Placebo | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD19 | 0.13 cells/mcL | Standard Deviation 0.12 |
| Placebo | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD8 | 0.03 cells/mcL | Standard Deviation 0.14 |
| Placebo | Change From Baseline in Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers at Week 24 | CD56 | -0.05 cells/mcL | Standard Deviation 0.08 |
Other Pre-specified
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET
FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
Time frame: Baseline, Week 2, 12, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | 5.14 units on a scale | Standard Deviation 9.42 |
| CP-690,550 1 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | 0.67 units on a scale | Standard Deviation 7.79 |
| CP-690,550 1 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 4.96 units on a scale | Standard Deviation 10.75 |
| CP-690,550 3 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 5.93 units on a scale | Standard Deviation 9.93 |
| CP-690,550 3 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | NA units on a scale | — |
| CP-690,550 5 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 6.97 units on a scale | Standard Deviation 8.97 |
| CP-690,550 5 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | 6.00 units on a scale | Standard Deviation 8.2 |
| CP-690,550 5 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | 3.62 units on a scale | Standard Deviation 7.07 |
| CP-690,550 10 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 9.13 units on a scale | Standard Deviation 6.83 |
| CP-690,550 15 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 8.81 units on a scale | Standard Deviation 8.86 |
| CP-690,550 15 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | 3.38 units on a scale | Standard Deviation 9.76 |
| CP-690,550 15 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | 7.47 units on a scale | Standard Deviation 8.7 |
| Adalimumab | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | 9.40 units on a scale | Standard Deviation 11.52 |
| Adalimumab | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | 5.10 units on a scale | Standard Deviation 9.32 |
| Adalimumab | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 8.73 units on a scale | Standard Deviation 11.87 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | 6.07 units on a scale | Standard Deviation 10.34 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | 8.85 units on a scale | Standard Deviation 11.84 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 7.59 units on a scale | Standard Deviation 9.93 |
| Adalimumab | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | 3.54 units on a scale | Standard Deviation 9.18 |
| Adalimumab | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | 3.78 units on a scale | Standard Deviation 11.39 |
| Adalimumab | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 7.80 units on a scale | Standard Deviation 12.39 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | NA units on a scale | — |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | 0.70 units on a scale | Standard Deviation 8.25 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 8.90 units on a scale | Standard Deviation 8.72 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | 3.33 units on a scale | Standard Deviation 9.97 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 8.63 units on a scale | Standard Deviation 6.01 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=54,0,51,0,48,59,56,52,0,57,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=44,0,46,0,45,55,54,45,0,46,0) | NA units on a scale | — |
Other Pre-specified
Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET
Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (A SOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\*100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 2, 12, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 0.20 units on a scale | Standard Deviation 1.26 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | -6.36 units on a scale | Standard Deviation 19.18 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | -3.23 units on a scale | Standard Deviation 13.46 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | 5.37 units on a scale | Standard Deviation 20.62 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | 0.30 units on a scale | Standard Deviation 22.55 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | -11.88 units on a scale | Standard Deviation 20.92 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 0.83 units on a scale | Standard Deviation 0.92 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | 0.37 units on a scale | Standard Deviation 21.8 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | -3.27 units on a scale | Standard Deviation 14.06 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | -8.43 units on a scale | Standard Deviation 14.3 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.09 units on a scale | Standard Deviation 0.47 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | -0.00 units on a scale | Standard Deviation 19.38 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | -6.56 units on a scale | Standard Deviation 21.22 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | -7.16 units on a scale | Standard Deviation 18.36 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | 0.00 units on a scale | Standard Deviation 19.66 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | -2.96 units on a scale | Standard Deviation 19.58 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | 0.00 units on a scale | Standard Deviation 26.38 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | 0.17 units on a scale | Standard Deviation 0.56 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | -4.58 units on a scale | Standard Deviation 18.39 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | 12.92 units on a scale | Standard Deviation 30.29 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | -8.89 units on a scale | Standard Deviation 16.32 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | -8.56 units on a scale | Standard Deviation 19.55 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | 15.45 units on a scale | Standard Deviation 28.73 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | 1.82 units on a scale | Standard Deviation 29.83 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.07 units on a scale | Standard Deviation 0.43 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | 4.17 units on a scale | Standard Deviation 25.01 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 0.52 units on a scale | Standard Deviation 1.49 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | -4.00 units on a scale | Standard Deviation 18.82 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | 1.33 units on a scale | Standard Deviation 34.2 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | 11.33 units on a scale | Standard Deviation 32.04 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | -12.48 units on a scale | Standard Deviation 24.26 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | -13.33 units on a scale | Standard Deviation 20 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 0.57 units on a scale | Standard Deviation 1.02 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | -11.78 units on a scale | Standard Deviation 25.66 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | 0.00 units on a scale | Standard Deviation 0.52 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | -16.42 units on a scale | Standard Deviation 30.92 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | -5.36 units on a scale | Standard Deviation 11.58 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | -14.44 units on a scale | Standard Deviation 17.7 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | -5.49 units on a scale | Standard Deviation 17.22 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | -7.83 units on a scale | Standard Deviation 31.97 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | -6.96 units on a scale | Standard Deviation 17.94 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | -11.95 units on a scale | Standard Deviation 21.04 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | -4.83 units on a scale | Standard Deviation 27.6 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | -12.18 units on a scale | Standard Deviation 17.21 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | -6.59 units on a scale | Standard Deviation 17.72 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | -1.18 units on a scale | Standard Deviation 20.65 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | -0.02 units on a scale | Standard Deviation 0.54 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 0.15 units on a scale | Standard Deviation 1.26 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | -2.13 units on a scale | Standard Deviation 12.63 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 0.45 units on a scale | Standard Deviation 1.5 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | -3.20 units on a scale | Standard Deviation 26.3 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | 6.52 units on a scale | Standard Deviation 26.52 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | 0.07 units on a scale | Standard Deviation 0.53 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | -8.25 units on a scale | Standard Deviation 14.46 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | -10.24 units on a scale | Standard Deviation 22.44 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | -16.98 units on a scale | Standard Deviation 24.82 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | -0.10 units on a scale | Standard Deviation 0.5 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | -3.91 units on a scale | Standard Deviation 28.16 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | -8.97 units on a scale | Standard Deviation 32.33 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | -0.10 units on a scale | Standard Deviation 1.12 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | -8.85 units on a scale | Standard Deviation 16.99 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | 9.66 units on a scale | Standard Deviation 26.39 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | -8.24 units on a scale | Standard Deviation 22.33 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | -2.67 units on a scale | Standard Deviation 19.81 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | -0.27 units on a scale | Standard Deviation 1.53 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | -0.13 units on a scale | Standard Deviation 0.64 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | -11.50 units on a scale | Standard Deviation 23.66 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | 6.67 units on a scale | Standard Deviation 31.77 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | 4.67 units on a scale | Standard Deviation 27.74 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | -9.78 units on a scale | Standard Deviation 19.33 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | -8.52 units on a scale | Standard Deviation 19.53 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | -5.11 units on a scale | Standard Deviation 21.34 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | -9.10 units on a scale | Standard Deviation 18.33 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | -1.67 units on a scale | Standard Deviation 15.34 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | 7.21 units on a scale | Standard Deviation 26.76 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | -7.29 units on a scale | Standard Deviation 18.56 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 0.19 units on a scale | Standard Deviation 1.16 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | -3.62 units on a scale | Standard Deviation 17.59 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | -5.73 units on a scale | Standard Deviation 16.87 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | 0.93 units on a scale | Standard Deviation 27.59 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | 1.78 units on a scale | Standard Deviation 20.37 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | -7.89 units on a scale | Standard Deviation 25.34 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.08 units on a scale | Standard Deviation 0.5 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | -12.33 units on a scale | Standard Deviation 24.35 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | -2.50 units on a scale | Standard Deviation 18.09 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | -6.38 units on a scale | Standard Deviation 22.8 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | 0.23 units on a scale | Standard Deviation 0.53 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | 5.83 units on a scale | Standard Deviation 25.75 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | -0.02 units on a scale | Standard Deviation 0.54 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | 3.56 units on a scale | Standard Deviation 25.33 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 0.37 units on a scale | Standard Deviation 1.2 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 0.16 units on a scale | Standard Deviation 1.11 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | -4.89 units on a scale | Standard Deviation 20.96 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | 5.83 units on a scale | Standard Deviation 23.95 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | -4.74 units on a scale | Standard Deviation 17.05 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | -6.90 units on a scale | Standard Deviation 18.39 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | -3.41 units on a scale | Standard Deviation 21.63 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | 2.33 units on a scale | Standard Deviation 26.26 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | -0.14 units on a scale | Standard Deviation 18.63 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | -12.52 units on a scale | Standard Deviation 22.44 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | -7.12 units on a scale | Standard Deviation 15.14 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | -7.95 units on a scale | Standard Deviation 15.26 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | 7.29 units on a scale | Standard Deviation 23.33 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | -4.07 units on a scale | Standard Deviation 30.8 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | -9.83 units on a scale | Standard Deviation 19.04 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.13 units on a scale | Standard Deviation 0.5 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 0.20 units on a scale | Standard Deviation 1.22 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | -1.69 units on a scale | Standard Deviation 19.75 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | -6.33 units on a scale | Standard Deviation 19.2 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | -9.82 units on a scale | Standard Deviation 18.09 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | -10.75 units on a scale | Standard Deviation 17.25 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | 9.30 units on a scale | Standard Deviation 27.38 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | -6.67 units on a scale | Standard Deviation 25.45 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.19 units on a scale | Standard Deviation 0.52 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 0.27 units on a scale | Standard Deviation 1.36 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | -1.40 units on a scale | Standard Deviation 25.6 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | -8.30 units on a scale | Standard Deviation 22.37 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | -11.09 units on a scale | Standard Deviation 18.31 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | -12.14 units on a scale | Standard Deviation 17.76 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | 10.00 units on a scale | Standard Deviation 29.19 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | -2.91 units on a scale | Standard Deviation 27.6 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | -16.14 units on a scale | Standard Deviation 22.21 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | 0.05 units on a scale | Standard Deviation 0.52 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 0.18 units on a scale | Standard Deviation 1.59 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | -2.18 units on a scale | Standard Deviation 24.55 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | -10.42 units on a scale | Standard Deviation 23.4 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | -12.08 units on a scale | Standard Deviation 23.49 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | 0.77 units on a scale | Standard Deviation 27.99 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | -11.70 units on a scale | Standard Deviation 18.44 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | -9.62 units on a scale | Standard Deviation 16.95 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | -9.43 units on a scale | Standard Deviation 18.65 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | -3.40 units on a scale | Standard Deviation 24.72 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.07 units on a scale | Standard Deviation 0.64 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | 0.08 units on a scale | Standard Deviation 0.52 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | -12.16 units on a scale | Standard Deviation 17.51 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | -4.56 units on a scale | Standard Deviation 21.39 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 0.39 units on a scale | Standard Deviation 1.06 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | 15.28 units on a scale | Standard Deviation 26.79 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | -1.51 units on a scale | Standard Deviation 19.55 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | -7.84 units on a scale | Standard Deviation 17.05 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | -8.89 units on a scale | Standard Deviation 17.59 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | -10.00 units on a scale | Standard Deviation 20.69 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | 10.77 units on a scale | Standard Deviation 26.33 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 0.30 units on a scale | Standard Deviation 1.34 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | -3.08 units on a scale | Standard Deviation 29.48 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | -13.20 units on a scale | Standard Deviation 23.25 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | -11.03 units on a scale | Standard Deviation 22.05 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | -8.40 units on a scale | Standard Deviation 23.32 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 0.62 units on a scale | Standard Deviation 1.24 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | 12.46 units on a scale | Standard Deviation 25.44 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | 0.00 units on a scale | Standard Deviation 27.26 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.05 units on a scale | Standard Deviation 0.61 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | -11.68 units on a scale | Standard Deviation 17.94 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | 9.33 units on a scale | Standard Deviation 27.91 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | -9.66 units on a scale | Standard Deviation 18.94 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 0.02 units on a scale | Standard Deviation 1.49 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | -0.13 units on a scale | Standard Deviation 0.44 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | -7.36 units on a scale | Standard Deviation 15.12 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | -7.41 units on a scale | Standard Deviation 15.38 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | -3.11 units on a scale | Standard Deviation 25.21 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | -0.89 units on a scale | Standard Deviation 27.29 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | 10.00 units on a scale | Standard Deviation 24.73 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | -0.04 units on a scale | Standard Deviation 0.47 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | -6.96 units on a scale | Standard Deviation 16.3 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | -1.04 units on a scale | Standard Deviation 21.08 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | -1.92 units on a scale | Standard Deviation 23.85 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | -0.90 units on a scale | Standard Deviation 16.38 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | -9.11 units on a scale | Standard Deviation 21.04 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | NA units on a scale | — |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 0.07 units on a scale | Standard Deviation 2.2 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | -1.15 units on a scale | Standard Deviation 16.53 |
| Adalimumab | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | -6.99 units on a scale | Standard Deviation 16.29 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | -11.50 units on a scale | Standard Deviation 22.93 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | -12.25 units on a scale | Standard Deviation 20.59 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | 21.00 units on a scale | Standard Deviation 26.68 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | 5.00 units on a scale | Standard Deviation 29.26 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | -13.44 units on a scale | Standard Deviation 26.54 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | -0.08 units on a scale | Standard Deviation 0.62 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | -5.50 units on a scale | Standard Deviation 23.24 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 0.23 units on a scale | Standard Deviation 2.39 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | 2.50 units on a scale | Standard Deviation 22.27 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | -1.21 units on a scale | Standard Deviation 14.75 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | -6.36 units on a scale | Standard Deviation 23.93 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | 11.14 units on a scale | Standard Deviation 21.15 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 0.50 units on a scale | Standard Deviation 1.19 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | -13.04 units on a scale | Standard Deviation 25.94 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | -10.92 units on a scale | Standard Deviation 20.62 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | -5.89 units on a scale | Standard Deviation 16.19 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | -1.67 units on a scale | Standard Deviation 18.53 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | -4.85 units on a scale | Standard Deviation 15.95 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | -10.19 units on a scale | Standard Deviation 18.39 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | -5.26 units on a scale | Standard Deviation 16.27 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | -10.35 units on a scale | Standard Deviation 13.71 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | 0.20 units on a scale | Standard Deviation 0.62 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | -2.11 units on a scale | Standard Deviation 39.38 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | -0.36 units on a scale | Standard Deviation 18.25 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | -6.18 units on a scale | Standard Deviation 18.81 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.00 units on a scale | Standard Deviation 0.56 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 0.35 units on a scale | Standard Deviation 1.57 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | 13.16 units on a scale | Standard Deviation 16.68 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 0.11 units on a scale | Standard Deviation 1.19 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | 5.82 units on a scale | Standard Deviation 19.79 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | -6.82 units on a scale | Standard Deviation 23.21 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | -9.32 units on a scale | Standard Deviation 18.57 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | -8.60 units on a scale | Standard Deviation 13.21 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | -5.26 units on a scale | Standard Deviation 16.11 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.11 units on a scale | Standard Deviation 0.57 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | -7.89 units on a scale | Standard Deviation 23.77 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,19,24) | -11.94 units on a scale | Standard Deviation 22.76 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=24,15,29,15,43,55,52,0,40,19,24) | -16.15 units on a scale | Standard Deviation 23.75 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=24,16,29,15,43,55,52,0,40,20,24) | 0.08 units on a scale | Standard Deviation 0.5 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 0.33 units on a scale | Standard Deviation 1.31 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,55,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,44,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,19,24) | 17.50 units on a scale | Standard Deviation 28.93 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=24,15,29,15,43,55,52,0,40,19,24) | -2.50 units on a scale | Standard Deviation 13.59 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,19,24) | -12.64 units on a scale | Standard Deviation 19.16 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,19,24) | 5.83 units on a scale | Standard Deviation 18.16 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,19,24) | -5.83 units on a scale | Standard Deviation 27.96 |
Other Pre-specified
Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24
Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgG, IgM, and IgA levels.
Time frame: Baseline, Week 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgM | 7.83 mg/dL | Standard Deviation 21.88 |
| CP-690,550 1 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgA | 6.28 mg/dL | Standard Deviation 44.81 |
| CP-690,550 1 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgG | -13.50 mg/dL | Standard Deviation 159.02 |
| CP-690,550 3 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgM | -9.73 mg/dL | Standard Deviation 35.26 |
| CP-690,550 3 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgG | -114.27 mg/dL | Standard Deviation 321.37 |
| CP-690,550 3 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgA | 7.07 mg/dL | Standard Deviation 164.76 |
| CP-690,550 5 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgM | -11.86 mg/dL | Standard Deviation 25.02 |
| CP-690,550 5 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgA | -38.50 mg/dL | Standard Deviation 55.58 |
| CP-690,550 5 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgG | -71.55 mg/dL | Standard Deviation 152.89 |
| CP-690,550 10 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgM | -3.73 mg/dL | Standard Deviation 27.32 |
| CP-690,550 10 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgG | -145.36 mg/dL | Standard Deviation 267.2 |
| CP-690,550 10 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgA | -45.36 mg/dL | Standard Deviation 59.51 |
| CP-690,550 15 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgM | 4.25 mg/dL | Standard Deviation 16.41 |
| CP-690,550 15 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgG | -53.81 mg/dL | Standard Deviation 164.31 |
| CP-690,550 15 mg | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgA | -24.53 mg/dL | Standard Deviation 48.01 |
| Adalimumab | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgM | -17.02 mg/dL | Standard Deviation 41.65 |
| Adalimumab | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgG | -131.50 mg/dL | Standard Deviation 183.76 |
| Adalimumab | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgA | -42.50 mg/dL | Standard Deviation 72.55 |
| Placebo | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgG | -86.44 mg/dL | Standard Deviation 175.79 |
| Placebo | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgA | -68.41 mg/dL | Standard Deviation 104.16 |
| Placebo | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgM | -22.73 mg/dL | Standard Deviation 33.64 |
| Adalimumab | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgM | -3.69 mg/dL | Standard Deviation 46.72 |
| Adalimumab | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgG | -49.81 mg/dL | Standard Deviation 192.28 |
| Adalimumab | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgA | -26.03 mg/dL | Standard Deviation 82.04 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgM | 3.00 mg/dL | Standard Deviation 30.44 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgG | 31.00 mg/dL | Standard Deviation 129.17 |
| Adalimumab to CP-690,550 5 mg (R) | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgA | 8.60 mg/dL | Standard Deviation 45.09 |
| Placebo | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgG | -59.75 mg/dL | Standard Deviation 163.33 |
| Placebo | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgA | -18.15 mg/dL | Standard Deviation 52.51 |
| Placebo | Change From Baseline in Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels at Week 24 | IgM | -2.50 mg/dL | Standard Deviation 37.27 |
Other Pre-specified
Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers
The following biomarkers were assessed: Cluster of Differentiation 3 (CD3), CD4, CD8, CD19 and CD56. FACS analysis for lymphocyte subset markers were used to assess the effects of repeated doses of CP-690,550.
Time frame: Baseline, Week 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.10 cells per micro liter (cells/mcL) | Standard Deviation 0.06 |
| CP-690,550 1 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | 0.23 cells per micro liter (cells/mcL) | Standard Deviation 0.18 |
| CP-690,550 1 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.16 cells per micro liter (cells/mcL) | Standard Deviation 0.67 |
| CP-690,550 1 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.84 cells per micro liter (cells/mcL) | Standard Deviation 0.41 |
| CP-690,550 1 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.75 cells per micro liter (cells/mcL) | Standard Deviation 0.42 |
| CP-690,550 1 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.21 cells per micro liter (cells/mcL) | Standard Deviation 0.16 |
| CP-690,550 1 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | 1.29 cells per micro liter (cells/mcL) | Standard Deviation 0.59 |
| CP-690,550 1 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.38 cells per micro liter (cells/mcL) | Standard Deviation 0.26 |
| CP-690,550 1 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.44 cells per micro liter (cells/mcL) | Standard Deviation 0.29 |
| CP-690,550 1 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.15 cells per micro liter (cells/mcL) | Standard Deviation 0.09 |
| CP-690,550 3 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.87 cells per micro liter (cells/mcL) | Standard Deviation 0.33 |
| CP-690,550 3 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.45 cells per micro liter (cells/mcL) | Standard Deviation 0.57 |
| CP-690,550 3 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| CP-690,550 3 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| CP-690,550 3 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| CP-690,550 3 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | 0.27 cells per micro liter (cells/mcL) | Standard Deviation 0.14 |
| CP-690,550 3 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.58 cells per micro liter (cells/mcL) | Standard Deviation 0.43 |
| CP-690,550 3 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| CP-690,550 3 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| CP-690,550 3 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.12 cells per micro liter (cells/mcL) | Standard Deviation 0.09 |
| CP-690,550 5 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.93 cells per micro liter (cells/mcL) | Standard Deviation 0.35 |
| CP-690,550 5 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | 1.31 cells per micro liter (cells/mcL) | Standard Deviation 0.46 |
| CP-690,550 5 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.37 cells per micro liter (cells/mcL) | Standard Deviation 0.2 |
| CP-690,550 5 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.11 cells per micro liter (cells/mcL) | Standard Deviation 0.08 |
| CP-690,550 5 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | 0.22 cells per micro liter (cells/mcL) | Standard Deviation 0.11 |
| CP-690,550 5 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.20 cells per micro liter (cells/mcL) | Standard Deviation 0.11 |
| CP-690,550 5 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.01 cells per micro liter (cells/mcL) | Standard Deviation 0.65 |
| CP-690,550 5 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.42 cells per micro liter (cells/mcL) | Standard Deviation 0.25 |
| CP-690,550 5 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.45 cells per micro liter (cells/mcL) | Standard Deviation 0.82 |
| CP-690,550 5 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.14 cells per micro liter (cells/mcL) | Standard Deviation 0.1 |
| CP-690,550 10 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| CP-690,550 10 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| CP-690,550 10 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| CP-690,550 10 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| CP-690,550 10 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| CP-690,550 10 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.20 cells per micro liter (cells/mcL) | Standard Deviation 0.46 |
| CP-690,550 10 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.86 cells per micro liter (cells/mcL) | Standard Deviation 0.35 |
| CP-690,550 10 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.30 cells per micro liter (cells/mcL) | Standard Deviation 0.13 |
| CP-690,550 10 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | 0.27 cells per micro liter (cells/mcL) | Standard Deviation 0.15 |
| CP-690,550 10 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.08 cells per micro liter (cells/mcL) | Standard Deviation 0.1 |
| CP-690,550 15 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.10 cells per micro liter (cells/mcL) | Standard Deviation 0.43 |
| CP-690,550 15 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.22 cells per micro liter (cells/mcL) | Standard Deviation 0.23 |
| CP-690,550 15 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.77 cells per micro liter (cells/mcL) | Standard Deviation 0.3 |
| CP-690,550 15 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.93 cells per micro liter (cells/mcL) | Standard Deviation 0.56 |
| CP-690,550 15 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.37 cells per micro liter (cells/mcL) | Standard Deviation 0.26 |
| CP-690,550 15 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.14 cells per micro liter (cells/mcL) | Standard Deviation 0.1 |
| CP-690,550 15 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.07 cells per micro liter (cells/mcL) | Standard Deviation 0.05 |
| CP-690,550 15 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | 0.17 cells per micro liter (cells/mcL) | Standard Deviation 0.11 |
| CP-690,550 15 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.31 cells per micro liter (cells/mcL) | Standard Deviation 0.18 |
| CP-690,550 15 mg | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | 1.31 cells per micro liter (cells/mcL) | Standard Deviation 0.73 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.19 cells per micro liter (cells/mcL) | Standard Deviation 0.09 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | 1.24 cells per micro liter (cells/mcL) | Standard Deviation 0.61 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | 0.31 cells per micro liter (cells/mcL) | Standard Deviation 0.16 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.92 cells per micro liter (cells/mcL) | Standard Deviation 0.51 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.85 cells per micro liter (cells/mcL) | Standard Deviation 0.49 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.37 cells per micro liter (cells/mcL) | Standard Deviation 0.19 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.33 cells per micro liter (cells/mcL) | Standard Deviation 0.15 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.05 cells per micro liter (cells/mcL) | Standard Deviation 0.05 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.27 cells per micro liter (cells/mcL) | Standard Deviation 0.61 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.14 cells per micro liter (cells/mcL) | Standard Deviation 0.12 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.89 cells per micro liter (cells/mcL) | Standard Deviation 0.35 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.40 cells per micro liter (cells/mcL) | Standard Deviation 0.21 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.14 cells per micro liter (cells/mcL) | Standard Deviation 0.1 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.04 cells per micro liter (cells/mcL) | Standard Deviation 0.03 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.14 cells per micro liter (cells/mcL) | Standard Deviation 0.36 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.82 cells per micro liter (cells/mcL) | Standard Deviation 0.26 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.32 cells per micro liter (cells/mcL) | Standard Deviation 0.14 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | 0.24 cells per micro liter (cells/mcL) | Standard Deviation 0.09 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | 1.30 cells per micro liter (cells/mcL) | Standard Deviation 0.51 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.20 cells per micro liter (cells/mcL) | Standard Deviation 0.12 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | NA cells per micro liter (cells/mcL) | — |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | NA cells per micro liter (cells/mcL) | — |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | NA cells per micro liter (cells/mcL) | — |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.43 cells per micro liter (cells/mcL) | Standard Deviation 0.23 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | NA cells per micro liter (cells/mcL) | — |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | 1.36 cells per micro liter (cells/mcL) | Standard Deviation 0.52 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | NA cells per micro liter (cells/mcL) | — |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.14 cells per micro liter (cells/mcL) | Standard Deviation 0.12 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.91 cells per micro liter (cells/mcL) | Standard Deviation 0.4 |
| Adalimumab | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.18 cells per micro liter (cells/mcL) | Standard Deviation 0.1 |
| Adalimumab to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.46 cells per micro liter (cells/mcL) | Standard Deviation 0.48 |
| Adalimumab to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.45 cells per micro liter (cells/mcL) | Standard Deviation 0.34 |
| Adalimumab to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| Adalimumab to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| Adalimumab to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| Adalimumab to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.09 cells per micro liter (cells/mcL) | Standard Deviation 0.09 |
| Adalimumab to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | 0.29 cells per micro liter (cells/mcL) | Standard Deviation 0.15 |
| Adalimumab to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.98 cells per micro liter (cells/mcL) | Standard Deviation 0.35 |
| Adalimumab to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| Adalimumab to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.63 cells per micro liter (cells/mcL) | Standard Deviation 0.69 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.80 cells per micro liter (cells/mcL) | Standard Deviation 0.34 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | 0.35 cells per micro liter (cells/mcL) | Standard Deviation 0.21 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.58 cells per micro liter (cells/mcL) | Standard Deviation 0.34 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | 1.17 cells per micro liter (cells/mcL) | Standard Deviation 0.49 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.15 cells per micro liter (cells/mcL) | Standard Deviation 0.12 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.12 cells per micro liter (cells/mcL) | Standard Deviation 0.09 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | 0.16 cells per micro liter (cells/mcL) | Standard Deviation 0.1 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | 0.12 cells per micro liter (cells/mcL) | Standard Deviation 0.05 |
| Placebo | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.01 cells per micro liter (cells/mcL) | Standard Deviation 0.52 |
| Placebo to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD3 (n=16,6,17,7,22,29,26,0,19,9,12) | 1.26 cells per micro liter (cells/mcL) | Standard Deviation 0.57 |
| Placebo to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD19 (n=30,0,34,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| Placebo to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD8 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.33 cells per micro liter (cells/mcL) | Standard Deviation 0.14 |
| Placebo to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD8 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| Placebo to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD56 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.07 cells per micro liter (cells/mcL) | Standard Deviation 0.06 |
| Placebo to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD56 (n=30,0,34,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| Placebo to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD3 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| Placebo to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD4 (n=16,6,17,7,22,29,26,0,19,9,12) | 0.91 cells per micro liter (cells/mcL) | Standard Deviation 0.45 |
| Placebo to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Baseline: CD4 (n=30,0,35,0,29,37,34,32,0,40,0) | NA cells per micro liter (cells/mcL) | — |
| Placebo to CP-690,550 5 mg (R) | Fluorescence Activated Cell Sorting (FACS) Lymphocyte Biomarkers | Week 24: CD19 (n=16,6,17,7,22,29,25,0,19,9,12) | 0.31 cells per micro liter (cells/mcL) | Standard Deviation 0.21 |
Other Pre-specified
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
Time frame: Baseline, Week 2, 12, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | 34.57 units on a scale | Standard Deviation 10.82 |
| CP-690,550 1 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 35.21 units on a scale | Standard Deviation 12.24 |
| CP-690,550 1 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | 28.39 units on a scale | Standard Deviation 11.55 |
| CP-690,550 1 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | 29.06 units on a scale | Standard Deviation 10.94 |
| CP-690,550 3 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | NA units on a scale | — |
| CP-690,550 3 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 31.53 units on a scale | Standard Deviation 9.98 |
| CP-690,550 3 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 5 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | 33.37 units on a scale | Standard Deviation 10.05 |
| CP-690,550 5 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 37.48 units on a scale | Standard Deviation 10.08 |
| CP-690,550 5 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | 30.52 units on a scale | Standard Deviation 9.7 |
| CP-690,550 5 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | 26.90 units on a scale | Standard Deviation 9.66 |
| CP-690,550 10 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 31.80 units on a scale | Standard Deviation 8.79 |
| CP-690,550 10 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | NA units on a scale | — |
| CP-690,550 15 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 35.00 units on a scale | Standard Deviation 10.34 |
| CP-690,550 15 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | 34.11 units on a scale | Standard Deviation 11.29 |
| CP-690,550 15 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | 30.31 units on a scale | Standard Deviation 11.84 |
| CP-690,550 15 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | 26.84 units on a scale | Standard Deviation 11.85 |
| Adalimumab | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 35.82 units on a scale | Standard Deviation 11.59 |
| Adalimumab | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | 26.75 units on a scale | Standard Deviation 12.19 |
| Adalimumab | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | 31.80 units on a scale | Standard Deviation 11.57 |
| Adalimumab | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | 37.11 units on a scale | Standard Deviation 11.5 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | 35.30 units on a scale | Standard Deviation 11.63 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 34.03 units on a scale | Standard Deviation 10.87 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | 25.74 units on a scale | Standard Deviation 11.32 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | 31.66 units on a scale | Standard Deviation 10.99 |
| Adalimumab | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | 29.15 units on a scale | Standard Deviation 12.08 |
| Adalimumab | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | 30.58 units on a scale | Standard Deviation 10.85 |
| Adalimumab | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | 25.87 units on a scale | Standard Deviation 11.93 |
| Adalimumab to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 34.90 units on a scale | Standard Deviation 10.47 |
| Adalimumab to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | NA units on a scale | — |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | 31.09 units on a scale | Standard Deviation 10.91 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | 28.23 units on a scale | Standard Deviation 10.38 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | 27.49 units on a scale | Standard Deviation 9.96 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 35.45 units on a scale | Standard Deviation 7.27 |
| Placebo to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=54,0,51,0,48,60,56,52,0,57,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=24,15,29,15,43,55,52,0,40,20,24) | 37.25 units on a scale | Standard Deviation 8.52 |
| Placebo to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=44,0,46,0,45,56,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=54,0,51,0,49,60,57,53,0,59,0) | NA units on a scale | — |
Other Pre-specified
Medical Outcome Study- Sleep Scale (MOS-SS)
Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 2, 12, 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | 36.44 units on a scale | Standard Deviation 22.04 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | 6.11 units on a scale | Standard Deviation 1.5 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | 25.00 units on a scale | Standard Deviation 27.82 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | 0.31 units on a scale | Standard Deviation 0.47 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | 45.06 units on a scale | Standard Deviation 22.24 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | 29.79 units on a scale | Standard Deviation 21.33 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | 46.60 units on a scale | Standard Deviation 28 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | 0.58 units on a scale | Standard Deviation 0.5 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | 38.58 units on a scale | Standard Deviation 27.93 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | 36.05 units on a scale | Standard Deviation 21.34 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | 58.18 units on a scale | Standard Deviation 27.39 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | 44.87 units on a scale | Standard Deviation 22.05 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | 42.01 units on a scale | Standard Deviation 25.44 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.45 units on a scale | Standard Deviation 0.5 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | 23.33 units on a scale | Standard Deviation 24.8 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 6.77 units on a scale | Standard Deviation 1.71 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | 29.44 units on a scale | Standard Deviation 20.8 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 6.31 units on a scale | Standard Deviation 1.56 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | 35.61 units on a scale | Standard Deviation 22.63 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | 46.11 units on a scale | Standard Deviation 27.22 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | 30.45 units on a scale | Standard Deviation 30.65 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | 41.64 units on a scale | Standard Deviation 20.16 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | 19.09 units on a scale | Standard Deviation 21.55 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | 23.33 units on a scale | Standard Deviation 20.14 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | 34.70 units on a scale | Standard Deviation 22.07 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | 40.74 units on a scale | Standard Deviation 27.26 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.39 units on a scale | Standard Deviation 0.49 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | 41.79 units on a scale | Standard Deviation 21.15 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | 30.83 units on a scale | Standard Deviation 18.55 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | 36.05 units on a scale | Standard Deviation 22.6 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | 30.93 units on a scale | Standard Deviation 18.06 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | 30.00 units on a scale | Standard Deviation 34.04 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | 60.00 units on a scale | Standard Deviation 28.89 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | 27.04 units on a scale | Standard Deviation 28.59 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 7.04 units on a scale | Standard Deviation 1.63 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | 22.96 units on a scale | Standard Deviation 22.79 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | 33.33 units on a scale | Standard Deviation 36.77 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 7.00 units on a scale | Standard Deviation 1.41 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | 0.31 units on a scale | Standard Deviation 0.48 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | 41.58 units on a scale | Standard Deviation 23.29 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | 36.00 units on a scale | Standard Deviation 21.65 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | 40.67 units on a scale | Standard Deviation 29.39 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | 43.37 units on a scale | Standard Deviation 19.86 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | 45.56 units on a scale | Standard Deviation 20.77 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | 30.67 units on a scale | Standard Deviation 18.14 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | 41.39 units on a scale | Standard Deviation 26.18 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | 0.55 units on a scale | Standard Deviation 0.51 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | 34.27 units on a scale | Standard Deviation 24.8 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | 32.32 units on a scale | Standard Deviation 18.93 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | 38.62 units on a scale | Standard Deviation 32.04 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 6.83 units on a scale | Standard Deviation 1.42 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | 43.19 units on a scale | Standard Deviation 19.05 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | 43.73 units on a scale | Standard Deviation 19.87 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | 31.59 units on a scale | Standard Deviation 21.84 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | 22.17 units on a scale | Standard Deviation 26.07 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | 59.66 units on a scale | Standard Deviation 26.52 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | 36.96 units on a scale | Standard Deviation 33.19 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | 38.93 units on a scale | Standard Deviation 21.68 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | 0.45 units on a scale | Standard Deviation 0.5 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | 51.30 units on a scale | Standard Deviation 28.17 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | 26.44 units on a scale | Standard Deviation 19.48 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 6.41 units on a scale | Standard Deviation 1.42 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | 43.14 units on a scale | Standard Deviation 26.72 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | 45.56 units on a scale | Standard Deviation 19.63 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | 52.40 units on a scale | Standard Deviation 25.12 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | 38.48 units on a scale | Standard Deviation 21.95 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | 33.20 units on a scale | Standard Deviation 18.4 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 6.65 units on a scale | Standard Deviation 1.61 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | 24.14 units on a scale | Standard Deviation 27.97 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | 32.16 units on a scale | Standard Deviation 30.22 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | 38.69 units on a scale | Standard Deviation 21.95 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | 44.48 units on a scale | Standard Deviation 25.12 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | 29.41 units on a scale | Standard Deviation 30.03 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | 26.80 units on a scale | Standard Deviation 28.46 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.35 units on a scale | Standard Deviation 0.48 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | 40.39 units on a scale | Standard Deviation 36.33 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | 6.51 units on a scale | Standard Deviation 1.62 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | 44.31 units on a scale | Standard Deviation 27.44 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.43 units on a scale | Standard Deviation 0.5 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | 48.34 units on a scale | Standard Deviation 19.98 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | 32.07 units on a scale | Standard Deviation 18.22 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | 39.33 units on a scale | Standard Deviation 22.54 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | 0.33 units on a scale | Standard Deviation 0.49 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | 45.33 units on a scale | Standard Deviation 26.96 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | 38.58 units on a scale | Standard Deviation 24.3 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | 30.67 units on a scale | Standard Deviation 33.69 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | 39.67 units on a scale | Standard Deviation 21.03 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | 36.00 units on a scale | Standard Deviation 33.97 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 6.60 units on a scale | Standard Deviation 1.35 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | 31.11 units on a scale | Standard Deviation 22.21 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | 34.42 units on a scale | Standard Deviation 31.27 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | 53.26 units on a scale | Standard Deviation 24.08 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.60 units on a scale | Standard Deviation 0.49 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | 31.84 units on a scale | Standard Deviation 34.14 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | 39.86 units on a scale | Standard Deviation 17.35 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | 34.30 units on a scale | Standard Deviation 18.69 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | 30.83 units on a scale | Standard Deviation 30.02 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | 45.10 units on a scale | Standard Deviation 23.73 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | 36.05 units on a scale | Standard Deviation 22.27 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | 30.39 units on a scale | Standard Deviation 17.54 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | 33.72 units on a scale | Standard Deviation 18.42 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | 37.51 units on a scale | Standard Deviation 17.81 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | 37.22 units on a scale | Standard Deviation 17.41 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | 33.19 units on a scale | Standard Deviation 24.39 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 7.14 units on a scale | Standard Deviation 1.06 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | 34.67 units on a scale | Standard Deviation 32.59 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | 48.67 units on a scale | Standard Deviation 24.36 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | 38.61 units on a scale | Standard Deviation 17.17 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 6.91 units on a scale | Standard Deviation 1.28 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | 51.04 units on a scale | Standard Deviation 25.54 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.47 units on a scale | Standard Deviation 0.5 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | 42.51 units on a scale | Standard Deviation 18.35 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 6.98 units on a scale | Standard Deviation 1.23 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | 26.25 units on a scale | Standard Deviation 28.03 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | 6.76 units on a scale | Standard Deviation 1.39 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | 35.69 units on a scale | Standard Deviation 22.2 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | 37.94 units on a scale | Standard Deviation 25.31 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | 37.81 units on a scale | Standard Deviation 23.4 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | 44.52 units on a scale | Standard Deviation 25.73 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | 35.85 units on a scale | Standard Deviation 16.91 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | 33.58 units on a scale | Standard Deviation 22.98 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | 16.00 units on a scale | Standard Deviation 22.4 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | 0.72 units on a scale | Standard Deviation 0.45 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | 20.82 units on a scale | Standard Deviation 22.35 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | 0.51 units on a scale | Standard Deviation 0.51 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | 22.79 units on a scale | Standard Deviation 29.79 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | 33.09 units on a scale | Standard Deviation 23.23 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | 44.86 units on a scale | Standard Deviation 17.6 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | 45.82 units on a scale | Standard Deviation 15.79 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | 41.31 units on a scale | Standard Deviation 24.93 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | 23.61 units on a scale | Standard Deviation 27.69 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | 48.34 units on a scale | Standard Deviation 22.61 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | 0.31 units on a scale | Standard Deviation 0.47 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | 6.59 units on a scale | Standard Deviation 1.76 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | 33.11 units on a scale | Standard Deviation 31.6 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | 38.91 units on a scale | Standard Deviation 25.57 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | 37.57 units on a scale | Standard Deviation 17.68 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | 37.75 units on a scale | Standard Deviation 16.8 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | 47.80 units on a scale | Standard Deviation 26.4 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | 19.32 units on a scale | Standard Deviation 23.18 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | 38.24 units on a scale | Standard Deviation 23.34 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.45 units on a scale | Standard Deviation 0.5 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 6.85 units on a scale | Standard Deviation 1.69 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | 30.85 units on a scale | Standard Deviation 29.79 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | 31.75 units on a scale | Standard Deviation 22.57 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | 35.09 units on a scale | Standard Deviation 18.32 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | 35.19 units on a scale | Standard Deviation 17.56 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | 49.82 units on a scale | Standard Deviation 28.06 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | 17.19 units on a scale | Standard Deviation 19.8 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | 36.47 units on a scale | Standard Deviation 25.9 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.51 units on a scale | Standard Deviation 0.5 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 6.80 units on a scale | Standard Deviation 1.55 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | 30.53 units on a scale | Standard Deviation 25.1 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | 29.12 units on a scale | Standard Deviation 21.44 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | 34.18 units on a scale | Standard Deviation 18.66 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | 34.18 units on a scale | Standard Deviation 17.79 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | 50.00 units on a scale | Standard Deviation 28.41 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | 21.45 units on a scale | Standard Deviation 21.72 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | 0.38 units on a scale | Standard Deviation 0.49 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 6.73 units on a scale | Standard Deviation 1.6 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | 28.73 units on a scale | Standard Deviation 27.96 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | 27.39 units on a scale | Standard Deviation 20.47 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 6.72 units on a scale | Standard Deviation 1.26 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | 31.26 units on a scale | Standard Deviation 22.84 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | 32.28 units on a scale | Standard Deviation 28.97 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | 35.50 units on a scale | Standard Deviation 21.27 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | 0.50 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | 23.16 units on a scale | Standard Deviation 28.98 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | 30.53 units on a scale | Standard Deviation 18.17 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | 33.57 units on a scale | Standard Deviation 19.91 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.52 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | 40.18 units on a scale | Standard Deviation 27.87 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | 28.68 units on a scale | Standard Deviation 29.49 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | 27.72 units on a scale | Standard Deviation 30.18 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | 36.15 units on a scale | Standard Deviation 21.04 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | 57.55 units on a scale | Standard Deviation 31.06 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 6.68 units on a scale | Standard Deviation 1.25 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | 51.73 units on a scale | Standard Deviation 30.53 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | 52.63 units on a scale | Standard Deviation 29 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | 45.77 units on a scale | Standard Deviation 22.68 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | 32.28 units on a scale | Standard Deviation 32.02 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.47 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | 6.33 units on a scale | Standard Deviation 1.38 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | 45.09 units on a scale | Standard Deviation 28.53 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | 33.85 units on a scale | Standard Deviation 21.69 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | 31.59 units on a scale | Standard Deviation 23.31 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | 23.02 units on a scale | Standard Deviation 27 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | 38.36 units on a scale | Standard Deviation 18.78 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 6.92 units on a scale | Standard Deviation 1.44 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | 31.54 units on a scale | Standard Deviation 29.73 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | 27.80 units on a scale | Standard Deviation 19.42 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | 32.11 units on a scale | Standard Deviation 22.33 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | 36.69 units on a scale | Standard Deviation 26.47 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | 0.42 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | 26.54 units on a scale | Standard Deviation 17.83 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | 31.30 units on a scale | Standard Deviation 25.45 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | 23.46 units on a scale | Standard Deviation 26.78 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | 44.39 units on a scale | Standard Deviation 23.35 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | 36.89 units on a scale | Standard Deviation 32.18 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | 19.11 units on a scale | Standard Deviation 24.85 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | 0.57 units on a scale | Standard Deviation 0.5 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | 21.51 units on a scale | Standard Deviation 28.24 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | 47.90 units on a scale | Standard Deviation 28.81 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | 39.16 units on a scale | Standard Deviation 27.48 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | 36.37 units on a scale | Standard Deviation 20.72 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 6.71 units on a scale | Standard Deviation 2.4 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | 37.22 units on a scale | Standard Deviation 28.22 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | 19.23 units on a scale | Standard Deviation 25.35 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | 38.33 units on a scale | Standard Deviation 28.59 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.58 units on a scale | Standard Deviation 0.5 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | 48.65 units on a scale | Standard Deviation 30.74 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 6.78 units on a scale | Standard Deviation 1.2 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | 49.56 units on a scale | Standard Deviation 24.49 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | 45.94 units on a scale | Standard Deviation 22.65 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | 39.24 units on a scale | Standard Deviation 21.81 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | 44.72 units on a scale | Standard Deviation 22.42 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | 37.09 units on a scale | Standard Deviation 20.82 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | 40.38 units on a scale | Standard Deviation 31.31 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | 38.46 units on a scale | Standard Deviation 21.36 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | 35.26 units on a scale | Standard Deviation 26.92 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | 38.74 units on a scale | Standard Deviation 25.95 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.43 units on a scale | Standard Deviation 0.5 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | 39.81 units on a scale | Standard Deviation 27.56 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | 42.26 units on a scale | Standard Deviation 32.02 |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | NA units on a scale | — |
| Adalimumab | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | 6.72 units on a scale | Standard Deviation 2.2 |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | 25.50 units on a scale | Standard Deviation 30.38 |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | 59.50 units on a scale | Standard Deviation 25.31 |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | 33.14 units on a scale | Standard Deviation 19.8 |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | 40.50 units on a scale | Standard Deviation 32.18 |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | 33.81 units on a scale | Standard Deviation 27.14 |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | 0.55 units on a scale | Standard Deviation 0.5 |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | 32.75 units on a scale | Standard Deviation 19.48 |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | 30.17 units on a scale | Standard Deviation 22.8 |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 6.95 units on a scale | Standard Deviation 1.41 |
| Adalimumab to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | 60.50 units on a scale | Standard Deviation 25.64 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | 34.26 units on a scale | Standard Deviation 18.2 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | 6.74 units on a scale | Standard Deviation 1.33 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | 53.11 units on a scale | Standard Deviation 24.94 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | 0.48 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | 16.44 units on a scale | Standard Deviation 23.85 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | 41.32 units on a scale | Standard Deviation 24.19 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | 34.00 units on a scale | Standard Deviation 31.19 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | 35.08 units on a scale | Standard Deviation 21.96 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | 16.79 units on a scale | Standard Deviation 22.49 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | 0.61 units on a scale | Standard Deviation 0.49 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | 43.21 units on a scale | Standard Deviation 25.31 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | 7.09 units on a scale | Standard Deviation 1.24 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | 40.35 units on a scale | Standard Deviation 18.9 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | 23.56 units on a scale | Standard Deviation 25.69 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | 40.18 units on a scale | Standard Deviation 19.48 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | 30.37 units on a scale | Standard Deviation 19.67 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | 33.68 units on a scale | Standard Deviation 21.13 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | 32.86 units on a scale | Standard Deviation 21.34 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | 31.17 units on a scale | Standard Deviation 21.2 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | 27.24 units on a scale | Standard Deviation 31.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | 31.39 units on a scale | Standard Deviation 19.85 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | 6.63 units on a scale | Standard Deviation 1.48 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | 0.47 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | 17.00 units on a scale | Standard Deviation 23.64 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | 49.72 units on a scale | Standard Deviation 24.24 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | 44.77 units on a scale | Standard Deviation 18.83 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | 33.13 units on a scale | Standard Deviation 24.58 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | 23.10 units on a scale | Standard Deviation 27.99 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | 0.75 units on a scale | Standard Deviation 0.44 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | 38.62 units on a scale | Standard Deviation 23.28 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 7.20 units on a scale | Standard Deviation 1.06 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | 46.12 units on a scale | Standard Deviation 18.54 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | 28.00 units on a scale | Standard Deviation 18.17 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | 33.56 units on a scale | Standard Deviation 18.52 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | 26.43 units on a scale | Standard Deviation 29.57 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=24,15,29,15,43,55,52,0,40,20,24) | 0.50 units on a scale | Standard Deviation 0.51 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=24,15,29,15,43,55,52,0,40,20,24) | 33.89 units on a scale | Standard Deviation 15.61 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=24,15,29,15,43,55,52,0,40,20,24) | 33.19 units on a scale | Standard Deviation 17.54 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=24,14,29,15,43,55,52,0,40,20,24) | 7.00 units on a scale | Standard Deviation 1.25 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=44,0,46,0,45,56,53,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=44,0,46,0,45,57,54,45,0,46,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=24,15,29,15,43,55,52,0,40,20,24) | 32.50 units on a scale | Standard Deviation 24.18 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=54,0,51,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=54,0,51,0,48,60,57,53,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: A SOB (n=54,0,50,0,48,59,57,52,0,56,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: A SOB (n=44,0,46,0,45,57,53,45,0,45,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: A SOB (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=54,0,51,0,48,60,57,52,0,57,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=24,15,29,15,43,55,52,0,40,20,24) | 36.46 units on a scale | Standard Deviation 21.42 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=54,0,51,0,49,61,57,53,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: A SOB (n=24,15,29,15,43,55,52,0,40,20,24) | 13.33 units on a scale | Standard Deviation 18.34 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=54,0,51,0,49,61,57,53,0,59,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=24,15,29,15,43,55,52,0,40,20,24) | 54.58 units on a scale | Standard Deviation 22.06 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=24,15,29,15,43,55,52,0,40,20,24) | 28.33 units on a scale | Standard Deviation 17.72 |
Other Pre-specified
Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels
Blood samples for immunoglobulin assessments were obtained to determine IgG, IgM, and IgA levels in serum.
Time frame: Baseline, Week 24/ ET
Population: FAS included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline measure. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | 356.76 milligram per deciliter (mg/dL) | Standard Deviation 242.48 |
| CP-690,550 1 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | 154.20 milligram per deciliter (mg/dL) | Standard Deviation 77.36 |
| CP-690,550 1 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | 305.62 milligram per deciliter (mg/dL) | Standard Deviation 160.91 |
| CP-690,550 1 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | 1261.68 milligram per deciliter (mg/dL) | Standard Deviation 331.53 |
| CP-690,550 1 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | 145.71 milligram per deciliter (mg/dL) | Standard Deviation 86.21 |
| CP-690,550 1 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | 1207.57 milligram per deciliter (mg/dL) | Standard Deviation 330.54 |
| CP-690,550 3 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| CP-690,550 3 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| CP-690,550 3 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | 1148.07 milligram per deciliter (mg/dL) | Standard Deviation 439.24 |
| CP-690,550 3 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | 435.00 milligram per deciliter (mg/dL) | Standard Deviation 405.07 |
| CP-690,550 3 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| CP-690,550 3 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | 144.73 milligram per deciliter (mg/dL) | Standard Deviation 73.08 |
| CP-690,550 5 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | 1068.08 milligram per deciliter (mg/dL) | Standard Deviation 266.71 |
| CP-690,550 5 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | 1157.79 milligram per deciliter (mg/dL) | Standard Deviation 290.29 |
| CP-690,550 5 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | 161.96 milligram per deciliter (mg/dL) | Standard Deviation 62.54 |
| CP-690,550 5 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | 237.00 milligram per deciliter (mg/dL) | Standard Deviation 87.21 |
| CP-690,550 5 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | 285.34 milligram per deciliter (mg/dL) | Standard Deviation 121.73 |
| CP-690,550 5 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | 172.81 milligram per deciliter (mg/dL) | Standard Deviation 72.41 |
| CP-690,550 10 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | 287.50 milligram per deciliter (mg/dL) | Standard Deviation 107.94 |
| CP-690,550 10 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| CP-690,550 10 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | 1142.75 milligram per deciliter (mg/dL) | Standard Deviation 315.33 |
| CP-690,550 10 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| CP-690,550 10 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | 153.08 milligram per deciliter (mg/dL) | Standard Deviation 69.05 |
| CP-690,550 10 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| CP-690,550 15 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | 1169.97 milligram per deciliter (mg/dL) | Standard Deviation 280.16 |
| CP-690,550 15 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | 1219.31 milligram per deciliter (mg/dL) | Standard Deviation 326.92 |
| CP-690,550 15 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | 294.97 milligram per deciliter (mg/dL) | Standard Deviation 136.28 |
| CP-690,550 15 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | 115.04 milligram per deciliter (mg/dL) | Standard Deviation 48.12 |
| CP-690,550 15 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | 122.46 milligram per deciliter (mg/dL) | Standard Deviation 46.08 |
| CP-690,550 15 mg | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | 321.58 milligram per deciliter (mg/dL) | Standard Deviation 171.12 |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | 140.06 milligram per deciliter (mg/dL) | Standard Deviation 59.51 |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | 1219.38 milligram per deciliter (mg/dL) | Standard Deviation 397.93 |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | 160.69 milligram per deciliter (mg/dL) | Standard Deviation 75.04 |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | 316.60 milligram per deciliter (mg/dL) | Standard Deviation 140.26 |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | 1111.42 milligram per deciliter (mg/dL) | Standard Deviation 286.08 |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | 280.65 milligram per deciliter (mg/dL) | Standard Deviation 118.5 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | 232.51 milligram per deciliter (mg/dL) | Standard Deviation 100.39 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | 1157.57 milligram per deciliter (mg/dL) | Standard Deviation 271.58 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | 304.14 milligram per deciliter (mg/dL) | Standard Deviation 164.97 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | 1073.66 milligram per deciliter (mg/dL) | Standard Deviation 274.31 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | 156.04 milligram per deciliter (mg/dL) | Standard Deviation 73.34 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | 128.25 milligram per deciliter (mg/dL) | Standard Deviation 56.26 |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | NA milligram per deciliter (mg/dL) | — |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | NA milligram per deciliter (mg/dL) | — |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | 323.49 milligram per deciliter (mg/dL) | Standard Deviation 134.21 |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | 1143.78 milligram per deciliter (mg/dL) | Standard Deviation 359.41 |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | NA milligram per deciliter (mg/dL) | — |
| Adalimumab | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | 144.27 milligram per deciliter (mg/dL) | Standard Deviation 103.26 |
| Adalimumab to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| Adalimumab to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | 1143.91 milligram per deciliter (mg/dL) | Standard Deviation 290.22 |
| Adalimumab to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| Adalimumab to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | 143.29 milligram per deciliter (mg/dL) | Standard Deviation 73.11 |
| Adalimumab to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| Adalimumab to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | 294.35 milligram per deciliter (mg/dL) | Standard Deviation 131.76 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | 153.24 milligram per deciliter (mg/dL) | Standard Deviation 80.78 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | 1221.28 milligram per deciliter (mg/dL) | Standard Deviation 402.84 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | 1153.76 milligram per deciliter (mg/dL) | Standard Deviation 350.08 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | 329.65 milligram per deciliter (mg/dL) | Standard Deviation 152.74 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | 169.78 milligram per deciliter (mg/dL) | Standard Deviation 83.8 |
| Placebo | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | 327.00 milligram per deciliter (mg/dL) | Standard Deviation 177.7 |
| Placebo to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgA (n=21,15,24,12,35,48,43,0,34,17,22) | 305.18 milligram per deciliter (mg/dL) | Standard Deviation 150.23 |
| Placebo to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgM (n=21,15,24,12,35,48,44,0,34,17,22) | 167.95 milligram per deciliter (mg/dL) | Standard Deviation 82.86 |
| Placebo to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgG (n=50,0,47,0,45,58,53,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| Placebo to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgA (n=50,0,47,0,45,58,51,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| Placebo to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Baseline: IgM (n=50,0,47,0,45,58,53,49,0,54,0) | NA milligram per deciliter (mg/dL) | — |
| Placebo to CP-690,550 5 mg (R) | Serum Immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) Levels | Week 24: IgG (n=21,15,24,12,35,48,44,0,34,17,22) | 1213.86 milligram per deciliter (mg/dL) | Standard Deviation 379.24 |